var title_f15_0_15360="Peripapillary staphyloma";
var content_f15_0_15360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripapillary staphyloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The optic disc itself is relatively normal in size and shape. The surrounding retina is deeply excavated and the retinal pigment epithelium and choroid are atrophic.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl C Golnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_0_15360=[""].join("\n");
var outline_f15_0_15360=null;
var title_f15_0_15361="CA125 by diagnosis";
var content_f15_0_15361=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Box plots showing CA-125 serum levels by histologic diagnosis of adnexal masses.",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 644px; background-image: url(data:image/gif;base64,R0lGODlhDAKEAtUAAP///wAAAEBAQICAgMDAwPDw8L+/v+Dg4D8/P6CgoNDQ0DAwMGBgYHBwcFBQUCAgILCwsH9/f5CQkLKyssXFxezs7BAQEOvr6/r6+vHx8S8vLw8PD4+Pj19fXx8fH1xcXIyMjLu7u7W1tSwsLGFhYaWlpTExMaysrJWVlby8vEpKSmxsbDs7O5GRkbGxscvLy4WFhaGhoeHh4SEhIYuLizo6OgsLC4qKigAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAMAoQCAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6xzBAR+CQd9Bwl+tbe2fbKtngMDfgKwfAQCfsXHxn3CvZ2/wcN7yH3TxMp8zM2bz8vRetXS1+HQ2tvAUedHuEbpQu2vQvDr59lPvFDrQ+3p5+uy4E7uHYFXhKC+Ifn62cIFsIlAIw+FPDRIsCIsXg2X5BvoTeKsgyAByNMFr165S9ygBEiScSURl+7OPZvm0mQTm0wAwgQA0+U0/2EZl+DU1y5mEZjVfBpDFlTJUCE4TabkRhUYs6ZIsKYcYnInzJnKnj09GWmrk50FxQ1Bu7OqSGU1OzIZm1Wt17XxlAFVe1MuUXZFkV5T+rZwlLFRvU2VyRjAVb5LtBZ17O2u0Wli/ZJt9OoVAwadQ4seHWB0ZwkLTJcOvdozaAKfCaB+tXqBBNO4X9nOjXs269+0X/m27Zv36N24Y4tW3rl18dWzo6c2fvw2buShscN+vd21993FqQufnpx7Z+2tCbSO7Ts29o+bGwWYT7++/fv48+vfz7+///8ABijggAQWaOCBCCaoIH2TxYfIfAJEKOGEFFZo4YUYZqjhhhxOyP/CCCZ0KOKIJJZo4okopqjiiiQ+EECDDhoy3ycVTEBBjKsM8CKOi8zoSY038oiKjjAKGYiPRia5CJFKyohWk1AKwmSUgiDJCQYVZEBlKFNu+YeVmwDp5SddjskHmJqIaSYnZa6ZB5qZqOlmJm3OaQecduapRp16yoFnn4COwWegSBSgABl/WoKlloRKMmgpE+qCjy4JSAoFVktEhESidySA4qFGyNnoI4+S8uQRCoAKQAEEzDLNAR8d0JGsCBEAakMKaCbSMHStdSoaDajaxAAdGGDssRpwcOyyy2rgl6jBjrrkjqy0dU5NAjSwgC0KPDCAAxIwYIEACTwzQLYLzDL/wAIMOMCASA5824BhQ7SrLQELCAGBAAUs0MBnCliwAGRH/XpGr0UMEIERCBiwBALP2kgEwtL6UeooAUgIADdxFZaaEKyGNUABD0g0L8e1rgTOviAD8MChDiSAb8sUc0oGxfosXETDD+taBM4V73GxKNYK0TEyO2E2wDTIoKwAuzrSu3E7CTBwQMkAiCsABJQ1YfMYQG+sMxE8KwGxE2EHjcfQoRTNE1SwIGMBfEpfre+7KG9ttNThElGABQ20A4EFXTPxtRhhK8yww2b7tejEPqvdB9ugJJ1aA0cbcy4BCUhwgAW2ijUABB+j/C8BmEv9t8wOCNGABQWIBBpqWTfA//USh4eR+NhDlJ3E2aFKzFXkkgtNbY5FlHvAObysQ8AACcT+fK7DKB/PMOdIMMDyAGy0qvagVj0EBANIEHsBEkhguMFm7L54z0eImnbxdFBOPxEPwEdF7mC4vzPjv4tYkOB2v0HYr4DemwL/vuA/sgEQCcCbC/EKaIcDUhAKF1qgFwQwMBE9gHdC8B0EO7gh0F0QEBZUEqvGoAD9XY807CuDAKwjHtiAEAAiPAICaBiaEJzABdmZ4AnlkMIkkQsLB5hXPMYVIQB0K3bre0MDe/dAHQoQckO02PHyBBsi0CoKr7sGQMrltRjeTIjuuGEOGXbF4WVxclu0kwM+sq52vf8rCtXAV6uIkK8oumGKIawiG+MnPAK+0XhFGlMfp7Y3InhqQsLKyxAUELgHqE8IDIjkETTYBUDiUJA7E+L8DpmGIgrpGijDI18K8BXicZILnlxjKNGGRlKuwZQ8QuW1kkchTTbkb/pwpRnBVkvF/Q9+RnicG225tjjOiV9GeRsUFDCb2GmPAA5QIgAWqYRXbiGWoCRbGw3JzAo6001k3JU7olCuX8yiAOW6nezKKMViqjGcvRtn4cpZB1zyaAGa7EK/XLipYYpBAVB0wgA8gICGOnQDGnCoRCW6AX0ilJ/mTOSYqDkGCMgTdwadg6xqOJqEYlRK5zzp/kKq0j75s6X/vvqEMmHaz5TS9AneVISobhqHl9I0p4nYKU/f4FOYAhURQh1qG4ra0qMqNUlMValTnyqkqJ50qoWYKVWXalNJUC+gV+iIOLR5B6yycEUBTepW0WDVPwiAAQNgAEBheZTxnUyjRzCLF8w6hWjlRAPMCiwHABtYYzmLkAM0gl/XGoa2ksOJD4idAhygt40trxYQcIADCnCuS2LTAdiTyFthYjXHCGB7G3ur9DjHOtWadnucPa30IMAAAShgX3d8JF55wlIGTpAACFiCAYILQX3+rJaMlYJju1Evz6WrAMzI2Payhb7UkAxW+bvaLFaS2QIcwCX9wiRoChA4ALBsAIBL/0ALAdC32BQArhvDmwAOEDBbxEwksbsvSOvZBOAKl7hWnMIok6vQrkaiHr+QwGnPBQyYPAZu2nOH+lbigNu5pFLRtMAvosYN9DlgYIwEAOGEQLhUPmN5AvCWH9tAMf8qYbgBFDByCfyE5WIjGgwgH3e268afPK8xK8mGSxYARY6FJsS2CVmIe7LkmFyNa3o1Al+l0GIAIwHGxT2CVo9L4y/YeA/ZSEC+CBBZIRzKwXHTi636aNu3lZeV3bvjxpQ4QzMvOXaemrMQKgyvJk9tZlnD65QP81srHwHLAQ5eYrnc5S58WQ8c5CADoChmDnINzYZhxroWsEvonnYlo0PIwP8Q+uEFtI4bCXjAW41xgFErQEKHMjEw5CqAeK0YrEnAdRK8y+jIGNoIiB6kopMgjAMk1NhL0HWjHz0Kbr5JZY7pHkGNAAtWT9sICH2eSJbp6//GeNhIEMbSCgBlAhjKCLCK9oyVyuxQkLsP83mvXL+lbHlz2gHK1le2NJuOKns7y1IYWDb3PfCPmjle7Jp0o/NqYHZv+OE+0hHBGD5xdbjIG5He0AJ+XYRg74yEI9JwAPInkpFf2zENJ3C7i/dwiAfgvdqi9xJgfu98m/e0/OYKD3MjAY4TweNk2/krfAhE3KiaAQ3YN9IrS4TJouYzJl24O1JOpQSQdQroGwCo4An/PZOdBdrWzkm0082EbAMjGv5+sc9xaFzIjbvc5y5CupcidXZQHUr9inoUSJYA0sEifbBRImjpaedpSoHXWMzJ2oUA9HwiltitOrbei2Bzld+9SV0XCW3DBuitZFYIB6h4TP9Y6H8nughq3Wfdr7ByVCzyXPTF2hB+vGEXRmhf8JE5VCZfMP4q3vTCJvTqs9D6U+iykbUKjUkLUGFtqQp12lzaitmQ9iQ0PoTrHvDwiVB8UxxfmrNvuf4koMTPvySY019D9a+89ggSYcuJ334Vug+pv4Af9KIxaZ7Z+65hkLleJzd6LFZ6avdtqFdIRqB98rcxl6ckoBFNvaUttRY7/+vCQVvnbAXle91WgAB3gIsWfwuoXA2YJKFXBpm3X25wUTmxARPVghrAgi3YUBX1eEiggiEogrtFJf8yBmL2dX7AKiSFG7x3g2BAfwU0aEQICkZ4P0j4B/CXhFawhPTThH6QelCIgyFIhX1ghVcIBVJYPFrIB1zYhQWWg4wVhmRoCV8oOWiYhpSwhmrThnnwhG5YYyPYCkBYBQmEKL3lCGNYh0kAh4+QanH1MvfXX6IHBYvVTX34Bo90Ipr0h4DIcGbYDLADMq6yKrmidehjPtJWLtKjDM9jKSADPvQFMrCwPLC1G+mnBovIBMRSWAaQLLJoWHIhiRJBimkoiI5gSf8mpTLeAgEPYDvwtS4QQDvIkACg1QBk1S8SkFl2AwBV82RWdzXwhYID6IU3FEiNQ3yVuH282AiTZQHDuDc+VhjcAFDI8AAQQBuOJGeOwTWp0S2qUjONCEv2BEH4xHbeOIkM+I3aEHoTlmlpFmJ7wRMPx32CY1t95Ck7Yo8aOCzb+EndWAR0iARR1oXhyAiq0gADeY5Ncw6ws47DoH/KAEWqZgtQBGcQSXraqI8VSQS4GGKAuJGL8ADxUluxozJqho7eclqF0S3M6GxvtS5CIAFY0y3fIl9Xt0n3+E35qEP76H5CMJMZeYU2uQi58nyaaGbnE2tL8xFxp07YFg0pwSr/qpIqrciDvSaRMGmAQ2CVk/FFWUCXJ5WVbAKQflNmVtCGBMA1mgNFnsSNcDl/VLOJnHUF6vU8iXmXd9gkZEcFY1kFbRhbD7At3OaWUhmTUdgOB0BZA7NuXgSaClgxeGkm+3EG0BUAZJVxHfJBbzlCFaICK0ACI6JiTeciBkcF3RIAu8lMp3kJHHUFuZIEHuWDZVAMryZmgil0vMEAEylLvSN0KTABIhCE13iUzfctVyAB29k6jqmXRjJXVvBWDUByIMNpq5IuhEcGgrkqmQmL0TmVt4iAsNgO0gMMQ+gE+Qmf4Qko6QQr1vMESsMVQDlPa4kGg0mRhQkAcumPwVkJ/9C0MduiYHKXf36jYdA1DAzQTkOAgU4ZkfIZm6fXmRD6mP9kf2hBe+5UBEMJTeRHkw0gTCK6BMb0Pg06BVcJhRFKCd+HFiPVGfp3R32jYeeSDdKHjdQXlTjagUNwkXklnlLXo5PwowUhfkTQN+bVOp3xGR/xiiHqkjU2n5xZlfZpo1K6cFQqCXMEgVDQL3BliPa3Te25pC+5mQ36oJO4ppHQRdIWD1JQnHL3EemkpOrHpMeUp2eqBDuahHx6YLrYBU9Up2tgg8PCUDEIUTH4UKI5qCeapjiyQgcVgC/xlGwQpEEopP64BY+KmqaaCFC6qpSYha+KVIsqq4GIojwlh/94MJOy2qpjwqt34KurCqxeIqy4igjGuiXImqyGsKxU0qx0EKvOOnWg+lO1egjE+qlQ9Qu/WWPfeK28VQhJtyIfcKvVyn26agqrcaA6Gq5ZIK1DAKZooyzHMli1WIshgK7fVHfQ+iaS9DQcxC2BYwxi5i8JU2sPoAvagpkK0C6mBhWY1EFQkXR8yYg1ijYPdH3ClYhYkK3Aua6lsBLvpZ8gQzgEYAG38WqYZCkDMC9/k3VCkD/4EjtztRIxKk0BMAsemaAHI5oCsLGLZ30eewUga0v/igcZg5MgU1sCwJPuoGoptg/0UAwdBDrnGGTD4BIu0ajjKqZUJrRSgAEhQAL/iOKvImsq3WOI4GKOYdGU0QRQTEeQbyNkjeS18kpOhyG2UXAB/KoFR0tKSVtW8RBZbZsAULu2sHBb3Nd/JUM6swABudKTOMulXBtNGAu2e/tzQ3sEfvuBe4W24joK12B1zLc1xkBJk1RbmfSOb/URmUVdqgsA0RIW5FITueiz7QO0fAsFn3u2U5q20nKKLCMFeat6GNS7UGAARduXogtTn+laxhu4MkYFQcu5U8C8wKumwntIGUS9VAZyIae8TkC2IcIiGQK+WTS48YEbxztDqXoe5NsEfnud8Zuq6jtE7NsIpLOfTBBbrduDlKoGA3a9Q8CxSfC7Y5C/J7S/jEBk/1cAX/+3MZEqZQxMS9Y7v0ygwGJwwRTkwIqQTg/7YeD5BG0LTOs5wGlQwBrMBNq7wM8rLa0rEhBMngYqIVfXLbUmT21qqATMu9grBS/cwTE8KmLUk0/gkcvzejSquckbxFBAtmYLw8E7urk0e0h8wxFydZi2MU2cjQLWwkrAwWHgwQUEwongV+f4BEA5qQCwWborQ0B8wJ1rBGQMBmZ8P2iMCH46u/S6a0k3wyUYx2eUwVD8BHf8BXlMP3uMCG3WBYNHyCzkv8QWUQ71gpuayQ2lAc1bBZ36nxUzWZQMBVaHnINAPfc7GpWXrI3sIMcLB9Rara0cH6/8Btu6p917Vf+LnAe3XJO5jFG17Aa9XIezvBnBnK6IRKvIzArFTBbHzAax7KzNfBLPvAbD7IbTXAd7SMqk2pe7rAXlKiJwK5N/m67ZXMhSQ22dfARDUZpfGwez6xT2Kou0aCwcIHpcGM+/+suakA1MAUXr9WPGYCgr1IlQ9DyeqAC/wCtxszy3c1Gt0nWiil8+3AaY4hhTCUBDbAUXrZH8nAnwKxvG0KEzewDeiTpLcZn8srCpRm6pkT7s1Y4fE11LswCACQusqUe1Q7vwmIFycNEGHJsb7cnrfIPnDDZwFVdLkS8sQ3JMAcGlTLud08PxwGBd4xKfF11G0S/aQsnHDNQZfcCiF6v/HY2VH40J/qwMqcFnhFGgU8NZC2ABEMDVsGEVOC1JWh1i6mFzX52IQY2nADDU4MYSRR2CR404/qcMnoI1Tr0UymB+OQZF+1KgeR2jef0M/bIuXv3NkeHXYc14+Py3Zc2jZ30JaT0EFkAp9+bYXPEZxqBg6xI9/jJvV4107HnZswYMO1jRbADWZqPRoQ26RDDajlralqCCcUcyx4ZQhzKZaol/Ytkq6XZROxsNEA16xhYN5sbba+DbvwPcWUDcRHjYpWTFm6TInK0E3i3Uha3O0mzcnWCpXvDJSfDVTJQhFvDZgX3fF0KbtpkhIMbK8D2F+uEK5JEbC6DfBnDgplGd//bLc+0tf+R9B8O5BUAID8epwr3t2b8t1kvAheJt1AOuCjZcBcUrEt6C2ewpyWaw3oAt2B7Y2e9t3uUQoLWAWooY4Onsp9ytBi7epDAuBSFu2COOChMa2xbqRRiaFrPnLZYCohbsChz+3R6OBUO+gBNeB6+3S8ONpUwOeu2oWfP6xXDw44ka2GOdJTIu4DSuDVaq5Mrn3lKGfj2eBmbuQFWeBCAe4eBY5Manolf6cARVDVAUjbSbb309Fwoe3GuOq1lOBz2cSvbAAN4yC7C9sB+q4d095ez94aLN58P36K5wR2SHXKhc6NstEbt1zJMZbpa8qZq6yaAOMqtc3G3u5v8VvAVuXOd2gMo1VOvLPKuAMtFgsF6arihqHuzCLn/VrAbXvIt+fkHNngbPToaijgrTjgbV7tG3zkzZruw9Fe0U9O3gTlTifoTpXQfRzObK/CPlLMvnngrynQbkzhHxqwTbbtbdTgmfOTAfY6MS5AbHPO9SpskIEOsOxT7XTPBYHu+IQDLDcAC/KSsfARN5OEmvFvGpbmaqwiom9UV7dD2jfMwIE0M5ZMbu/FTXrpgl7A5KFDhiti4KgLjZsk0v20fu8joXcVpztcWYSTrGSKF2FC9zUzsDgJ6ZGwcl/zBVhPL0TVUrb6JeNGJzU1k76Td6ZH7CQDL60joPxp6t5mf/KVHXLC7HhsP0dZUE6x5uT6/yDn8IL2sEHSo+ZMYuV78qtXb0PwY3KYvDXYM0eCFrtMtp7lrf6c72Z9/h56fn7+4Ubc9ub28I3eI3NFwPnzmQekYZOSsMk49F6/hOJSNrnSdoh8/OroT2i48E15zykL/vk1Bb7XiNAd6h+MI1C/uXqaH31PgAsNAunDMvD/Yt2AQMskaN6snrP5v4VJ76NFgFrD9UUU+cC10vumDSSerQ5rU0zaP9sFs+s9A8JJGkBHEO8KDQMkPmGZv2y48XxMTtRmLogzBlFAgLvNefsbP0is/+YeBp5gYEBcIAUAAckcmjcVhkEo1K6ZSKNA4I/8Xqltv1fsFhsXgQII7RafV6Tciy4etAIK50DBoJh4QqcSQaBhwABCTcDhEP6bYQDJQCEhNfKmQiLS8JHiwEEhYWAAW7/ED3/gIH65Du8vZSXV9h08rOYmttb3HT5nZ5F18hAh4UthQeAiCOBBYEmJudmX2pGh+fnz8mUKq1t5ktghWKj7/CkQHIa4GFc9fZ4Wbb4ePDFA7i6b/mYAmaHeqnDhw4WJZFwJst0aZMS4JQSYUJFNo8eCAgoMCCXQBaJJBxoD5+/uSFFInk3UiTIQksiLIGQgIknRY0OAJh2YJhxVYeZOiuABYFLqckUDCkJyGDVXYmUYgk6RGHENUMGP+YIAFRWlWEWs06oOgrrj6BnhS7ruRYs7cEgDQ3TIwAM0gsGLFp7oieuleRNmWzEaPBi1z0Alh6JHAcAQP8HTjaN4niW3zPRq5VVnJlOAoYIGHW4NOYAWcUCDgygA8SCKKPLPCSz+zfg1wGAygMx7Vl27dhUca924uEsBf3KWnwbMrnI8EBGNdcDgADtjrP1qYSOLZeDBUysJHOm3t3L7q9hx/tNwvyMMqRK2+emeTiKazHbpdC3dHCLU+1uxe/Pzx4/tyx0Kw81JAYzpnizijggSMYKIcB9trrAj6x5HsEtvqYuu+h/P7rsL+3PPSOAJmSGVAMAh58oxAIHjCCs0P/kFBNwtnYqdA+RjAkTEOo1LAxxB/H8g9Iy1Sqq54DwvriM+UKkACxu5Y8DkLozGrgOaQMyFLLLQ3QgAMuaVzDyiHJjEzIMs9KYEp2ClhArbzE40ZOAtGs087RQLyzMgmuXAcC5gAL887rstPT0O7OPFRRNCZcVAr8HI3UzDwlrRSMRi2F1NJNQ0qU008xrVTTT0nNxdNSKw0V1VVZrePUVhVVFdZZaf2O0lolldVRQnHtlYxbfY1VUDtHDdbY4oA99k5dFy1W2WdffdYLIaKgFqM3Y2HWsgTm7JYZoJyV1thoxd2CABDL0E8JqnLRth0FSORigA645JIDDerlsgO8/1IZs1xDyf13in2KZGYjoBLwZwABnHMDgAQgCMgfbhmox+HkRqOoz/eGfYzOKgaIYAsDEOAiAn7r8FHgEANeOYl9JPBNgoKQu6iBzBSAwDgBGmgyMz2EWFA5OvwwB9DpOrbFvC1CHrnkLU4+gteU1XWZ5WSt5mKfNlWiGbWL4iKJCOBEc0BFBYZ++JONOT5raZBFroJkk88INw2Vs96v5ayD29mNr7OIxm8AgvuroLQJb+ABlB9Jupa3qWha7qeriBoAu9HAO+8PGd98YDoLUkC1NgkCCu2xTZRAJgUBUB2AA+hQwIjTZnT748jjpmJuqOvekGrPh9zb6qUvEkigLP9CY0Zn1AkXrQAGPEFGQZ7poEkZthu3/bvcp9i98s45BP5H4cU/y10lonBeiiuyMCJ9LdjXAvLiuJfCeyosf6WAw1ZXf4v3c5KE+AWwfF7BWgF5c76XFYQTRUrCKvTAh33soxMFgGAr5icFyemOcvg7w9TgIIEAcOYBy6iguRh4QilcsDQIzM0BXRikJc1QgQJ0S7yUkI7n7G+EpvnGcTbRrQfUTwn3m0IEJiKAa2TDW97yRgC41cMu8BCHUtBhDGNBPiyaaoZLquESBFHCJB3nI0UIY2f2wYx+EG4BmEAEA4iYBCNKIQIMcEMKJiACN+4xEQnYhEQWIEYu9MQBgvz/nBqxtcU1aNFO/mIHINjQpAE8ZwgIqyKcToQM0XBFCV8hwE8Ip8nk9KQnn3RJBjsZRyTMUQmWw5wYErA4TixslOYSJSc1WEpQKtJVMESTyjRXhzYRMAwKglgb2YiiM5htNY57mLmwNUbING97TqNbLTjxhjFyYZtSmCYv48DIsZzGAX96AwGQsTAH0OMBDCCCgcpBgIA8oH0MOExdIrbGhzHsSAlYmFAkRjgHMCyAAwAKOu1ZtYHJyDh5eJ2MDnC7tpkFlUnYYPc6eETwrSGY4BSLOE9CkwIgiXaEgEDRctYmQwBAeg84wAHcRDoAIDMQhOiZBH7mgKARjp4K4gpO/81RD6AmQUbJSUsxlDCEGb5JeWkxio6SQczsUVSiGlTlEViZBMuBkDYK9ehZQGqScibBpQdYUCeEUqLjDMcCBHCdUYrxGXs+NTjMJMRQAEfNJllECQRCHBIUg4icWBACnBnGX3wRoEBprwsXtV9G6dg7HnX1q7wJ60hqg9MGlGZEi3sqTQ6r1BKl5BChpabh/qbW4CxAAkL4mF/PgBClLkktb40YAOxqgQgtlqrVnNw1L+c7w3i1sh/15W4GwJ5hKKhF5pidaASQztW1saRtLIAF2GLa4LiOdTUzUQCMwK2+ig2qgE1ETsTbusy47rYMSuRUx1JRklwVAFlFgiuFS//Z4t7msiJ53jLOwAASWW8u1msTRWi6AOghrybMC85/F4AM71Izlgz7mB1HE1sxcIYi7mPGXIpQVCrFt6qptCbvsEnc/Y6kv2ZxaXciSpZuzseZsCgA9jrpAQTsmMc91sAGehzkHXtgo2qQ3Ypt02KxqCk8N8NFJ/BRY5EElo979AdXkXwnJWeZDV+s0yu5PL7jhpkdXkYTmMncoS2neQxmLhOa2ay3McfZFm6m851JMmc8v8LOe6bzmv08Yk5hOdByLnKhU9FnIMEZ0UnWc6PlIOUfMRrSkgF0nC8m6E1RutJgfXQcwNG6GTtqABPpDNPeiWN5FVnRubjxjHoRa1n/o+alnRbPpakQkzKIg1PGUdAw/PkG2dHjpSrV5pOCGjMjHMBJQFEPJm8jX9mcWI6oebatLftpOEBCGQH5lHLa6M59aNKEnzGrOwkxAJoQpJzobokyk8NqSeNC2nqZowFEgwEQtADb3sH1e4ARiBIrKrlDcBM93QpdZzMPpjPJDNmOoACcblLeu6k3tVcpGk732yT/XuEc9ICKTS3MoEFbkkv+MjjkFM5EDCjnzOJdO9xc/LdF1Hh+Oc5fbbMBID2L7rdpcYCwaSHlzLtuXWQC8UX0reIzH3h5MWq/m082544+dAGfHcvkPvwNxlmYTL7uJrqKxuUGijlvo/30ade8/9oZrjpyd343eDnjkpGqtQA/GfEo3D3UrzPIkV9NuGG/7r0LmbfHJIRxrFr76m8XiceZsg9eqN2jraa32u0NWXwDQN/8drzVRXKP/XbRi4dXGuYVX9+pfx708GAYMAKg6hiS/jOWf4ysZZ16A8xhBDhnvVkgv5DTlHBN3cm0/nBZhz9F2eKoZ3vGg0v13wcp7mqAhAXcSfnKXHsM8JoCA0ZdzAVAQewyT3vin794t09/Uo2vQyADMHF4vNSfUfAnUCRZj8Af+WHJPcMQDKKSrCWo+s8lOuGbYqwIhkKx2uKeCKf4Jur8AEP3GI/92i8eCMAC3MQCWogsIkwCVONmRv+EAPbnmBQjr+5gH4hAEOSJCA4wZsDvCFxKBBtgCBbnKNTtOBaHRQIoETYG/NRDxKDNNmiOg6SO8/bNAj3N/VjmDGziDuzPbJTJu8zK7ZqLdV7sOFSDdqCQjKRAAKJgwixqhsbIddSjBs2PCJ3PCG0u+pQQ+KpPDWZmrOBBOQriABhAIg6A5D4jtYwiPYjAF+gAIdporPBQDyGHQMQQCXxQCSzgMwxmPNLQMoow6tpw495wMuIQDRqAF44GF5QjLqIgENKrCKhwQWJuLhqOnpZgn1BxFLHgdnTKC59qDE8uqdzgQfzBkYaQEtfQEtsOEzPxhZhw26BgoOpQlojAAdz/SR3sSRD44AEaoJCyoOzuiSakAhmwkQFKwwKAghlLTXYeEVB8gxY7agxjpJmaD/3YsO3ObhhZbBPbrByGow6xACSGYiUUwx+ohf+IjR9J0AogQ0FWIh+XICCtQEb2T6q44O78SR2djh2BEfreER47RR7FwAECQBnizx498jwgcA1wAiJDBPdMchfyDTssMh6LMZI00gLq7hbujh34LwwQsg5EbxIzxfdWkh2CD9Fsr0OEsSfdASPDwI9Qks2C8j+GkigXySjBwBuaISb3aymdElqg8gtgEs+s8iqP5SePwMnurCvFg9C80hbAkhAmTylNjyl58iyzKCu9wEA2gy1L/6Up4fI85DLnyDI88DIvlWQvuYAumaEDN2W2XLAe2pL53oUhteMkITMyk3I3Ao/N0tIteiH8CM6OHCZh1g4e+pIKzjEMBCBHLkQMNm8d4ywtkak5Fkb7tOwqxmSElMFF9EAomgHYhuMBAEEAmovDwFAn0ULFMsc0cURqLsAx1U81LVMwD6I0hoOWvu0wAuQiwCs5ku4OmUmekiMzCiAA6mGztAAAxBPt1mE0waA0wUAhLuAt3TEiV9M5q8AtOFLAYNNOCo4vrNMLEStDEMc4TsM3m65GiHMM1PML2NM9KRI+m7MlRRIzdaoqSOXZ9pOlBuEvhk63/nOSmov7aMz1Cv+0LYyzChJU+o6QOdMsLWmFQgPnACwI5d4A3ZLr7BbhM3Aiogb0PEOUNEdUGnpUbu5TJKStstJSAQaqLkuFXQrksOwJKPylJw4jvIACNdiFYsrRPF2BbdDzCw7UC2KjC1KTQePARbOGNdcyzbqSIAgvCbbUC7q0CxQCA5ITTIMUJeqUCrIACyrzX9ISiugA3dB0MZ8HegThStq0C970NAGgPU20DVF0kQJiOD5RWvo0E0bkTvPmJOPydjBTMj21F35UCkoUTD+1VE3VUzF1YIKh8JQlLReHAeZA5MLMKp+HMwqVTXc0PUNVCUaVC8JUAt2BGSXVZYpUdgJCORVFLOX/kCLKoQCiM7yEsBfjQE1nshZhIVGPMwx+VQ3rIE9JUPaCRUVbJQHXoLWErh5aoQFIxKBI8hW0NFe5dFeVQl4dVUzhgEyt5icFYO6mklQw7GF20zDTM3CWQLdCrF1z4VC5AFtJtD7kFFm31Rf/TD7nQ/Imk1OKakaPLgm4xRnYRuiMQB0+U580DRcUdgsY1kePgFHplDeG9KvElVVgC+q+oE3iaRk0crdKdjixiV6PoFdHJlXb4WU96idpTzMPZWY/sy6eoU/aZJu4UxKx1GTh1U19VjDqg2V9VWjZgWjB6SdnjVSUVlCeVoAeyiBmcWp5NhZSNiGudjntNcx+0g0e/8AQVHBCEWZK58EZXCI0/vV1KC80p+Bk5/Nqv3RrXZZrsY5iAS5jSGWYcsGu1JY/OtVUbWAEZkAyFfcsXfURG8ACZHVTIOkWRlc4JeUvAbOxGFcKFOCJsMsuSQV1U5dpVndgqjaGBJc7ZHd2I6d2Gy13ebdUYnYsFzN4YWV46Qx4d8MsjZcN0jIUImpSV0x5cWN3mzfPHFQNvJFBNtdzqPc2rPd6k8N3I89xA/UuFVR8fyV70yB6IGArRaS0iIEq12BPYeF7l4z29Hd/SQ9pZzctYS8ALIBVK8MMPiP8vBZBWJd+t614n4yA57MDImCCKbiCJ3jHLDiDKbgDuncYVf90DyUAgiUDISAmoKAUGfepYl7HnzjBSPVpYRjACJgBMdyAKpDEjKI0lOwpZxiGaR1wcm+jTbH1Ye+Lvt4TDbwPHpFXPAyYXXnGZ8jTBUUDaDKBp0hwcaC4pmgnRXoCJquC7FYwMxbmAFrXJf6AcIzgjIHYNoTYOLUWACb4CyLWJjvYz8DWYuegjttFfiEubOrqbCYsOB6x9s4OPUTDYAFAQzUs5vZQQE03iKsWW984jr1gjsEggftNX/kVSbsDIZSOP1XED5UOEQr5/0RDEGk0w8wqnXKUO9pYCibZiBcUDTAZ25Y4PDzZRJCJdrhrQQIZukpjGPBg/epKwgZhQ1P/gkFamTde2WRkGW5pWY/xLC0JsxC8YyPrEuJEhxmdB3oijJrGrggEYgEGAab21ZDNITdTOeaghyKWeTeaGWqeWfXaQJrv7DJjzX8VCX9rVi0MNZKNk4iPgJJbVg2WJrukwEXxFbCQlctYM0Zfk8z4mQtkpwk8UzRC+W7cWLgIGnENGjUI4qUw+jiaQwCHwVvtNz7Zl1Gg8zDsOVguYaK34DSm0QGmUSoeRIbdiX/39wE2mkc6emQWh6f5d64GNZCIL4aTo5B8U3mW2qZ/bs/wuT7r8au2Qaa3wKwgIRnyhGGIWn99GpY5ep4NYKi/mvbmCk+g4SrOxRiykHBWNdCK/xRCC0BCF8WCwHWK8JE0QEIAAZYxzeI0BMGm90DBlDqeK4eshfbBBAypDfsKLCKJ0klYo3qayRdVSAMO7vYIysmPIHsIUENyd3YkKjoxCYFw1Ko4uyCogbSeSTotYuycSrrkTjo5vtWOL1ucBZiB0aRNXiKfRNiiflhATAqqyHW0TWKkkuCfNVoKBBqOFdu1kQChlUChA2ihpTq36XMBctskdEYzbmpN/GmGFFiABpilzFozkBWrewSgxRqoo/ujLbJP6fGlLYMBIW65E6G8kQBQAYFb4oUBpRWe3VsJYlmOF9u+GzQeHlGcQxdgyAOcX6KL+Hs94CIKQEzAkSZOCv88CQ68khN8vnO7E3dBeu1EScNZv0lZg2jhQciqfbJQhdfYMhAbf+I7DWrZ1lR0Dk3cTsg1v9NTIjAamznBHJahyA/2kdm4wxMbwaXbg7v7U/62Dv2XvdOAF0lTgi34Bk4gASgYgzU4gzn4yTNRX6uBt8vErPLaFaAMYQ1lvLsIBCagBM66f+t3zasObGNNwcvFyscifK/3ls83dtNXfcFgx5k1zvzc0MuEmj0Rdhm9THP7LSyIz8Vl0U+CeSP90Ce9viGdUwC9edNSIzlSYJEM000i1I03LS1otxXdgf2y0Deddle6+/whJ2elJtsB1WddzbT7DKRzVbiRuOOB123/oXJPtVQtPZPJNzQsIIk2gVXMCpFD5zkM8jis3SCEgC22HSIJl41/9Ll/9m3p+T++HVfmthcsoMclZbPocIY7o+xGJyZc/EGG48YWZw/iqhV469wro23feNxRc9lTzIWoWZ8lxaWY7Kmq8DpdJEEggD02a5jNiETWexH8XTIAHucON2g7JONnJS2pwoJC0lKKAZ0Mtj8lYBOYZzSSiBMi6gHWKebXSeZAPjp+NOCxduA//nbHJbfrFlY7ElVuOhsZHhXNQRjUWL3WJxTM6ME/1Fp/idw7vrXN3efDddJTgmcIfjeykMl4pgVNikUU4wH+pGfGz61iBgsEzElQhLdZ/+PmW4Pqyd2SXRnrfSUtH9GAu/42msQK+IAqFOt0EoOvi+D+CqCu2VXxqxzj8R7cq0Dcd15b+/4V5J5VHB0SFAx2L59Ccp7j677yXaHzMTu3mwQCegLP99nx72Tjqa7qdUf0U4H0hTfKuUxT1TLZdX/3d//zX7/ueT/4hX8OHh/dyZfbzvRThAAXcJ1KaB+z6J7nr97gyXdfCRPNDQXJ1+AA4iV5nGokbb74/z36Kb/nqb/WVwZFGiNXP5dAkMku+s/bxV/jw31O51X6KXf+Q558OxYIBEJBA2A8IpPKJbPpfEKjR8fBOFgwHAwpkiA4BsDHRTQQBggI3DW7LRUYmv+XCSWJiK8NXze/z0z7BQoOEjYNBAwUQh2aNe4pQkYmkVklApwdJQwJKSh5HQkkAChgMnQ+mRkBSrKuwcnR2eFx6bXaqqrd6u7yHVruHhAQLCwIn/Iicz0OWGJyfRodMAgMWBwN5DqlomUn774yzdUh3bHVeheuoq+j+6ILscf/XTcnaW4eH0EjJWxZdTPZpk6eJHBcyuV5RNDNwIUOFbnjFWxYMQL5HiYTUKCSEWdRFEgotjFYggdVjFBCdaYhRkEGpSCkpbBlFJY0b66JuItRowAzcdpKYEmYFTZCmVU5MCDBRiME/KnEBdTlLCUYLjQ9ElPKualObHoNm0Snrnv/m4qItbXgYqQCC05GTetHQM+6AUZMgGF3L9+eP+UCDjwWkeDCT0DeggBByjbDhCrEcix5chuylC8vbIzZDeRxmz9/tgx69C7NpE+jTm2FsOrWkEy7ji07sOjZthn3za17N+/evn8DDy58OPHixo8jT7771+3mZZRDjy59OvXq1q9jX+58OxTYtztzD4+stnju3m2DL6+eFfn1t8+7jy8/J+vmBYQRyFoTSoNOAMXCZxh+AxJYoIEHIphggfrN11p7rRHwADMP/NeER0sA8pcTzMgTYDwHwLVGAAiQWKKJJWqwQYk1jGDCiS/CGKOMG1TITgFsNVjIg6pBw2EBA1Cz/5EwCYiiCQNnKOCAAIsBMIBSBwCSyAFCCSCBEUkumYQQTiaQlChTAplAklQA8GOQABDVpBVPxkUTh21cuIQBCBwhzi0I1LjOPjlCsmNqwxAAgQBVMJDIAFtU00ACEDhQwAFhHPBWAYD45CSlaFJYgEmRHjBpNwwwkB8gn0SYn4QFSLBFoU0iWs8l1IS4hIfsvMlGnErMWWdkreCJ0Z586ljfbREyQw0A1hhhzZsOMBmGBNQAmQgml0KTxrPFMvfmqF9Uq8YnyB7bpKu3KjHrOrWKGEWuRthpS68P/QrsIH6iBk0BYWAShra56BuqMFVMq0YY3R6KX4j7osntHtteIv/Gm2eQm4S57TDHRcRHrIvMuw7FK28g9J4GjQIPAMAsmg6Ia0QDidyLaVOdBNxwtxG+jMQAaJmsScJSfWIyAShLUMSjHeGGE7oWq0tnMhsv1LHHfYBMGgEWCLHWKEN08uak1JyRwAICLLBYzAMvrIbXYDMZzdcKRCjANDtzs7MCWJf5ABEQF33T0YwlfcRVDEbCNEFOP+1G1IVPNnEgQrJcZpNqMLh3GX2zuysrgstDeBRNfZEV446vdzjijinuhwQOJLAyyg7cnIADVtpcMd9QZNwur3miozkUXnjhdVOnpz4AyqELOzplzCCPfOl+jBxA2hAE8ABbBSto4MVG1G7/uSQISFC9999X/+zidKF1RPNpqye68VMln/zyfBzggANfezsEmTbbvYn++w9xPQAZ8wIBX+MfAQtowAPq72t++JEDHrAAUURDfvRzj/rW54TUBeIo2ADAASQwgFNg8Dm7EBMBBvCjJv3IIhCkhxv8B8BdYC4euntCoNCAQiOQ0ISy404FLbgEtwCODVX6FwAUBQEKGcEBuAOD/wgRjCQQIFYcgRPlAPC3Oy0xGTOMwgqR8MT49NCHY4FgoKaRRS1V6E1QEqHedtidKtrucmfkxRbFqIQw2hEl1xjUyKDYvliBLRRaWqFGutNEb0jujbRTGgDiuL057qKOebxG8Sbp/woWNsyLBGJQUsKWCYVssE0tSSQq4Ki9wEFSF5K0JB7zuAxX6eOPTHiT72yWxfftxI2lXKQ3YsiOVU6ylXZ8JdE0OSAG5SJLtUQCA6RYrkMmg5TaqGIAU3kLYOZRmGIM1RShWTJioCUAA0SLW9joJl1Ok5dGuKK7rGkLbNpRmz5coy6WYs6WEKmFBtgnP/vJTw5ogJ8hmIAI/GnQgyI0oRpwZysUUD5LLqKSEJVCA6DCCq/lbTMI5N8HJoCCjYK0gDiaaFjkSdJ44BI06TkpBSXKUrmk9KUydYhJZ4qMmNo0p+1wqU5xglPMYKACGegpD3lK1Jb89DIrPaptaspUSf8klTJLfWpsnEpVRUR1MlO9qmqsytVBZPWrYuWCV8fah7BKRoPtWytb2+rWt8I1rl006xLKKhYCBACCCQhAhTSkhP4wAbBxY0I+UepNicy1FRj4AAki4NjHQjayknWsBzow2ctiNrOZ7YBfr8nQ5tg1LBRRRTFwuMFHWQQAEECKUwYggQK4pXujYAbkFiBbBYzEtSECVX5wW6ZO3KiEuJXAa1ubCxA5Jbn5EaWvOquIrbJhK8noCiLR2VLr/okICSBAAwBRKC9AAK/2bECgHlAACBSDuAd4wKokEN5irHdVaRgZBEKoClgxjFhHbAAEViW8nxlqXJxgLrycWwjorkH/usigbjSxmz6j8mhQQoBSFClEAPFh4rwDoNDp4KKOEhprFWlgQGJTFjdSlW1n5q2biSHmzGfiBJ6cOWV0qzJdA7PHweUJrVc+ASpuEIsZokDSA7onkitYYDGAcAt55ZtM3tXVEvlN8Sfy1eJiGjLGOCbES9ygYF4weDw6Fg+Pp/IJ2HLjABZoykbOsK+mCOrEe+CQiJ9iCf0gDMU8+4LVInXlTGb5JjJmiI3b8OVdhJkX0rzudvYEiJIcagtuk8DIhMdhajywSURgMgMWYCgipHkBDahoFySkAK91V2F7Vq2nPalm4eHtns3lxWI/q5VCg3nLkVg08cY8mhshwbdl/0qtU5LS25FE0XzAjSJyR9EJYRNbk1fCLXBP4VtgDzsrT8zFHNHahk4tYdBsQPBBcI1oXffJjSPdTpnpmlFvqAEb2NYHuv1AbpiYWxeJzqUnbNhsMkPY3btmq7fJKr/uog9TcV34wkFA4wTn+xYGkBDDK85wYyGhAKDytAPW3dSACxwiBD9sIfBqEk9Q3OIqT94DIh6FQ+s75SufefIwPph6dxXkM0VMINIUjeWqNuEWIvm8tIBwKOK8D102tMtbse96VkzjDeC4x2fTbj5ZzQ+invpGovWAxbjlxRIjuiDi3Vuk0/oDtjYCzCWe9HnJTg1f+Hd4rt4goUQDTGJnAv/nBOaUPTxF1t4Atyfe3oZ7v7zprHj6LRJZ9dvYfT6FbNIDxWdM/ABuSgujQq1Sog2yv9Pw4354udnBeFvw+sG+PmlKHubH5EmRuwzYCKMaeAzyBpom4l4D4qHQdlucvhWp37HOX0pMQP/8mIGVwHqvRLJ/5L4lu3eF4p3we6eL3g/DB/jqSXp8j5QQ9hk/AgMo/fwCgEuwn9cyMpZeY9NnH2rdd07k5XM/13Oh0p3eyDSusELPDx377UKtBcL1LV789cL8gVbxsVTgcdBJWNN95EMwZAXeRR9GOBQvQEYJaFYHVlYHgmAIRhZnsUNhyUv9yYcg2cLIBBGMhccG0lz/DMogW5VYyKFgfNzHLSjA3iFBwQlG74VcYdxgEDIRERrhxzDgERaCDyohVw2hETIhYATVUDXh8SRhFQZCFMoFEGIh+1xhF/KBFqYFF4Kh3nxhGdoK6GEGGaIhRjwhEYphG8rUGwZhHMohS9GhoDFDcXlRDfrBlAgCIGahGhaGUiQPDZxADMzgIsrSHRrCGaZGwYSEfgiiIlRiH1xiGBLiLXSJIhCAB0CWw3GgCE7WB5IiZnnA2iVDJuZIHp4TLiRAqvRHEaSOADxALa7Y1AnBRijK6zzC5I0CLXZXkQGAKagMAZyN1XiNAjnUpIDCjQxQC/bgJtoCWPABATBSI5Ee/74Rgi8JGgK6hiuOEstYgFJ8Hdt8waGUSQBUQQNYSVO4IxqkQfwUyfD8HauUibIUAfqhmWqhTABshH98QZbE2Yr1wwXehDW6ATYigSMxXTeqIjJMX1VBImpsGNiIwpt8Av5xiKDYYiKswicMxEbWg5oBQNCMgpIo0Pxs0Ce4TsmEF9UEEkLShEK2AUNCggG+XETSETg6SEWeBrpoZDq6CjOwYMqow9c9H739GYm9xbEI5JVIQDlCg/SQzDCICDW2gk2yAU4qgk76Hk9Gkk/mnAJGYrYMBVEWk1GaF5SAZDbs1VyRZDG1TbLgVnehkKagoxVICEpYCSu64FRw5Rp4pf8VYUUBVl9YysVEhiNQkoYJAkBhZWBh7UE+GYkEiIL6mWQSTCYEPYISXYkAoE4RPEuWZCAHTV4BdJfJEFhNiqVTZKNDvt8geKPukWUkOibibN862OFcvCaaxOY2Jh5ELiY4PhRpiGNsNIpX9KbS/WZhyibEEWda7B4ENMCkQIk0TkZyMlVbNScfuA0jIg8DZGM3JuYTIEChiOd6ttXb9NwCUA0PSgZ3HpV3aiUrhOd6kmfgnKf1qSd7Auh4xp8XxKdF5iZoMIrbqAHduYEhJhapmY4QMIkCTMPsRSYABqBXDOYzZCM79QFYoudvhl4gWCd2AiNo0OfgPKV1mlgfoEr/1h0BPZkObEmPanXC6ViBH05jWGyoFECncPpefzZBbUqfcZYlGB3nA9jNqX1Nnw0BWkxdpnXBT3BTZA4j7LTByWWCP5QTTbZEj0bBj3oGH4Co9YloKzDmT5rlaagZ6+SC1hgBo8DkzniQEWjpPU7CNWwB+tmD/rBFSWApGjxlEsnndzLEcwbnmHqZkDIBkc6ax6QoQWgYFpgYlijQGYjkAFlAN8TL97mBpyBBnEFfa34povLndN7VbRromqpGy7yJBUQlpg6k0OEpEngqP/jpLFUMJoTS+mmoqeYkoy6BoxbY00RqPGDmRohPquTjXX7B62gaq1UBBORDp2ISNJ0a/wchEfNFaxJpZ0fcZ0EA6zodph+U6ZCeKSuk6ZG6xwGkmgmVyTQcwNyMZryyzh4k6HWajxAcpz1FpmeugWqKJpPka1PIqK8K5rhqo6I+JG2mqySsK26yanjsYBHNHxDpAmh6KUao3yB8YihOwCieImSZ4shKVirKxWme4IE6hxfYXBvY10UdZ4bOhiEijygGqAzKZxse61UZqiNmE8sCbREObRf2LFX9LE1MYdGWlNAWbdK2BBsy7U5N7NSCq3hIrdWOh9MOLdRiRNZq7U5wLdB6bdiubNVabdmaLZ8crVjch8+1xeMRgtqug/6owAqQQEjp7d7uLc+O7WwQSwPcqf8iqOwt0K0fdCxj9NNAFVRCOe7jagAHPO7kIpQaQqZOta1o7cHKnIzbCAkyioKgdJw91N5GiEn3AGIZCYACCIo/pBqTOMkH/QK8IqxhgCmWLez2COsuyV93/q1sQAPqjEIVMGuiLEqjrJd+gBqOfqQwpCMfWYAoCC/YnVylRIq3YGhg2q47OUN0IiZUfQzaFk7m9hjVPAA5nY4CLYt6IhEo8MtgzWUmcQh3CcCmAtpBktjGpsXtIp+77G469W59/m5sbOTw2NZ9qCUadI8wKO/7hmQCu9kAoFcnXMoRwCq41G5h8G+4Dun/Wkj4+q74tuwesM4lmG4CC48ROIqtqoH/nD7wnyHPPpaWM2yYgx2uc1KR35RrsIKv9okwpA6wa9jLA5WE2yRwETVpiATS6sIvBFeCW4jmDHsRQApeYGxwQwLpovZwABMV+boG/0rBQVYxUGzEHpQx92Ixw9KmBwcECCsB54AOKwVx4YBxFAxuBk+FW2gClF2xrqixIJzr5PhwuKVBKCzAt+rmHBuhfQZGA/gE5wyQ3nJwo7KxrPCt/vTlD5EPSXnxSTGyXGiC3cDrEIGPMEzysFZyuZSygazKG1ualMrxDzsGT7pTzLqBAuhWNCSPlb6bV5zQF4TXYKWLDiOyFkeCGkpODaVjMRurIosFAtYbxvoBsyTAmqFJ/0XkgsaS6lR0UR9Xzh9/7zG7MWF5sjOXFAdRiZUEM5pAgDSIJnBVaNed5EmIiaZZqM2QUX/VMcN4EY7dMHiisR/r7hYnYAirx8Bkikm8ZMl0ybORDLRSa8OUX7K4ayKI6hjs0bwuZWuJ3xuXI5pQTTM9o/4+c0B/80CL8yALsCwbBtlIRTk2X2ROQxhkQTsTTR8dpAUoj5ZcaxJMBOYtQSujWUhcwy2dMi94852kssSMc091si24dNzsYSJUFMDgEAPY70r8jMAMCE930+shjxT9WLkUNUnzqEkrNUEbDkuzrTkzJ9wAwnqdXJYMTS5wbtfYoirAzkXcaoxuUhKM9f+VCElKiPQ27y9ae+hXLnUPNjXmuvVURPUqaIHz3Q3l7SKgRa8Kz88C2KMRVCn++ahPCEHoNukpdKlhl3QOn/SppjQXO/Vjx8fBCp+OEq1jCJuImEhHoYCM8HZvI8AGaIBvC/eLqCGD5tRTkwaEtgJGjTGPDEgKENQqS/d0K4jfsvUd/vPaMpp2t9BRc7cFIbdNZfc6LO13L0R4z9R4owPYmnefwLYSqrc3sHd7B8t1y2F8J8N80/e8vPcR4vd+W11/Q6F3AzgQ23cb/jetCVWBn4uAA8U9jG6wzawgFC4fVHh3z8ZtH4F+QwFdZIdwXPfDGgZ6o14ijEyIzNsXJZv/UwDd5hzDFy0B28AF22zEvPl0i+NxarAEhz+B+y1eeTZBBFw3gdOGgxuNlJVQAxUy5WVBFlQDoazMXGN1A1gzPzLlFTQ5AHiSlkNAqlzBYmTB1CXMvdQ4QGrCFTxegkPCjmex0i32E7xQkA/5dlNQIkyNmQiJE7eonaEBWkw0s155PRxkTI8ChtX4zuRvP2hKnHZ2QBA5RtRxIPi4JMQ5Ewh5Kzy6XJC48NmNMQ4lDFO1p4XYcZHM4MZvGPBjPKLa20ylsZAKGazF1DypWX9GpM/FmztBpS/BpbNCpqfFpudY7NwjR2IDJdBZNhDBTJy6ykjAilHxPozMXnI5GfSR/8X4+kKwRHnjJ643ga4rAa+rdd0ZeRsJ+84Q+3rVl6cJM/QAxLJzUAD4g20lKBoohklAQ1x6thLZsqxcO0GwOTgPwqRHgrcnAbi3NvEdeGHAbZqk7puy+Gxtl9nABaHHqCikyS9wa5m4VrbispOgswozx2plfI6jxr9XI7czAcEjgcG/Bp3rVP5Cdr/Lg8lvJcrLCZBb+pz3Wn2GhZorgq27+YLh/K7rvOoxOBPxxWx4+IfXhc3jytB/+3W4PFXl4Aru7CXIfDxk+4LXvNBLActj1dQ7RwFsdml1oh/cg5jwqxKo4B+Wz9ZYzVHSukb9B49/hdMngcofAdgvodg3x/9Ec5CSZQMD+3XGrXi5x4sD/lwbUPkjoKScRqYNZz070Py2e30U8P3c+v1tQKv5WIACMUCUEy819KUCiPpcfXoS3B8WTHZXfmYugEv2am9rVH5B4D0S6L0RZD5Ybb5tjMwDdP5IFgqfpsxTEj8mxUvrwRIO5SraSQWgGSNqgwbQg+ftYwzUF3zRI/x6HICgFMEqTF209Ii0bMJYpCXb97Truy+W9SrNfrGI3/3lQ8HuC8LkG824L0RWiCT2VgIQKBYAwGAAsByIy6WRSBAwiVGiExCQJgTbrUIKgC4bCcBhWCV8vwGs2v2Gx+Vz+jQtxVQydf5SYOgLZDJAoIs4Epz/a0tkbHSMGwhAfKSsFHRoIIBYgABgaIA4eIBIWDhakNg8KoWAcGA6YGA4KJBY8GISKKhCXKRTsCXYJVggYJg8i2OzZG72u2OqmKBwzgWsViM0nHT2xf52juQGJ3csSDBSAqiVAFAYSCBIq0VHfB/AfTIiODAiY0L35M44OfUGqCMAb4kxRd7KPXwjANoSadS+/YEIQNucQ98cZgRJR1xIks5SbVLX6Ba5AgtSwllWUqaaiuAEsMGZU+dOnj19/sRJcObQciOJHu2T8CAlYORa0YmJVOpUqlWtzjF6VetWSlG5fgUbViyjrGPNnvV6tlKePWrdvn1UFu5cqmnpCqp5/1fv3i9y+f7NaBewnLyDDbv1e1gxM8GLvxR2HFlrYsmV+zS2nFkzVcqbPa/5+Fn0aIidSXvGXJntadbfTHtWKmEXrH/MDtRmdPtRasmQSRIAGlz48J4TWwd6vXkAAwK2ZhPR3Sx6o+mMeEf2HUciMwKFGiG41gyBcWyh9ybXbEViAgmfFDQAkKCBgAfy6e9qsGAL/gQOJFABQJcl3otvvgfaYQCXTEoRYKVS9HOngQIA1EWI/eS4zrHs4NjOku4cAa+a8R4yTy/0MnOigCQGGEWBMJZbJwAlGmhnNhoDlOgAB8joj4kXGVjHgiLgU7GA2Vy5YhcvwhCgEwiieGCXBP+AVKbE46TosJIPvwuPmRHLsZKuEy1jsUEyrHixF14AeJK+IzpkcqI0icDiACElgE8BBxqMwgFT0gijRwcgIMCCLSCs8ko6sqRkS0ZCdOZLcsKca8zKrFgTjCisaMMIBaIs4k1oRnlAijmvIIKBUpSwYEkqgEkiDAAe+BSMZBoibbU6GH3E0UQgFY+8aiiFy1LJMA31iU3VDPXTAg4QQNQlEggAN02TRRWMB6hotYD5ijCSVllZRASVMqxVI8PFNoxIWEZ8FQRYL91thti3jI0sAdz0JYJAfgMkgl8tGJCAjAbysfMLf/8B0IE7FBBgR/j+azJC6ARcZ75BMbT3MHb/3eDVEXgDkdcSScHpWC18FeUDWavU5WqXAebpA7LZonhunQBpbtS7R7s0mV7GiJCZ50aK1pmJYY7IuZmVWabDgaargnkrBwYYw79eJRKglOeuXqC/dnoGEehKTvaIiKuzHruRtcWWQgKJB3gFm6ehNosLvW9KWSsIAqC1kgkDgE+Kv4kjzudfzaYEAcQf32mJvwOnZPJ8mPg0gE5ckwRvx+QBHfSqtYJiCwdemkNXoul+IGwf6YsY9XcVj5fxR9AuT1nTZQ+k9Nil0NHPkC25my5vt5DNnan7qOcApfjx54sGqGzEFSqOH0DKW2Hq26rsZ1YA3Tgg0wTg7JuYkIDw/7WknWTbQRTakk4LAF/8Pr5X39oEXPyec6EkE0A7+pGG4fFBCLKJxSxqsRJYAIgsDDCS2trRgMIphGN74QdepqEG+xUwESPrQ8nOFr9K+CKDHuIddEjoiOLNJQA5U4AFIKSfBRTOFl1wh34w9oxMyYoJzAmYgdpGBwvkrA0qItr23DC6wXxMDR4UBAj5IMLGrXA3i2khXBrwgDGoo0OzuYUQ7DArKVFvjNjy4RKSASMkAmRvlyPAtragBMot4nQX9BzIrEgHKdaBirfbYyO6N5YswgUYDAhchwawBQsoxQ6FOpQDd9ZDSQIsUx2TVXtsFbFFzAyPefwCFHvXvhC+7/87gbQOFjtHmgZIS252UI88lMhDNFYSQJzKwhsxd4Y0EqBuRSAhEwGjujmIMimknKIpH4XKRAxSLIV0iwO8YIY07KgWr4ij+qIkijSYqzqTrGUom8CsOnACAFrbBTWXILVPfsaJoWQmHPpIhz/Cj0Sq/F++9uSwfjngFfPBmheeNIBiZCximyPCfAQQvi3sbwuFa8I//lXJOBSAAQHslwCAeDFcjeadWIrnG+Y5h3qe8p6KgaZjOiGK5SWiJS1lBj/b6ZmPggM4kMNpTkN6pZQu5qLSbIZ8yCHUjoLSqKDs6VG5IkylNjUySXXqy5y5F2JG9ahQtepUmMqXmma1NVj/9epRtrqXroaVNGA160zGqpeypvUzaHUrSdYaV7pyBa51hchc8brXqdyVryibql6q+tfR+JWwwwrsXdr6FheFzrGPhWxkJTvZx8KUL4Y1S5lc9zpnpPGDFL1MYqVSgMvVYbFuEYAGELBa1rbWtQjYgGpfO1va1ta1G0ClAix7FcwSkmm0OkBwdTvN22SvH/+4x8NI66KFPIe0ZSiuEoTRr+BKwIK18CRpCwCN6aJjhXpFimfpcFq1YMSPyqxiH4xZld4+s1wJWUANXxQ2W2SioKkgBgH1k4AHKEEUnCUoe/r0D1qRwhinSAU2o5CEMgjpGFBA6BvAexTxXsm89EQv/yDVu1OZtDcsy4FvEah0qk4hIiHRCtA/sAaAVgJYTU+6ljvas2CEhqHF6XiAPP4zU7hU+DgXJmmG7cmH9XJmlcdZJDxkZuJl0YkXLcnEMcBZpCK62MmzigUZGDCoHfvSUNf6b3/jaAQLcg+DoI3DYAcDZDmUdIQbPouHwYIsNDU5W/ugghOydFEzXguXAGhPqbIVBjDKgwqYeIWdZrPbK4g2vGiGA3nPwuY4uDm9ROZwSeT8FTozGVslhjIDTAFOd8jIVHY+4iq3rNBZUXAB26XC3+7A3+X0OV2OpjCk3yDpvAmZCJbWMKbjfOTWBBcW6niuscEAHSVsN7hK0O1CKv+ZbIQM6Dnqey4Y7pDtZS9hu6VdIq6J4uPxbdAxlIYDsIe8q0yTZNOfKbJMJjxuXZMG3W9Qt0mFnVliH/YJfSVzwOc9lPxS1uAHR3jCFb5wyC7A1wDI96MksPCC8juf/j5KwAUuboIbam8fBzkLRmACkJfc5CdHecpVvnILPDziv9LhygXQyGFfXDLOAzdEmsKM7YKOTRE2s17IHWlzL+bebnh5vFAZb6m8WyoXZZ3FHHETXQipX0pkYPUANOYUuaSodBn6rouumKOrIekkW3q7Q+L0o4ixX/EpBi3QkbwywGPb1pVdGzbG4iHGBxHBRUcK35CfrUuSITx+S9jdwOv/sZT9C2cPYdprLho7RZhc6pv4joVACixMKAEokUIbpkSE/mJpNgHeMSwcOzUfjhk3swTNmfPoeClAfoqSt/honhQA1/mwuFhQlZP7Iw8pM+GIQnI7E9ZITn0EXHa+J5Q/xRBMjs9E8aOhPRNs70fcE7Lfn4mhi6hQinhgoUNYSPI+Qr9OCNwIS+O88hKcFzrWU7ST1Jd9INQMmOwvYfv07L5n+j7LoAU1Er8zAr5/wAIt8Lb1CxgHYLD3uyRT0bjnA5DZ+K+EyrnQqz6ZuL7HGLvD6L9fe7hfCcAPG8DK+JRjEAAisYABIAVTcAAs+JTlaAOo05omWCUV+SUmuKNP/2MeRFqK/2CR2oA9Dsy/mglBwxhBiCtBpYOz3BsNeUiJ7VISQCEaYbC6MjihhZCHAeGdw1O23AIdDJyugLE5OunAkiCQQGA8sRAADjCAOaTDOrRDA9AAObzDPeTDPrRDDUClg5m8o/KlRbIfQegacnCWr8M4olAomYPESPy4DfwLtjsLFxE8QdguRcxE41vDRgRF4knBUKSaTxSL/SNFx7DEVES8zHhDVlSZUYRFsTLFsHjFWfS+NMTFkhg4tbjFXZwzWQRGXqzFYTTGKhDGYwyMYlRGYFzFZuzFs0DFZqyUZKTGSWFGrvjFa+wra+TG8sjGrdjGb8w4byTHegkASf9Ux3Vkx0gUOZJrx3iUx3mkx3q0x3tkxwcwx3OUn5zyx38EyIAUyIEkyII0yINESH/URX7kDh0rBoqbuMgKgIaLSFmqyGBojoecSGKISFRQOFlguI0EHY+0yJIEDuJjDpD8SOaILIwMHZc0yZM0yY2cSJhEOJWELJwEHZ10SYz0yWJQSZJEOJt0LJ2MSZmUB5EESYwMyorsRIbEhg/MBXr5CEbJElmRlTboEKZzGUUAKVo6vzXpSkjIJ/HyrCxZhLBEFamEPzfoSmRpPSrASjtjuqHrSkbxhU46gnFBBKaDys6qN3iSsCeaiKuUSyrQyjvgyoU0vq88I7V0grGEA8n/jDHOmsolSMs7aAMsYMtMUYO35Ia4VJbRjCU+sEuCwMvGXBO+PKO/LInOJLU1IMzLHM0YS8zWxArGxEzHBCfIPALKdMuyrKSzhIbMvDLODEwpoEzQtMwYm0tsqUtIu8uJyEv4Y83YdE2QgM0EEDyh4E6ASInoiA5E+E7sjIMvvJ8sSInyLE8TSwPgVAP0VINvOhf1bIJpUQdE2Mvk9BF6kU8vpA35+wfxJAP0ZDr67M8vKM8qYIJJ+MLoMFC1y87e4c+j8MsO003rq1CiuFCZ6NAJFZkNHYoPXbsM9UARnQkSDQkVBdEoQlEPlVBygE+pgM0UjVFyYNEW7QME1YoF/+WK/9wKHr0KH+UKItXRI0XSJFXSJWXSJnXSJx2NvrOKc/A2qKOKUBiQPdkci0KxmRiiRYKgfqqYdbDScqBSoilTpUnTJwEqd9DSZmAuMd3SNK3SLmWTiMEFPRlTKHUDYwhHQdACACGYczpEkDiABqA50tOt0hvUHXlNBliEHtGkWVlUJWjUQqWEQF2CS5UCTmWpWqHUAii9SiCXJaAVUbXUdnDUH1JVMvhUQTvVUeXTL3CePw0EYAAQUIEAWyuJ7ao4M0goMtBVXi2HWt3UThDVMjiDMSAjNiFWS8BVU92FXZWCYS0QInAJYGUxTDXN4tNWZrVWJrBWosrWZeXWJ/+1VQrdzcq00DtgzTao0RKiJeRcE3h9UdMEEHt1wFORiOskVU9LFn1VTX41NM+cVdn80XytTaSAkzw7AoHlxXmNMSeA2G/woYodNLosWGz519qk2IW9MoL114N1wK3woXBl2Dv4VmGd1mcFk2Ndh1JZ2WalVnI42ZatVpwl1+AyV2awgplFWdLT2cIp12Al2XT5Ch/iVKnIklhNVUJVq2l5hUl1Wk9o1XJQ2qtlsTTw1CgB1aolnkmo2qXNBKuF2ldVVFQ9WjdqKK14RC/gUhPFBoh5KDlFUzsNiUBNxCLQqNnQ0znFW2x4WzK10yqLW8nBU7u1BL1R3MMlAsNd08T/ddM9XdvKxSCXvYrDs9zN3YwuFAvP5dzQFd3RJd3SNd3TRd3UVd3VZd3Wdd3Xhd3Yld3Zpd3atd3bxd3c1d3d5d3e9d3fBd7gFd7hJd7iNd7jRd7kVd7lZd7mdV5FiVNBiN4+mN7nhV09YYOKaxPBg4LamEHA8QK6rdtccKabcAOIKZz5uJwH6MHzbUHrHV07CYBjGLVzYgMpnQI2EFu6ARwwCACPg6j8HZAzdAPn8aLQAA4quAlo+JsIs0J3wIUEhl/RbYAj86907N/PvAmCWAbgiLtQ6jy+qZYC4D02IRwWwwkgMd/4TMf8hQYHELQreAAL4D1I1Rz/vdcJ1tEF/44bzVmAAPACg9DBcaAWILmp+8USLKjgRS2VGTxUIP4bVZWRFf4CCQ6QiYSOIwMcVyCcv4kCK9Zhy70JoNNHPwWSRxxiH5GhXXgW//UG8xXhZYji1ikCnYACBG7hK74DCTA1OtkULG5hMA7jtaUWrzMwnaiyvjgyasEY9fHfLRRgSMUFdbAAfWwHahkbI1lhCRgiBchgfcSFbTG+P06DQM7jQa7cOLZBXJhBdKEPwPliO44EnLAW842hdPzhVGEDNv5h/ZhI8yXhAPYE3vvhEauWUa7jUo5lnMhhVP5LCDCCTrCuhYDBvgi4unO+c/AUBUUEbcYH6CgzNolmvzNh2USB5mpOFUguggJdCoXoBzI7V2fW4emZg2CW53uGVkbD533m5372538G6IAW6IEm6II26ING6IRW6IVm6IZ26IeG6MMKAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Box",
"    </strong>",
"    : range of the middle 50 percent of the CA-125 levels;",
"    <strong>",
"     line inside the box",
"    </strong>",
"    : median;",
"    <strong>",
"     whiskers",
"    </strong>",
"    : the 5th and 95th percentile;",
"    <strong>",
"     *",
"    </strong>",
"    : data points that lie outside the whiskers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Van Calster, B, Timmerman, D, Bourne, T, et al. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst 2007; 99:1706. Copyright &copy;2007 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_0_15361=[""].join("\n");
var outline_f15_0_15361=null;
var title_f15_0_15362="Androgens in the development of the pilosebaceous unit";
var content_f15_0_15362=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Androgens in the development of the pilosebaceous unit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Solid lines indicate effects of androgens; dotted lines indicate effects of antiandrogens. Hairs are depicted only in the anagen (growing) phase of the growth cycle. In balding scalp (bracketed area), terminal hairs not previously dependent on androgen regress to vellus hairs under the influence of androgen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rosenfield RL, Deplewski D. The role of androgens in the development of biology of the pilosebaceous unit. Am J Med 1995; 98:80S. Copyright &copy; 1995 Excerpta Media, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_0_15362=[""].join("\n");
var outline_f15_0_15362=null;
var title_f15_0_15363="Patient information: Neck fracture (The Basics)";
var content_f15_0_15363=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83611\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/46/15074\">",
"         Anatomy of the neck",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"          Foods and drinks with calcium and vitamin D",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/61/25554\">",
"         Patient information: Advance directives (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/12/36034\">",
"         Patient information: Calcium and vitamin D for bone health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/34/30243\">",
"         Patient information: Fractures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/31/23026\">",
"         Patient information: Neck pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/53/27475\">",
"         Patient information: Paraplegia and quadriplegia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/60/23491\">",
"         Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/35/27188\">",
"         Patient information: Neck pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/13/19670\">",
"         Patient information: Quitting smoking (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Neck fracture (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/neck-fracture-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H865629768\">",
"      <span class=\"h1\">",
"       What is a neck fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A &ldquo;fracture&rdquo; is another word for a broken bone. A neck fracture is when a person breaks 1 of the bones in the neck. The medical term for the bones in the neck is &ldquo;cervical vertebrae&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef72120 \" href=\"UTD.htm?14/46/15074\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      There are different types of neck fractures, depending on which bone breaks and how it breaks.",
"     </p>",
"     <p>",
"      Some neck fractures are much more serious than others. In a serious neck fracture, the bundle of nerves that runs down the back (called the spinal cord) can also be damaged. This can lead to paralysis. Paralysis is when people are unable to move certain muscles or parts of their body.",
"     </p>",
"     <p>",
"      Because a serious neck fracture can lead to paralysis, people with a possible neck fracture should lie still and not move (or be moved) after an injury. They should wait for emergency workers, who can bring them safely to the hospital. Otherwise, if people with a possible neck fracture move (or are moved), it could make their neck fracture and spinal cord damage much worse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H865629800\">",
"      <span class=\"h1\">",
"       What are the symptoms of a neck fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of a neck fracture can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Neck pain",
"       </li>",
"       <li>",
"        Neck muscle tightness or spasm",
"       </li>",
"       <li>",
"        Being unable to move the neck or turn the head",
"       </li>",
"       <li>",
"        Weakness or paralysis in the arms or legs",
"       </li>",
"       <li>",
"        Numbness or tingling in the arms or legs",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H865629815\">",
"      <span class=\"h1\">",
"       Is there a test for a neck fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will ask about your symptoms and do an exam. He or she will also order a test, such as an X-ray or CT scan. A CT scan is an imaging test that creates pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H865629830\">",
"      <span class=\"h1\">",
"       How is a neck fracture treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the type of neck fracture a person has, how serious it is, and whether it also causes paralysis.",
"     </p>",
"     <p>",
"      People with a severe neck fracture or paralysis are treated in the hospital. There, the doctor can monitor them and treat their medical problems. For example, some people might need a breathing tube to help with breathing or medicines to help reduce swelling in the spinal cord.",
"     </p>",
"     <p>",
"      A severe neck fracture is treated with surgery. During surgery, the doctor will put the neck bones back in the correct position. He or she will attach (fuse) the bones to each other so they stay in place.",
"     </p>",
"     <p>",
"      Neck fractures that are not as serious are usually treated with a special neck collar or brace to hold the neck in place so it can&rsquo;t move. People need to wear the collar or brace until their fracture heals.",
"     </p>",
"     <p>",
"      Treatment for a neck fracture also includes medicine to treat the pain. Doctors can prescribe a strong pain medicine if people have a lot of pain or a severe fracture. For mild fractures, doctors usually recommend that people take an over-the-counter pain medicine. Over-the-counter medicines include",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (sample brand name: Tylenol&reg;),",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;), and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"       naproxen",
"      </a>",
"      (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"     </p>",
"     <p>",
"      After your fracture heals, you might need to work with a physical therapist (exercise expert). He or she will teach you exercises to strengthen your neck muscles and help your neck move more easily.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H865629862\">",
"      <span class=\"h1\">",
"       How long does a neck fracture take to heal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A neck fracture usually takes months to heal, depending on the fracture.",
"     </p>",
"     <p>",
"      Healing time also depends on the person. Healthy children usually heal much more quickly than older adults or adults with other medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H865629877\">",
"      <span class=\"h1\">",
"       Can I do anything to improve the healing process?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It&rsquo;s important to follow all of your doctor&rsquo;s instructions while your fracture is healing. Plus, doctors usually recommend that people with a fracture:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eat a healthy diet that includes enough calcium, vitamin D, and protein (",
"        <a class=\"graphic graphic_figure graphicRef79375 \" href=\"UTD.htm?18/13/18647\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Stop smoking. A fracture can take longer to heal if you smoke.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H865629915\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor or nurse will tell you when to call him or her. In general, you should call if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You can&rsquo;t move your arms or legs.",
"       </li>",
"       <li>",
"        You have no feeling in your arms or legs.",
"       </li>",
"       <li>",
"        You have no control over your bladder or bowel.",
"       </li>",
"       <li>",
"        You have problems with your neck brace, such as fluid draining from around the screws or sores where the brace presses on the skin.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H865629930\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/31/23026?source=see_link\">",
"       Patient information: Neck pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=see_link\">",
"       Patient information: Fractures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/53/27475?source=see_link\">",
"       Patient information: Paraplegia and quadriplegia (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=see_link\">",
"       Patient information: Advance directives (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/35/27188?source=see_link\">",
"       Patient information: Neck pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       Patient information: Quitting smoking (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?15/0/15363?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83611 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_0_15363=[""].join("\n");
var outline_f15_0_15363=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865629768\">",
"      What is a neck fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865629800\">",
"      What are the symptoms of a neck fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865629815\">",
"      Is there a test for a neck fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865629830\">",
"      How is a neck fracture treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865629862\">",
"      How long does a neck fracture take to heal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865629877\">",
"      Can I do anything to improve the healing process?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865629915\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865629930\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83611\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/46/15074\">",
"      Anatomy of the neck",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"       Foods and drinks with calcium and vitamin D",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=related_link\">",
"      Patient information: Fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/35/27188?source=related_link\">",
"      Patient information: Neck pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/31/23026?source=related_link\">",
"      Patient information: Neck pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/53/27475?source=related_link\">",
"      Patient information: Paraplegia and quadriplegia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_0_15364="Major branches of the ulnar nerve at the wrist";
var content_f15_0_15364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F57601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F57601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Major branches of the ulnar nerve at the wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 656px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This illustration describes the major branches of the ulnar nerve at the wrist. The numbers 1 to 4 relate to the main sites of clinical syndrome associated with injury to the nerve:",
"    <br>",
"     <ol>",
"      <li>",
"       Main trunk of the nerve proximal to or within Guyon's canal.",
"      </li>",
"      <li>",
"       Deep motor branch proximal to the branches supplying the hypothenar muscles.",
"      </li>",
"      <li>",
"       Deep motor branch distal to the hypothenar muscles.",
"      </li>",
"      <li>",
"       Superficial branch (mainly sensory).",
"      </li>",
"     </ol>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_0_15364=[""].join("\n");
var outline_f15_0_15364=null;
var title_f15_0_15365="Principles of Doppler echocardiography";
var content_f15_0_15365=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Principles of Doppler echocardiography",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/0/15365/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/0/15365/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/0/15365/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/0/15365/contributors\">",
"     Nelson B Schiller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/0/15365/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/0/15365/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/0/15365/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While M-mode and 2D echocardiography create ultrasonic images of the heart, Doppler echocardiography utilizes ultrasound to record blood flow within the cardiovascular system. Doppler echocardiography is based upon the changes in frequency of the backscatter signal from small moving structures, ie, red blood cells, intercepted by the ultrasound beam.",
"   </p>",
"   <p>",
"    The principles of Doppler echocardiography will be reviewed here. The principles of other echocardiographic techniques, as well as the normal views and protocol for an echocardiogram, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4662?source=see_link\">",
"     \"Echocardiography essentials: Physics and instrumentation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7897?source=see_link&amp;anchor=H2#H2\">",
"     \"Tissue Doppler echocardiography\", section on 'Technical aspects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14167?source=see_link\">",
"     \"Transthoracic echocardiography: Normal cardiac anatomy and tomographic views\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BASIC PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A moving target will backscatter an ultrasound beam to the transducer so that the frequency observed when the target is moving toward the transducer is higher and the frequency observed when the target is moving away from the transducer is lower than the original transmitter frequency (",
"    <a class=\"graphic graphic_figure graphicRef70672 \" href=\"UTD.htm?33/6/33891\">",
"     figure 1",
"    </a>",
"    ). This Doppler phenomenon is familiar to us as the sound of a train whistle as it moves toward (higher frequency) or away (lower frequency) from the observer. This difference in frequency between the transmitted frequency (F[t]) and received frequency (F[r]) is the Doppler shift:",
"   </p>",
"   <p>",
"    &nbsp;Doppler shift (F[d]) &nbsp;= &nbsp;F[r] &nbsp;- &nbsp;F[t]",
"   </p>",
"   <p>",
"    Blood flow velocity (V) is related to the Doppler shift by the speed of sound in blood (C) and &oslash;, the intercept angle between the ultrasound beam and the direction of blood flow. A factor of 2 is used to correct for the \"round-trip\" transit time to and from the transducer.",
"   </p>",
"   <p>",
"    &nbsp;F[d] &nbsp;= &nbsp;2 &nbsp;x &nbsp;F[t] &nbsp;x &nbsp;[(V &nbsp;x &nbsp;cos &oslash;)] &nbsp;&divide; &nbsp;C",
"   </p>",
"   <p>",
"    This equation can be solved for V, by substituting (F[r] &nbsp;- &nbsp;F[t]) for F[d]:",
"   </p>",
"   <p>",
"    &nbsp;V &nbsp;= &nbsp;[(F[r] -F[t]) &nbsp;x &nbsp;C] &nbsp;&divide; &nbsp;(2 &nbsp;x &nbsp;F[t] &nbsp;x &nbsp;cos &oslash;)",
"   </p>",
"   <p>",
"    Note that the angle of the ultrasound beam and the direction of blood flow are critically important in the calculation (",
"    <a class=\"graphic graphic_figure graphicRef52145 \" href=\"UTD.htm?22/33/23071\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For &oslash; of 0&ordm; and 180&ordm; (parallel with blood flow), cosine &oslash; = 1",
"     </li>",
"     <li>",
"      For &oslash; of 90&ordm; (perpendicular to blood flow), cosine &oslash; = 0 and the Doppler shift is 0",
"     </li>",
"     <li>",
"      For &oslash; up to 20&ordm;, cos &oslash; results in a minimal (less than 10 percent) change in the Doppler shift",
"     </li>",
"     <li>",
"      For &oslash; of 60&ordm;, cosine &oslash; = 0.50",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The value of &oslash; is particularly important for accurate assessment of high velocity jets, which occur in aortic stenosis or pulmonary artery systolic hypertension. It is generally assumed that &oslash; is 0&ordm; and cos &oslash; is therefore 1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Spectral analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the backscattered signal is received by the transducer, the difference between the transmitted and backscattered signal is determined by comparing the two waveforms with the frequency content analyzed by fast Fourier transform (FFT). The display generated by this frequency analysis is termed spectral analysis. By convention, time is displayed on the x (horizontal) axis and frequency shift on the y (vertical) axis. Shifts toward the transducer are represented as \"positive\" deflections from the \"zero\" baseline, and shifts away from the transducer are displayed as \"negative\" deflections (",
"    <a class=\"graphic graphic_figure graphicRef81517 \" href=\"UTD.htm?32/55/33663\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Multiple frequencies exist at every time point. Each received frequency is displayed, with the magnitude (or amplitude) shown as the \"brightness\" of each frequency shift component.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DOPPLER MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several Doppler methods used for cardiac evaluation &mdash; continuous wave, pulsed wave, and color flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Continuous wave Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous wave Doppler employs two dedicated ultrasound crystals, one for continuous transmission and a second for continuous reception of ultrasound signals. This permits measurement of very high frequency Doppler shifts or velocities. The \"cost\" is that this technique receives a continuous signal along the entire length of the ultrasound beam. Thus, there may be overlap in certain settings, such as stenoses in series (eg, left ventricular outflow tract gradient and aortic stenosis) or flows that are in close",
"    <span class=\"nowrap\">",
"     proximity/alignment",
"    </span>",
"    (eg, aortic stenosis and mitral regurgitation). Differentiation of the signal from each component may still be determined from the characteristic timing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    profile.",
"   </p>",
"   <p>",
"    An ideal Doppler profile is one with a smooth \"outer\" contour, well-defined edge and maximum velocity, and abrupt onset and termination (",
"    <a class=\"graphic graphic_figure graphicRef77381 \" href=\"UTD.htm?10/33/10783\">",
"     figure 4",
"    </a>",
"    ). The continuous wave Doppler profile is usually \"filled in\" because lower-velocity signals proximal and distal to the point of maximum velocity are also recorded. Although the maximum frequency shift depends on &oslash;, the profile, onset, and termination of the Doppler signal are not dependent upon this value, resulting in inappropriate underestimation of true velocity. For this reason, continuous wave Doppler positioning is often integrated with 2D and color flow imaging to allow for good alignment with flow, ie, &oslash; less than 20&ordm;.",
"   </p>",
"   <p>",
"    Continuous wave Doppler is typically used to measure higher velocities as in pulmonary hypertension and aortic stenosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76308 \" href=\"UTD.htm?8/38/8800\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef63455 \" href=\"UTD.htm?43/41/44703\">",
"     waveform 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pulsed Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to continuous wave Doppler which records signal along the entire length of the ultrasound beam, pulsed wave Doppler permits sampling of blood flow velocities from a specific region. This modality is particularly useful for assessing the relatively low velocity flows associated with transmitral or transtricuspid blood flow, pulmonary venous flow, left atrial appendage flow, or for confirming the location of eccentric jets of aortic insufficiency or mitral regurgitation (",
"    <a class=\"graphic graphic_figure graphicRef87117 \" href=\"UTD.htm?27/1/27671\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81391 \" href=\"UTD.htm?13/18/13601\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    To permit this, a pulse of ultrasound is transmitted and then the receiver \"listens\" during a subsequent interval defined by the distance from the transmitter and the sample site. This transducer mode of transmit-wait-receive is repeated at an interval termed the pulse-repetition frequency (PRF). The PRF is therefore depth-dependent, being greater for near regions and lower for distant or deeper regions.",
"   </p>",
"   <p>",
"    The distance from the transmitter to the region of interest is called the sample volume, with the width and length of the sample volume varied by adjusting the length of the transducer \"receive\" interval. In contrast to continuous wave Doppler, which is sometimes performed without 2D guidance, pulsed Doppler is always performed with 2D guidance to determine the sample volume position",
"   </p>",
"   <p>",
"    Because pulsed wave Doppler echo repeatedly samples the returning signal, there is a maximum limit to the frequency shift or velocity that can be measured unambiguously. Correct identification of the frequency of an ultrasound waveform requires sampling at least twice per wavelength. Thus, the maximum detectable frequency shift or the Nyquist limit is one-half the PRF. If the velocity of interest exceeds the Nyquist limit, \"wraparound\" of the signal occurs first into the reverse channel, then back to the forward channel; this is known as aliasing.",
"   </p>",
"   <p>",
"    Techniques that can minimize aliasing during pulsed Doppler include using a lower frequency transducer and shifting the baseline. Another solution is to increase the number of sample volumes, or high PRF. As noted above, when a pulse is transmitted, backscatter along the entire length of the beam is received. Depth resolution is achieved with pulsed Doppler using the duration of the \"wait\" period. However, signals from exactly twice (or 3x, 4x, etc) the distance will reach the transducer during the \"receive\" phase of the next (or subsequent) cycle. As a result, signals from 1x, 2x, 3x, 4x, 5x, etc have the potential for analysis.",
"   </p>",
"   <p>",
"    The latter signals are generally of low amplitude and do not interfere with the spectral display. If, however, the sample volume is deliberately placed at one-half the depth of interest, backscattered signals from the 2x sample volume, the true depth of interest, will return to the transducer during the \"receive\" phase of the following cycle. This recording of signal at a higher PRF permits measurement of higher velocities without signal averaging. Even greater velocities could be achieved using additional sample volumes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Color flow imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler color flow imaging is based upon the principles of pulsed wave Doppler echocardiography. Along each scan line, a pulse of ultrasound is transmitted, and the backscattered signals are then received from each \"gate\" or sample volume along each line. In order to calculate accurate velocity data, several bursts along each scan line are used, known as the burst length. The process is performed for each scan line across the image plane. As with pulsed Doppler, the PRF is determined by the maximum depth of the Doppler signals.",
"   </p>",
"   <p>",
"    With color flow imaging, velocities are displayed using a color scale, with flow toward the transducer typically displayed in",
"    <span class=\"nowrap\">",
"     <strong>",
"      orange/red",
"     </strong>",
"    </span>",
"    and flow away from the transducer displayed as",
"    <strong>",
"     blue",
"    </strong>",
"    . Lighter shades are assigned higher velocities within the Nyquist limit (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54278 graphicRef68049 \" href=\"UTD.htm?41/44/42693\">",
"     image 3A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57208 graphicRef68945 \" href=\"UTD.htm?40/61/41942\">",
"     image 4A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75366 \" href=\"UTD.htm?8/36/8771\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59244 \" href=\"UTD.htm?30/20/31044\">",
"     image 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    At the Nyquist limit, and each multiple of the limit, aliasing is depicted as color reversal. Turbulent flow is characterized by varied blood velocities and directions. The variance of velocities within jets is usually color coded as",
"    <strong>",
"     green",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    Color flow imaging is typically used in the screening and assessment of regurgitant flows (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79069 \" href=\"UTD.htm?15/58/16288\">",
"     image 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55534 graphicRef77039 \" href=\"UTD.htm?15/41/16023\">",
"     image 8A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef65598 \" href=\"UTD.htm?35/3/35892\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef80498 \" href=\"UTD.htm?2/25/2448\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef70063 \" href=\"UTD.htm?25/7/25716\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef76115 \" href=\"UTD.htm?7/27/7604\">",
"     movie 4",
"    </a>",
"    ). It is also useful in the assessment of intracardiac shunts (eg, atrial and ventricular septal defects) and pulmonary vein flow, and to assist in continuous wave Doppler alignment for tricuspid regurgitation velocities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RELATIONSHIP BETWEEN DOPPLER VELOCITY AND PRESSURE GRADIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most powerful attributes of Doppler echocardiography is the ability to estimate the pressure difference across a stenotic valve (eg, aortic stenosis) or between two chambers (eg, estimation of the pulmonary artery systolic pressure from the tricuspid regurgitation velocity). This relationship is defined by the Bernoulli equation and is dependent on the velocity proximal to a stenosis (V1), velocity in the stenotic jet (V2), density of blood (p), acceleration of blood through the orifice",
"    <span class=\"nowrap\">",
"     (dv/dt),",
"    </span>",
"    and viscous losses (R[v]). The pressure gradient",
"    <span class=\"nowrap\">",
"     (&Delta;P)",
"    </span>",
"    can be calculated from:",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     &Delta;P",
"    </span>",
"    &nbsp;= &nbsp;[0.5 &nbsp;x &nbsp;p &nbsp;x &nbsp;(V2 x V2 - V1 x V1)] &nbsp;+ &nbsp;[p &nbsp;x &nbsp;",
"    <span class=\"nowrap\">",
"     (dv/dt)]",
"    </span>",
"    &nbsp;+ &nbsp;R[v]",
"   </p>",
"   <p>",
"    If one assumes that the last two terms (acceleration and viscous losses) are small, and then enter the constants, the formula is simplified to:",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     &Delta;P",
"    </span>",
"    (mmHg) &nbsp;= &nbsp;4 &nbsp;x &nbsp;(V2 x V2 - V1 x V1)",
"   </p>",
"   <p>",
"    In most settings, V2 is greater than V1 by a factor of three or more. Thus, the terms (V2 x V2 - V1 x V1) is close to V2 x V2. As an example, 3 x 3 - 1 x 1 = 9 - 1 which is almost equal to 9.",
"   </p>",
"   <p>",
"    Thus, the Bernoulli formula may be further simplified (",
"    <a class=\"graphic graphic_figure graphicRef63058 \" href=\"UTD.htm?5/12/5313\">",
"     figure 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef52855 graphicRef60384 \" href=\"UTD.htm?35/21/36185\">",
"     waveform 2A-B",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     &Delta;P",
"    </span>",
"    (mmHg) &nbsp;= &nbsp;4 &nbsp;x &nbsp;V2 x V2",
"   </p>",
"   <p>",
"    It is important to remember that this simplified Bernoulli formula measures the",
"    <strong>",
"     pressure",
"    </strong>",
"    &nbsp;",
"    <strong>",
"     difference",
"    </strong>",
"    , not absolute pressure. In addition, it is imperative that accurate measurement of V2 be obtained. Due to the squaring of V2, a 10 percent error in V2 will result in a 20 percent error in the pressure estimate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1208?source=see_link\">",
"     \"Aortic valve area in aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H738946\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A moving target will backscatter an ultrasound beam to the transducer so that the frequency observed when the target is moving toward the transducer is higher, and the frequency observed when the target is moving away from the transducer is lower than the original transmitter frequency (",
"      <a class=\"graphic graphic_figure graphicRef70672 \" href=\"UTD.htm?33/6/33891\">",
"       figure 1",
"      </a>",
"      ). This difference in frequency between the transmitted frequency and received frequency is known as the Doppler shift. This principle can be used in the measurement of blood velocity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Basic principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several Doppler methods used for cardiac evaluation &mdash; continuous wave, pulsed wave, and color flow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Continuous wave Doppler employs two dedicated ultrasound crystals, one for continuous transmission and a second for continuous reception of ultrasound signals. This permits measurement of very high-frequency Doppler shifts or velocities. The \"cost\" is that this technique receives a continuous signal along the entire length of the ultrasound beam, which may result in overlapping signals in certain settings (eg, left ventricular outflow tract gradient and aortic stenosis, aortic stenosis and mitral regurgitation). Continuous wave Doppler is typically used to measure higher velocities as in pulmonary systolic hypertension and aortic stenosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Continuous wave Doppler'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to continuous wave Doppler, which records signal along the entire length of the ultrasound beam, pulsed wave Doppler permits sampling of blood flow velocities from a specific region, a technique that is particularly useful for assessing relatively low velocity flows. A pulse of ultrasound is transmitted and then the receiver \"listens\" during a subsequent interval defined by the distance from the transmitter and the sample site. As a result, pulse wave Doppler is always performed with 2D imaging to localize the same volume. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pulsed Doppler'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Doppler color flow imaging is based upon the principles of pulsed wave Doppler echocardiography. Along each scan line, a pulse of ultrasound is transmitted, and the backscattered signals are then received from each \"gate\" or sample volume along each line. With color flow imaging, velocities are displayed using a color scale. Color flow imaging is typically used in the screening and assessment of regurgitant flows, intracardiac shunts and pulmonary vein flow, and to assist in continuous wave Doppler alignment for tricuspid regurgitation velocities. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Color flow imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the most powerful attributes of Doppler echocardiography is the ability to estimate the pressure difference across a stenotic valve (eg, aortic stenosis) or between two chambers (eg, estimation of the pulmonary artery systolic pressure from the tricuspid regurgitation velocity). This relationship is defined by the Bernoulli equation and is dependent on the velocity proximal to a stenosis, velocity in the stenotic jet, density of blood, acceleration of blood through the orifice, and viscous losses. The modified Bernoulli equation (Delta P = 4 * V2 * V2) is the most commonly used application relating peak velocity to peak pressure gradient. It measures the pressure gradient across a valve (not absolute pressure). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Relationship between Doppler velocity and pressure gradient'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5315 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_0_15365=[""].join("\n");
var outline_f15_0_15365=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H738946\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BASIC PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Spectral analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DOPPLER MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Continuous wave Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pulsed Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Color flow imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RELATIONSHIP BETWEEN DOPPLER VELOCITY AND PRESSURE GRADIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H738946\">",
"      SUMMARY",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5315\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5315|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/38/8800\" title=\"diagnostic image 1\">",
"      Continuous wave Doppler across the aortic valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/18/13601\" title=\"diagnostic image 2\">",
"      Pulsed wave Doppler LV outflow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/0/31746\" title=\"diagnostic image 3A\">",
"      Apical 4 chamber color Doppler diastole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/52/13135\" title=\"diagnostic image 3B\">",
"      Apical 4 chamber color Doppler systole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/62/17378\" title=\"diagnostic image 4A\">",
"      Parasternal long axis color flow Doppler I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/33/39440\" title=\"diagnostic image 4B\">",
"      Parasternal long axis color flow Doppler II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/36/8771\" title=\"diagnostic image 5\">",
"      Parasternal short axis color Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/20/31044\" title=\"diagnostic image 6\">",
"      M mode color Doppler LV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/58/16288\" title=\"diagnostic image 7\">",
"      TEE color Doppler severe AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/12/18627\" title=\"diagnostic image 8A\">",
"      Apical 4 chamber color flow Doppler MR II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/23/32112\" title=\"diagnostic image 8B\">",
"      Color flow Doppler severe MR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5315|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/6/33891\" title=\"figure 1\">",
"      Doppler effect echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/33/23071\" title=\"figure 2\">",
"      Angle of Doppler beam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/55/33663\" title=\"figure 3\">",
"      Doppler signal echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/33/10783\" title=\"figure 4\">",
"      Doppler jet patterns AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/1/27671\" title=\"figure 5\">",
"      Pulsed wave Doppler pulmonary venous flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/12/5313\" title=\"figure 6\">",
"      Doppler estimation of RA RV gradient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5315|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?35/3/35892\" title=\"movie 1\">",
"      Apical 4-chamber echocardiogram MR 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?2/25/2448\" title=\"movie 2\">",
"      Apical 4 chamber echocardiogram with color Doppler TR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?25/7/25716\" title=\"movie 3\">",
"      Apical 5 chamber echo with color Doppler AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?7/27/7604\" title=\"movie 4\">",
"      Parasternal long axis color Doppler echo AR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5315|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?43/41/44703\" title=\"waveform 1\">",
"      Continuous wave Doppler AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?4/59/5048\" title=\"waveform 2A\">",
"      Continuous wave Doppler MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?34/58/35744\" title=\"waveform 2B\">",
"      Doppler derived AV gradient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1208?source=related_link\">",
"      Aortic valve area in aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4662?source=related_link\">",
"      Echocardiography essentials: Physics and instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7897?source=related_link\">",
"      Tissue Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14167?source=related_link\">",
"      Transthoracic echocardiography: Normal cardiac anatomy and tomographic views",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_0_15366="Methenamine, phenyl salicylate, methylene blue, benzoic acid, and hyoscyamine: Drug information";
var content_f15_0_15366=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methenamine, phenyl salicylate, methylene blue, benzoic acid, and hyoscyamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/7/5237?source=see_link\">",
"    see \"Methenamine, phenyl salicylate, methylene blue, benzoic acid, and hyoscyamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6789429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hyophen&trade;;",
"     </li>",
"     <li>",
"      Prosed&reg;/DS",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6789433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6789455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Urinary tract symptoms:",
"     </b>",
"     Oral: One tablet 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6789454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Urinary tract symptoms:",
"     </b>",
"     Children &gt;6 years: Oral: Dosage must be individualized",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6789456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6789460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hyophen&trade;: Methenamine 81.6 mg, phenyl salicylate 36.2 mg, methylene blue 10.8 mg, benzoic acid 9 mg, hyoscyamine sulfate 0.12 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Prosed&reg;/DS: Methenamine 81.6 mg, phenyl salicylate 36.2 mg, methylene blue 10.8 mg, benzoic acid 9 mg, hyoscyamine sulfate 0.12 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6789431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6789458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration should be followed by liberal fluid intake.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6789435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinary tract discomfort secondary to hypermotility resulting from infection or diagnostic procedures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13940387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6789447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Flushing, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Discoloration of stool (blue), nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary: Discoloration of urine (blue), micturition difficulty, urinary retention (acute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Dyspnea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6789441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methenamine, hyoscyamine, methylene blue, phenyl salicylate, benzoic acid, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6789442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Belladonna alkaloid allergy: Use with caution in patients with a history of intolerance to belladonna alkaloids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Blurred vision: Discontinue use immediately if blurred vision occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dizziness: Discontinue use immediately if dizziness occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Salicylate allergy: Use with caution in patients with a history of intolerance to salicylates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Tachycardia: Discontinue use immediately if tachycardia occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with pyloric or duodenal obstruction, or gastric ulcers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Glaucoma: Use with caution in patients with glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Obstructive uropathy: Use with caution in patients with obstructive uropathy (bladder neck obstruction or prostatic hyperplasia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Avoid use in this age group due to potent anticholinergic effects and uncertain effectiveness (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Not recommended for use in children &le;6 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Urine/stool discoloration: May cause urinary and/or stool discoloration (blue).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6802901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): MAO Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Indirect-Acting): MAO Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: MAO Inhibitors may enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists (Ophthalmic): MAO Inhibitors may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of MAO Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: MAO Inhibitors may enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Methenamine may decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome. Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: MAO Inhibitors may enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: MAO Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: MAO Inhibitors may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May enhance the adverse/toxic effect of MAO Inhibitors. Management: Avoid concurrent use of carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May diminish the therapeutic effect of Methenamine. Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclobenzaprine: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: MAO Inhibitors may enhance the hypertensive effect of Dexmethylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: MAO Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diethylpropion: MAO Inhibitors may enhance the hypertensive effect of Diethylpropion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxapram: MAO Inhibitors may enhance the hypertensive effect of Doxapram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HYDROmorphone: MAO Inhibitors may enhance the adverse/toxic effect of HYDROmorphone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: MAO Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: May enhance the adverse/toxic effect of MAO Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: MAO Inhibitors may enhance the adverse/toxic effect of Linezolid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: MAO Inhibitors may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maprotiline: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: MAO Inhibitors may enhance the serotonergic effect of Meperidine. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: MAO Inhibitors may enhance the adverse/toxic effect of Methadone.  Management: Initial safety testing, where small incremental doses of methadone are given with the patient closely monitored (including vitals, etc.), is recommended if methadone is to be used with (or within 14 days of) an MAO inhibitor. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: MAO Inhibitors may enhance the hypertensive effect of Methylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orthostatic Hypotension Producing Agents: MAO Inhibitors may enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxymorphone: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pizotifen: MAO Inhibitors may enhance the anticholinergic effect of Pizotifen.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: MAO Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension).  Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: MAO Inhibitors may decrease the metabolism of Serotonin 5-HT1D Receptor Agonists.  Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Eletriptan; Frovatriptan; Naratriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: Methenamine may enhance the adverse/toxic effect of Sulfonamide Derivatives. Specifically, the combination may result in the formation of an insoluble precipitate in the urine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrahydrozoline (Nasal): MAO Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors. Management: Consider alternatives to combined treatment with tramadol and monoamine oxidase inhibitors due to an increased risk of serotonin syndrome and seizures. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: MAO Inhibitors may enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6789436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6789437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with this combination. Methenamine and hyoscyamine cross the placenta. Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6789439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6789440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methenamine and hyoscyamine are excreted in breast milk. Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6789457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Foods/diets which alkalinize urine (pH &gt;5.5) decrease activity of methenamine; cranberry juice can be used to acidify urine and increase activity of methenamine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F6855268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Hyophen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81.6 mg (100): $218.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Prosed/DS Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     81.6 mg (100): $268.38",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/0/15366/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9486 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-BE5EBB4FC7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_0_15366=[""].join("\n");
var outline_f15_0_15366=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789429\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789433\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789455\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789454\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789456\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789460\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789431\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789458\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789435\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13940387\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789447\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789441\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789442\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299685\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6802901\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789436\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789437\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789439\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789440\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789457\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855268\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9486\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9486|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/7/5237?source=related_link\">",
"      Methenamine, phenyl salicylate, methylene blue, benzoic acid, and hyoscyamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_0_15367="Porokeratosis histopathology";
var content_f15_0_15367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histopathology of porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A column of parakeratotic cells consistent with a cornoid lamella is present within the dermis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_0_15367=[""].join("\n");
var outline_f15_0_15367=null;
var title_f15_0_15368="Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy";
var content_f15_0_15368=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/0/15368/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/0/15368/contributors\">",
"     Lawrence J Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/0/15368/contributors\">",
"     Hiba Arif, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/0/15368/contributors\">",
"     Jeremy Moeller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/0/15368/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/0/15368/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/0/15368/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/0/15368/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/0/15368/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It can be difficult to make a diagnosis of epilepsy, and misdiagnosis is not rare [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/1\">",
"     1",
"    </a>",
"    ]. In most cases, a detailed history and a reliable account of the event by an eyewitness is sufficient to make a diagnosis, but this may not always be available. In addition, certain types of nonepileptic events can be difficult to distinguish from seizures, and certain types of seizures can be misdiagnosed as nonepileptic events [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An interictal electroencephalogram (EEG) can provide evidence that helps to confirm or refute the diagnosis of epilepsy, but has many limitations. The most helpful finding on EEG is interictal epileptiform discharges (IEDs), but this finding has imperfect sensitivity and specificity. For patients with recurrent events and nondiagnostic interictal EEG findings, or lack of response to treatment, EEG monitoring is often required to distinguish epileptic seizures from nonepileptic events (",
"    <a class=\"graphic graphic_table graphicRef81289 \" href=\"UTD.htm?31/38/32364\">",
"     table 1",
"    </a>",
"    ). EEG monitoring can be done in the outpatient setting (ambulatory-EEG monitoring) or in the inpatient setting, with combined continuous video monitoring (video-EEG monitoring).",
"   </p>",
"   <p>",
"    This topic discusses the use of EEG monitoring in the diagnosis of seizures and epilepsy. More detailed discussions of routine EEG, and the use of other diagnostic tests in the evaluation of patients with seizures and epilepsy are presented separately. The differential diagnosis of seizures is also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32425?source=see_link\">",
"     \"Electroencephalography (EEG) in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/49/13082?source=see_link\">",
"     \"Neuroimaging in the evaluation of seizures and epilepsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=see_link\">",
"     \"Evaluation of the first seizure in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AMBULATORY-EEG MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulatory-EEG (aEEG) monitoring allows prolonged EEG recording outside the hospital or clinic setting. The technology has evolved such that portable recordings of up to 36 channels, over several days are possible [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/2\">",
"     2",
"    </a>",
"    ]. Typically, computer software designed to detect electrographic seizures and interictal epileptiform discharges (IEDs) assists in interpretation. However, no program has high specificity and sensitivity, and prolonged segments of the study, ideally the entire study, should be reviewed in their entirety as resources allow. Patients and observers also have the opportunity to \"tag\" portions of the recording during clinical events using a push button device. Some systems have the added capability of simultaneous electrocardiogram, pulse oximetry, polysomnography,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    video recording.",
"   </p>",
"   <p>",
"    aEEG is less expensive than inpatient video-EEG monitoring, with costs that are 51 to 65 percent lower than a 24-hour inpatient admission for video-EEG monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, inpatient video-EEG has several advantages that make it the gold standard test in differentiating epileptic from nonepileptic seizures. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Video-EEG monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     IED detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of its longer recording time that generally includes one or more periods of sleep, aEEG can increase the yield of interictal epileptiform detection compared to a routine EEG. One study found that the yield of IED detection after an initially normal routine EEG was greater with a 24-hour aEEG than a sleep-deprived EEG (33 versus 24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/5\">",
"     5",
"    </a>",
"    ]. In another series, aEEG monitoring for seven days revealed IEDs in 81 percent of 100 adult patients with confirmed epileptic seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the sensitivity and specificity of IED detection on aEEG has not been extensively evaluated. Computer algorithms may miss a substantial proportion of IEDs, and many computer-detected \"spikes\" are not true IEDs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/7\">",
"     7",
"    </a>",
"    ]. In one study of 159 adult volunteers without epilepsy, overnight aEEG monitoring revealed spikes in four individuals, two of whom had a family history of epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/7\">",
"     7",
"    </a>",
"    ]. Migraine was also a risk factor for spikes in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ictal recording",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of aEEG to record clinical events may be an even more important contribution of the technology than IED detection. Clearly, the baseline frequency of clinical events contributes to the yield of aEEG in this regard. In one study of 157 children whose parents reported at least three spells per week, 140 patients (89 percent) had a typical event during aEEG (mean duration 1.9 days); 76 percent of these were suspected to be nonepileptic based on the lack of an EEG correlate on aEEG [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/8\">",
"     8",
"    </a>",
"    ]. Other larger studies have reported a similar yield of aEEG in distinguishing epileptic from nonepileptic events [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. It should be noted that lack of an EEG correlate does not necessarily suggest a nonepileptic spell, as the majority of simple partial seizures and a portion of complex partial seizures have no definite scalp EEG correlate.",
"   </p>",
"   <p>",
"    A finding that has been repeatedly observed in aEEG studies is that patients with epilepsy are often unaware of seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/5,8,11-13\">",
"     5,8,11-13",
"    </a>",
"    ]. In one study, 18 (38 percent) of 47 computer-assisted aEEG recordings contained partial seizures that were not identified by the patient; only 7 of these 18 patients also had self-reported clinical seizures during the study [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/13\">",
"     13",
"    </a>",
"    ]. As a result, both ambulatory and video-EEG monitoring may have diagnostic utility despite a low frequency of seizure events reported by a patient. We often use aEEG to help quantify seizure frequency, particularly in patients who are not always aware of their seizures. In addition, we often use 24 to 72 hours of aEEG to confirm lack of seizures before allowing patients to resume driving after a period of apparent seizure freedom. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32568?source=see_link\">",
"     \"Driving restrictions for patients with seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When electrographic seizures are recorded, the tracing can also help distinguish partial versus generalized seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/10\">",
"     10",
"    </a>",
"    ]. Some studies suggest that aEEG can also help localize the focus of partial epilepsies in patients being considered for surgery and may provide prognostic information in patients being considered for antiepileptic drug withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     VIDEO-EEG MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video electroencephalography (EEG) monitoring is the synchronous recording and display of EEG patterns and video-recorded clinical behavior. Short recordings of several hours can be performed as an outpatient in an EEG laboratory, while longer recordings of 24 hours or more are generally done in a hospital inpatient setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27881599\">",
"    <span class=\"h2\">",
"     Advantages of video-EEG",
"    </span>",
"    &nbsp;&mdash;&nbsp;While considerably more expensive than aEEG, there are several advantages to this test, including the continuous video-monitoring that allows for analysis of both the clinical and electrographic features of a recorded event [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Staff trained in EEG monitoring may detect seizure activity on remote viewing of the video or EEG at the nursing or monitoring station. They can interact with and test the patient during a spell or seizure aura, and push the event button. This can be very important for characterizing impairment of awareness and subtle lateralizing features, including postictal aphasia or hemiparesis.",
"     </li>",
"     <li>",
"      Both video and EEG quality are usually superior with inpatient, monitored recordings. Video cameras in inpatient units usually allow infrared viewing of patients in the dark, as well as remote control of the camera, including zooming in as needed, from the nursing or monitoring station. As a result, when a seizure occurs, subtle clinical features with lateralizing importance can be better appreciated, such as dystonic posturing, eye deviation, facial clonus, postictal nose-wiping, brief Todd's paresis, etc. Video can also help identify artifacts produced by nonseizure-related rhythmic movements (blinking, chewing, toothbrushing, scratching) that can mimic seizures on EEG",
"     </li>",
"     <li>",
"      Electrode application can be more frequently monitored and maintained, limiting artifact. Additional electrodes, such as inferior temporal electrodes, are impractical in the outpatient setting, and can be more easily monitored and maintained in the inpatient setting. These electrodes can provide information that would be unavailable from the standard electrode array. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32425?source=see_link&amp;anchor=H12#H12\">",
"       \"Electroencephalography (EEG) in the diagnosis of seizures and epilepsy\", section on 'Special electrode placement'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The inpatient setting is a safer environment in which to withdraw antiepileptic drugs or use other measures designed to induce clinical events [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H27881943\">",
"       'Safety'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27881886\">",
"    <span class=\"h2\">",
"     Duration of a recording",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of recording an event (and therefore making a diagnosis) increases with the duration of recording. In a recent case series of 248 adult patients admitted to an epilepsy monitoring unit, the median time to first diagnostic event, whether epileptic seizure or nonepileptic event, was two days; 35 percent of patients required three or more days of monitoring, and 7 percent more than one week [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/17\">",
"     17",
"    </a>",
"    ]. When a first video-EEG study is not diagnostic, repeat testing can be helpful; in one study a second study was diagnostically useful in 35 of 43 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of recording will depend on the indication: subjects undergoing presurgical evaluation often require a significantly longer period of long-term monitoring to obtain clinically relevant (and previously unreported) information (mean 3.5 days) compared to patients who are being recorded for diagnosis or classification (2.4 and 2.3 days, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27881730\">",
"    <span class=\"h2\">",
"     Provocative techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of techniques can be used to provoke typical events in the epilepsy monitoring unit:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Routine activating techniques such as hyperventilation and photic stimulation should be part of any inpatient video-EEG recording session. One group performed hyperventilation for five minutes at a time, every three hours between 6 am and 12 midnight; 25 percent of all recorded focal-onset seizures were activated during hyperventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/20\">",
"       20",
"      </a>",
"      ]. The seizures provoked during hyperventilation did not differ from spontaneous seizures in characteristics or severity. Another video-EEG monitoring study found that hyperventilation had an activating effect on the EEG only in those who were also undergoing antiepileptic drug (AED) tapering [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/21\">",
"       21",
"      </a>",
"      ]. Overall, 14 out of 80 patients, most of whom had localization-related epilepsy, had seizures activated by hyperventilation. In this series, patients underwent hyperventilation for six minutes at a time, and this was repeated a mean of 3.5",
"      <span class=\"nowrap\">",
"       times/day.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32425?source=see_link&amp;anchor=H10#H10\">",
"       \"Electroencephalography (EEG) in the diagnosis of seizures and epilepsy\", section on 'Routine activating techniques'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sleep deprivation can increase the diagnostic yield of routine outpatient EEG recordings (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32425?source=see_link&amp;anchor=H11#H11\">",
"       \"Electroencephalography (EEG) in the diagnosis of seizures and epilepsy\", section on 'Sleep and sleep deprivation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Sleep deprivation is also frequently used as a technique to provoke seizures in patients admitted for video-EEG monitoring, although there is no direct evidence supporting the effectiveness of this technique. In one series, patients who were kept awake every second night during video-EEG monitoring did not have more seizures than patients who were allowed to sleep normally [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antiepileptic medications may be withdrawn in order to provoke seizures. Several studies have shown that the rapid reduction of AEDs during video-EEG monitoring increases the risk of partial seizures and secondarily generalized tonic clonic seizures [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Up to half of all patients who have never had a generalized seizure at baseline will have one in the context of rapid medication withdrawal [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/23\">",
"       23",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The rate of AED withdrawal is variable, and there is no generally accepted standard. Most experts advocate gradual withdrawal of one AED at a time, reducing each AED by 25 to 50 percent of the baseline total daily dose each day [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/25\">",
"       25",
"      </a>",
"      ]. The rate of AED taper should be adjusted for each patient based upon risk factors for status epilepticus (eg, frequent seizures at baseline, poor seizure control, frequent generalized seizures, prior status epilepticus) and the risk of adverse outcomes associated with seizure clusters and generalized seizures (eg, low bone density, concurrent cardiovascular disease, history of postictal psychosis). Benzodiazepines and barbiturates should be withdrawn at slower rates than other AEDs because of the high risk of status epilepticus associated with rapid withdrawal of these medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Other techniques used during video-EEG monitoring in order to provoke seizures include physical exercise, alcohol consumption, video games and mental and concentration tasks [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/26\">",
"       26",
"      </a>",
"      ]. While there is no evidence to support the effectiveness of any of these techniques for provoking seizures, physical and mental activity should be encouraged to prevent boredom and deconditioning during long admissions for video-EEG monitoring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Techniques for provoking psychogenic nonepileptic seizures are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=see_link&amp;anchor=H19#H19\">",
"       \"Psychogenic nonepileptic seizures\", section on 'Spell induction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27881943\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inpatient video-EEG monitoring unit is the safest environment in which to diagnose paroxysmal events. In one series of 149 patients monitored for a mean duration of five days, adverse events requiring intervention occurred in 21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/27\">",
"     27",
"    </a>",
"    ]. In another series of 507 patients monitored over 596 video-EEG recording sessions, 44 patients (9 percent) experienced 53 adverse events requiring intervention and resulting in prolonged hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/28\">",
"     28",
"    </a>",
"    ]. The most common adverse events were status epilepticus, injuries from falls, vertebral compression fractures, and psychiatric complications including postictal psychosis. &nbsp;",
"    <br/>",
"    <br/>",
"    In order to minimize adverse events, inpatient video-EEG monitoring units should be staffed by nurses and other health professionals with experience in dealing with seizures, and the layout and furnishings should be designed to minimize the risk of injury and falls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27881622\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with recurrent clinical events, video-EEG recording in an epilepsy monitoring unit is the best, and sometimes the only, way to make a definitive diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Approximately 20 percent of patients referred for video-EEG monitoring for medically refractory seizures do not have epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/10,32,33\">",
"     10,32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective review of 213 admissions (from 196 patients) to an inpatient epilepsy monitoring unit, a definitive diagnosis was reached in 88 percent of patients after a median stay of five days [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/33\">",
"     33",
"    </a>",
"    ]. Epilepsy was diagnosed in 71 percent and excluded in 22 percent of admissions. In patients diagnosed with epilepsy, the median time since the onset of symptoms was 18 years. Perhaps more worrisome was that patients determined not to have epilepsy had been treated with antiepileptic drugs (often multiple medications) for an average of nine years. The National Association of Epilepsy Centers guidelines recommend referral for video-EEG monitoring if spells are uncontrolled after one year, or if the patient has failed treatment with two to three antiepileptic medications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients misdiagnosed with epilepsy are eventually found to have either psychogenic non-epileptic seizures (PNES) or (much less frequently) syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. It is also well known that some patients with presumed PNES are found to have epileptic seizures on video-EEG [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=see_link\">",
"     \"Psychogenic nonepileptic seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accurate interpretation of video-EEG monitoring requires careful analysis of the clinical events with any changes in the EEG occurring before, during, and after the seizure. Some caution is required for interpretation. While the majority of seizures with impaired awareness reveal an ictal EEG correlate, the tracing may be obscured by muscle artifact. Only 15 to 33 percent of simple partial seizures or seizure auras, which often involve a limited area of cortex, are associated with surface EEG abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/39\">",
"     39",
"    </a>",
"    ]. Some studies suggest that synchronized seizure activity must involve approximately 10 cm",
"    <sup>",
"     2",
"    </sup>",
"    of cortex for it to produce a focal pattern on a scalp EEG [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/40\">",
"     40",
"    </a>",
"    ]. Frontal lobe seizures may also not be correlated with electrographic abnormalities on an EEG [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/41\">",
"     41",
"    </a>",
"    ]. Therefore, the absence of an ictal rhythm on EEG does not exclude epilepsy.&nbsp;",
"   </p>",
"   <p>",
"    A study of interrater reliability of video-EEG found substantial agreement (kappa = 0.7) for epileptic seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/42\">",
"     42",
"    </a>",
"    ]. There was more variability in interpretation for psychogenic and physiologic nonepileptic seizures. Limitations of this study that differ from \"real-life\" use of this test include a forced choice paradigm based on analysis of a single episode and no access to other clinical data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Seizure classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video-EEG monitoring can also help with seizure classification, which in turn impacts the most appropriate selection of an antiepileptic drug (AED) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/10,31,32,43-47\">",
"     10,31,32,43-47",
"    </a>",
"    ]. The clinical history can be misleading in this regard. As examples, a patient with staring spells may have absence or complex partial seizures, and a patient with generalized convulsions may have primary or secondarily-generalized epilepsy. Although the presence of an aura strongly suggests partial-onset seizures, one study reported that symptoms interpreted by the patient as a seizure aura (often brief, nonspecific dizziness) occurred in up to 70 percent of those with primary generalized epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two case series that compared seizure classification based on an informant's description versus video-EEG monitoring, reclassification occurred in 12 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. However, it was not clear that this reclassification led to an alteration of treatment strategy in these patients. In contrast, in a study of 40 patients who underwent video-EEG monitoring, newly recognized epileptic seizure types were identified in eight patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/44\">",
"     44",
"    </a>",
"    ]. Monitoring led to altered treatment regimens in some patients and was associated with a reduced seizure frequency in 24 patients over a six-month follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27882136\">",
"    <span class=\"h3\">",
"     Seizure quantification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video-EEG also has an instrumental role in quantifying seizures. As with aEEG, case series of video EEG studies reveal that many patients with epilepsy have more events than they are aware of [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/11,51\">",
"     11,51",
"    </a>",
"    ]. In one series of 31 patients admitted to an epilepsy monitoring unit, 23 had epileptic seizures, but only 26 percent of patients were aware of all their seizures and 30 percent were not aware of any [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/11\">",
"     11",
"    </a>",
"    ]. Similarly, another study of 91 video-EEG-monitored inpatients found that 56 percent",
"    <span class=\"nowrap\">",
"     (323/582)",
"    </span>",
"    of seizures were not documented by patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/52\">",
"     52",
"    </a>",
"    ]. Complex partial seizures (CPS) in particular were underreported; only 25 percent of patients with CPS were aware of all seizures; 51 percent failed to document any CPS; and 73 percent of all CPS were unreported. Even secondarily generalized tonic-clonic seizures were often (42 percent) unreported. Only 38 percent of patients documented all their seizures.",
"   </p>",
"   <p>",
"    Another study found no correlation between self-reported outpatient seizure frequency and time-to-first-seizure during inpatient video-EEG monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/51\">",
"     51",
"    </a>",
"    ]. These data demonstrate that reports of seizure frequency obtained from patients are often unreliable and that a low self-reported seizure frequency should not deter referral of a patient for monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Epilepsy surgery planning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video-EEG monitoring is performed in individuals with pharmacoresistant partial epilepsy for surgical localization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15368/abstract/2,9,53-55\">",
"     2,9,53-55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=see_link\">",
"     \"Surgical therapy of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/0/18434?source=see_link\">",
"       \"Patient information: EEG (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electroencephalography (EEG) is one of the most important diagnostic tests in evaluating a patient with possible epilepsy, providing evidence that helps confirm or refute the diagnosis. EEG also assists in classifying the underlying epileptic syndrome and thereby guides management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of its longer duration of recording that typically includes one or more periods of sleep, ambulatory EEG (aEEG) monitoring can increase the yield of routine EEG in detecting interictal epileptiform discharges (IEDs). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'IED detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ambulatory EEG is most helpful in quantifying or capturing clinical events and associating these with the presence or absence of electrographic seizures. However, absence of an EEG correlate does not exclude epilepsy and aEEG cannot \"rule out\" epileptic seizures. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Ictal recording'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While relatively inexpensive and convenient to perform, the absence of simultaneous high-fidelity video recording, lack of ability to interact and test the patient during a spell, and a higher potential for artifact and misinterpretation are significant disadvantages of ambulatory EEG monitoring compared with inpatient video-EEG recording. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ambulatory-EEG monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inpatient video-EEG monitoring combines both a video and EEG recording of clinical events, allows ongoing maintenance of video and EEG quality, permits interaction with the patient during or after an event, and allows medication withdrawal in a safer, monitored setting. (See",
"      <a class=\"local\" href=\"#H27881599\">",
"       'Advantages of video-EEG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Video-EEG is used most commonly to determine whether epilepsy is the cause of recurrent seizure-like events (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Differential diagnosis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Video EEG can also aid in seizure classification, quantification, and determination of patient awareness of their seizures. It is also vital for presurgical evaluation of epilepsy patients. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Seizure classification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/1\">",
"      Kanner AM. Common errors made in the diagnosis and treatment of epilepsy. Semin Neurol 2008; 28:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/2\">",
"      Cascino GD. Use of routine and video electroencephalography. Neurol Clin 2001; 19:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/3\">",
"      Schomer DL. Ambulatory EEG telemetry: how good is it? J Clin Neurophysiol 2006; 23:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/4\">",
"      Foley CM, Legido A, Miles DK, et al. Long-term computer-assisted outpatient electroencephalogram monitoring in children and adolescents. J Child Neurol 2000; 15:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/5\">",
"      Liporace J, Tatum W 4th, Morris GL 3rd, French J. Clinical utility of sleep-deprived versus computer-assisted ambulatory 16-channel EEG in epilepsy patients: a multi-center study. Epilepsy Res 1998; 32:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/6\">",
"      Walczak, T, Scheuer, M, Resor, S, Pedley, T. Prevalence and features of epilepsy without interictal epileptiform discharges. Neurology 1993; 43:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/7\">",
"      Schachter SC, Ito M, Wannamaker BB, et al. Incidence of spikes and paroxysmal rhythmic events in overnight ambulatory computer-assisted EEGs of normal subjects: a multicenter study. J Clin Neurophysiol 1998; 15:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/8\">",
"      Olson DM. Success of ambulatory EEG in children. J Clin Neurophysiol 2001; 18:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/9\">",
"      Morris GL 3rd, Galezowska J, Leroy R, North R. The results of computer-assisted ambulatory 16-channel EEG. Electroencephalogr Clin Neurophysiol 1994; 91:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/10\">",
"      Yogarajah M, Powell HW, Heaney D, et al. Long term monitoring in refractory epilepsy: the Gowers Unit experience. J Neurol Neurosurg Psychiatry 2009; 80:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/11\">",
"      Blum DE, Eskola J, Bortz JJ, Fisher RS. Patient awareness of seizures. Neurology 1996; 47:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/12\">",
"      Gotman J. Automatic seizure detection: improvements and evaluation. Electroencephalogr Clin Neurophysiol 1990; 76:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/13\">",
"      Tatum WO 4th, Winters L, Gieron M, et al. Outpatient seizure identification: results of 502 patients using computer-assisted ambulatory EEG. J Clin Neurophysiol 2001; 18:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/14\">",
"      Koepp MJ, Farrell F, Collins J, Smith S. The prognostic value of long-term ambulatory electroencephalography in antiepileptic drug reduction in adults with learning disability and epilepsy in long-term remission. Epilepsy Behav 2008; 13:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/15\">",
"      Worrell GA, Lagerlund TD, Buchhalter JR. Role and limitations of routine and ambulatory scalp electroencephalography in diagnosing and managing seizures. Mayo Clin Proc 2002; 77:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/16\">",
"      Moien-Afshari F, Griebel R, Sadanand V, et al. Safety and yield of early cessation of AEDs in video-EEG telemetry and outcomes. Can J Neurol Sci 2009; 36:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/17\">",
"      Friedman DE, Hirsch LJ. How long does it take to make an accurate diagnosis in an epilepsy monitoring unit? J Clin Neurophysiol 2009; 26:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/18\">",
"      Muniz J, Benbadis SR. Repeating video/EEG monitoring: why and with what results? Epilepsy Behav 2010; 18:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/19\">",
"      Alving J, Beniczky S. Diagnostic usefulness and duration of the inpatient long-term video-EEG monitoring: findings in patients extensively investigated before the monitoring. Seizure 2009; 18:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/20\">",
"      Guaranha MS, Garzon E, Buchpiguel CA, et al. Hyperventilation revisited: physiological effects and efficacy on focal seizure activation in the era of video-EEG monitoring. Epilepsia 2005; 46:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/21\">",
"      Jonas J, Vignal JP, Baumann C, et al. Effect of hyperventilation on seizure activation: potentiation by antiepileptic drug tapering. J Neurol Neurosurg Psychiatry 2011; 82:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/22\">",
"      Malow BA, Passaro E, Milling C, et al. Sleep deprivation does not affect seizure frequency during inpatient video-EEG monitoring. Neurology 2002; 59:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/23\">",
"      Marciani MG, Gotman J, Andermann F, Olivier A. Patterns of seizure activation after withdrawal of antiepileptic medication. Neurology 1985; 35:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/24\">",
"      Marks DA, Katz A, Scheyer R, Spencer SS. Clinical and electrographic effects of acute anticonvulsant withdrawal in epileptic patients. Neurology 1991; 41:508.",
"     </a>",
"    </li>",
"    <li>",
"     Fisch BJ, So EL. Activation Methods. In: Current practice of Clinical Electroencephalography, Third, Ebersole JS, Pedley TA.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/26\">",
"      Millett CJ, Johnson AL, Thompson PJ, Fish DR. A study of the relationship between participation in common leisure activities and seizure occurrence. Acta Neurol Scand 2001; 103:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/27\">",
"      Noe KH, Drazkowski JF. Safety of long-term video-electroencephalographic monitoring for evaluation of epilepsy. Mayo Clin Proc 2009; 84:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/28\">",
"      Dobesberger J, Walser G, Unterberger I, et al. Video-EEG monitoring: safety and adverse events in 507 consecutive patients. Epilepsia 2011; 52:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/29\">",
"      Labiner DM, Bagic AI, Herman ST, et al. Essential services, personnel, and facilities in specialized epilepsy centers--revised 2010 guidelines. Epilepsia 2010; 51:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/30\">",
"      Cuthill FM, Espie CA. Sensitivity and specificity of procedures for the differential diagnosis of epileptic and non-epileptic seizures: a systematic review. Seizure 2005; 14:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/31\">",
"      Nordli DR Jr. Usefulness of video-EEG monitoring. Epilepsia 2006; 47 Suppl 1:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/32\">",
"      Binnie CD, Rowan AJ, Overweg J, et al. Telemetric EEG and video monitoring in epilepsy. Neurology 1981; 31:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/33\">",
"      Smolowitz JL, Hopkins SC, Perrine T, et al. Diagnostic utility of an epilepsy monitoring unit. Am J Med Qual 2007; 22:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/34\">",
"      Scheepers B, Clough P, Pickles C. The misdiagnosis of epilepsy: findings of a population study. Seizure 1998; 7:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/35\">",
"      Eir&iacute;s-Pu&ntilde;al J, Rodr&iacute;guez-N&uacute;&ntilde;ez A, Fern&aacute;ndez-Mart&iacute;nez N, et al. Usefulness of the head-upright tilt test for distinguishing syncope and epilepsy in children. Epilepsia 2001; 42:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/36\">",
"      Oto M, Russell AJ, McGonigal A, Duncan R. Misdiagnosis of epilepsy in patients prescribed anticonvulsant drugs for other reasons. BMJ 2003; 326:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/37\">",
"      Zaidi A, Clough P, Cooper P, et al. Misdiagnosis of epilepsy: many seizure-like attacks have a cardiovascular cause. J Am Coll Cardiol 2000; 36:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/38\">",
"      LaFrance WC Jr, Benbadis SR. Differentiating frontal lobe epilepsy from psychogenic nonepileptic seizures. Neurol Clin 2011; 29:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/39\">",
"      Devinsky O, Kelley K, Porter RJ, Theodore WH. Clinical and electroencephalographic features of simple partial seizures. Neurology 1988; 38:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/40\">",
"      Tao JX, Baldwin M, Ray A, et al. The impact of cerebral source area and synchrony on recording scalp electroencephalography ictal patterns. Epilepsia 2007; 48:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/41\">",
"      Verma A, Radtke R. EEG of partial seizures. J Clin Neurophysiol 2006; 23:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/42\">",
"      Benbadis SR, LaFrance WC Jr, Papandonatos GD, et al. Interrater reliability of EEG-video monitoring. Neurology 2009; 73:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/43\">",
"      Dreifuss FE. Role of intensive monitoring in classification. Adv Neurol 1987; 46:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/44\">",
"      Sutula TP, Sackellares JC, Miller JQ, Dreifuss FE. Intensive monitoring in refractory epilepsy. Neurology 1981; 31:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/45\">",
"      Benbadis SR, O'Neill E, Tatum WO, Heriaud L. Outcome of prolonged video-EEG monitoring at a typical referral epilepsy center. Epilepsia 2004; 45:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/46\">",
"      Asano E, Pawlak C, Shah A, et al. The diagnostic value of initial video-EEG monitoring in children--review of 1000 cases. Epilepsy Res 2005; 66:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/47\">",
"      Cascino GD. Video-EEG monitoring in adults. Epilepsia 2002; 43 Suppl 3:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/48\">",
"      Boylan LS, Labovitz DL, Jackson SC, et al. Auras are frequent in idiopathic generalized epilepsy. Neurology 2006; 67:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/49\">",
"      Heo JH, Kim DW, Lee SY, et al. Reliability of semiology description. Neurologist 2008; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/50\">",
"      Hirfanoglu T, Serdaroglu A, Cansu A, et al. Semiological seizure classification: before and after video-EEG monitoring of seizures. Pediatr Neurol 2007; 36:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/51\">",
"      Eisenman LN, Attarian H, Fessler AJ, et al. Self-reported seizure frequency and time to first event in the seizure monitoring unit. Epilepsia 2005; 46:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/52\">",
"      Hoppe C, Poepel A, Elger CE. Epilepsy: accuracy of patient seizure counts. Arch Neurol 2007; 64:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/53\">",
"      Cambier DM, Cascino GD, So EL, Marsh WR. Video-EEG monitoring in patients with hippocampal atrophy. Acta Neurol Scand 2001; 103:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/54\">",
"      Porter RJ, Sato S, Long RL. Video recording. Electroencephalogr Clin Neurophysiol Suppl 1985; 37:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15368/abstract/55\">",
"      Quesney LF, Gloor P. Localization of epileptic foci. Electroencephalogr Clin Neurophysiol Suppl 1985; 37:165.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2235 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_0_15368=[""].join("\n");
var outline_f15_0_15368=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AMBULATORY-EEG MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IED detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ictal recording",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      VIDEO-EEG MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27881599\">",
"      Advantages of video-EEG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27881886\">",
"      Duration of a recording",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27881730\">",
"      Provocative techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27881943\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27881622\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Seizure classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27882136\">",
"      - Seizure quantification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Epilepsy surgery planning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/2235\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2235|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/38/32364\" title=\"table 1\">",
"      Differential diagnosis of seizures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/51/32568?source=related_link\">",
"      Driving restrictions for patients with seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32425?source=related_link\">",
"      Electroencephalography (EEG) in the diagnosis of seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/49/13082?source=related_link\">",
"      Neuroimaging in the evaluation of seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=related_link\">",
"      Nonepileptic paroxysmal disorders in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/0/18434?source=related_link\">",
"      Patient information: EEG (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=related_link\">",
"      Psychogenic nonepileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=related_link\">",
"      Surgical therapy of epilepsy in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_0_15369="Crush-related acute kidney injury (acute renal failure)";
var content_f15_0_15369=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Crush-related acute kidney injury (acute renal failure)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/0/15369/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/0/15369/contributors\">",
"     Raymond Vanholder, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/0/15369/contributors\">",
"     Mehmet S Sever, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/0/15369/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/0/15369/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/0/15369/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/0/15369/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/0/15369/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;High circulating plasma myoglobin levels secondary to rhabdomyolysis can cause heme pigment-associated acute tubular necrosis (ATN), which results in an abrupt rise in serum creatinine, or acute kidney injury (AKI) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=see_link\">",
"     \"Definition of acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rhabdomyolysis may be due to either traumatic or nontraumatic muscle injury. Much of our knowledge on rhabdomyolysis-associated ATN derives from observations of rhabdomyolysis that occurs as part of the crush syndrome resulting from large scale natural or man-made disasters.",
"   </p>",
"   <p>",
"    The clinical features and prevention of AKI due to traumatic rhabdomyolysis will be reviewed here. ATN due to nontraumatic rhabdomyolysis and hemolysis and general overviews of rhabdomyolysis, hemolysis, and drug-induced myopathies are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link\">",
"     \"Drug-induced myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic manifestations which are induced by crush injury are often referred to as crush syndrome. Crush syndrome develops in 30 to 50 percent of cases of traumatic rhabdomyolysis and is frequently seen after catastrophic earthquakes. According to some estimates, the incidence of crush syndrome ranges between 2 and 5 percent of all injured victims of catastrophic earthquakes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. All disaster victims should be considered at increased risk.",
"   </p>",
"   <p>",
"    The incidence of AKI and the frequency with which dialysis is required in these cases have varied widely in different studies. The following reports have analyzed these aspects as part of crush injury following catastrophic earthquakes:",
"   </p>",
"   <p>",
"    In a report from Bam, Iran, dialysis was required in 6.5 percent of 1975 patients admitted to the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/9\">",
"     9",
"    </a>",
"    ]. The majority of victims were rescued in less than four hours. In contrast to other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/10\">",
"     10",
"    </a>",
"    ], the authors detected a direct correlation between time under the rubble and outcome. The short time under the rubble might thus explain at least in part the lower rate of requiring dialysis in Bam compared with other reports, although this is not entirely certain.",
"   </p>",
"   <p>",
"    Much higher rates of dialysis requirement were noted in two other catastrophic earthquakes: 54 percent in the Kobe earthquake and 75 percent in the Marmara earthquake [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. In the Kobe earthquake, the need for hemodialysis correlated directly with increased serum creatine kinase (CK) levels, as dialysis was required in 84 and 39 percent of patients with a CK level greater or less than 75,000",
"    <span class=\"nowrap\">",
"     units/L,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Kobe and Marmara earthquakes, the time under the rubble correlated inversely with both serum creatine kinase (CK) and the frequency of requiring dialysis. A possible explanation for these counterintuitive findings is that victims with more extensive muscle injury and higher CK levels died before they were extricated and transported to the hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most typical local finding of traumatic rhabdomyolysis is compartment syndrome, due to swollen muscles. Patients suffer from severe pain, weakness, paresthesia, paresis or paralysis and pallor in the affected extremities. Distal pulses may be absent when intracompartmental pressure is very high, although increased intracompartmental pressure may be present even when distal pulses are palpable. In traumatic rhabdomyolysis, signs of blunt or penetrating trauma are also present.",
"   </p>",
"   <p>",
"    AKI resulting from heme pigment-induced ATN is usually characterized by an initial oliguric period followed by polyuria, which usually starts within one to three weeks after the primary event. Some cases may present with a nonoliguric course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hypovolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with rhabdomyolysis have been immobile or comatose for significant periods of time. As a result, hypovolemia due to absence of fluid intake plus ongoing losses may be observed. This is particularly important among patients with rhabdomyolysis due to crush injury, since they may have been immobilized for hours to days. In addition, third spacing at the site of muscle injury (compartment syndrome) among such patients significantly worsens hypovolemia. The latter phenomenon typically starts only after decompression, due to reperfusion of the traumatized muscle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dark urine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic manifestation of heme pigment-induced ATN is discolored urine. Marked release of myoglobin leads to red or brown (or even black) urine, unless pigment excretion is limited because of a low glomerular filtration rate, extreme dilution of the urine due to preventive fluid administration, or clearance from the plasma by the reticuloendothelial system [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/12\">",
"     12",
"    </a>",
"    ]. Urinalysis also reveals pigmented granular casts.",
"   </p>",
"   <p>",
"    The plasma is typically normal in color with myoglobinuria. This is in contrast to conditions resulting in hemoglobinuria-induced ATN, such as massive hemolysis, which are characterized by red-tinted plasma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of renal insufficiency ranges widely from a mild elevation in the serum creatinine concentration to oliguric AKI requiring immediate hemodialysis. This variability is due to differences in severity of injury to muscle and presence or absence of volume depletion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    underlying additional comorbid conditions, particularly sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     BIOCHEMICAL ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biochemical abnormalities that characterize rhabdomyolysis-associated AKI include hyperkalemia that may be life-threatening, hyperphosphatemia, hypocalcemia (which is occasionally followed by hypercalcemia during the recovery stage), a high CK, and a low fractional excretion of sodium. These are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with rhabdomyolysis-induced ATN typically present with a red to brown color of the urine, pigmented granular casts in the urine, varying severity of kidney dysfunction, and a marked elevation in the plasma CK level. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intermittent excretion of red to brown urine can be seen in a variety of clinical settings, including heme pigment-induced ATN. The approach to this issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H4#H4\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Red to brown urine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AKI can also be caused by other conditions or abnormalities commonly observed in patients with traumatic rhabdomyolysis. These include drug-induced AKI (such as aminoglycosides and nonsteroidal antiinflammatory drugs), sepsis, severe hypotension due to marked hypovolemia, and others. This is also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general goals for preventive therapy in all cases of heme pigment-induced AKI are the correction of volume depletion, if present, and prevention of intratubular cast formation. In the case of disaster crush victims preventive measures should be applied at the disaster field, in the field hospitals, and after admission to regular hospitals.",
"   </p>",
"   <p>",
"    The most important preventive measure at the disaster field is the correction of volume depletion. During volume resuscitation, the timing and rate of fluid administration, volume of fluids, and also types of fluid should be considered.",
"   </p>",
"   <p>",
"    The approach to prevention of AKI in the patient with rhabdomyolysis due to crush syndrome varies based upon the location of the patient and ability to closely monitor the victim.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Before and during extrication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive fluid repletion should be started before the extrication of entrapped subjects prone to develop the crush syndrome, if possible (",
"    <a class=\"graphic graphic_algorithm graphicRef83615 \" href=\"UTD.htm?1/44/1742\">",
"     algorithm 1",
"    </a>",
"    ). Third spacing at the site of muscle injury worsens hypovolemia. Thus, patients with rhabdomyolysis may require massive amounts of fluid to initiate and maintain a vigorous diuresis.",
"   </p>",
"   <p>",
"    The goals of volume repletion are to both enhance renal perfusion (thereby minimizing ischemic injury) and increase the urine flow rate to wash out obstructing casts. Volume resuscitation should be initiated before the crush is relieved, or as soon as possible thereafter, before heme pigment and other intracellular elements have been released into the circulation and before third spacing at the site of muscle injury worsens hypovolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/2,15-17\">",
"     2,15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for this approach is based upon the observations that early adequate fluid resuscitation is very important to help prevent AKI in patients with rhabdomyolysis due to crush injury.",
"   </p>",
"   <p>",
"    Practically all of the published experience with volume resuscitation in patients with heme pigment-induced ATN has come from retrospective reports of rhabdomyolysis in subjects with crush injury [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/2-4,16-18\">",
"     2-4,16-18",
"    </a>",
"    ]. The following studies serve as examples of the importance of early fluid repletion in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seven patients with crush syndrome who were trapped under rubble (all with CK concentrations &gt;30,000",
"      <span class=\"nowrap\">",
"       units/L)",
"      </span>",
"      were treated with alkaline diuresis immediately after extrication; none developed renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/17\">",
"       17",
"      </a>",
"      ]. One patient who did not receive prophylactic volume repletion developed AKI and required hemodialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sixteen earthquake victims trapped for a mean of 10 hours (12 had CK concentrations &gt;20,000",
"      <span class=\"nowrap\">",
"       units/L)",
"      </span>",
"      were treated initially with isotonic saline at 1",
"      <span class=\"nowrap\">",
"       L/hour,",
"      </span>",
"      then with an alkaline-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      solution [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/16\">",
"       16",
"      </a>",
"      ]. The four patients who required dialysis were treated approximately nine hours after extrication and received significantly less fluids compared with 12 patients who did not require dialysis, who were treated four hours after extrication.",
"     </li>",
"     <li>",
"      In other reports of earthquake-related crush injury, AKI occurred in over 50 percent of patients for whom therapy was instituted much later [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/18,20\">",
"       18,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, preventive therapy appears to be less effective after the first 6 to 12 hours, when the kidney injury may already be established.",
"   </p>",
"   <p>",
"    The optimal fluid and rate of repletion are unclear. No studies have directly compared the efficacy and safety of different types and rates of fluid administration in this setting.",
"   </p>",
"   <p>",
"    Prior to and during extrication, we agree with the Renal Disaster Relief Task Force (RDRTF) of the International Society of Nephrology (ISN) isotonic saline rather than isotonic bicarbonate be administered because saline solutions are more readily available in disasters and have a well-described efficacy for volume replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/21\">",
"     21",
"    </a>",
"    ]. If available, isotonic saline plus 5 percent dextrose may be used since it provides the advantage of supplying calories and attenuating hyperkalemia.",
"   </p>",
"   <p>",
"    Isotonic saline should initially be given at a rate of 1",
"    <span class=\"nowrap\">",
"     L/hour",
"    </span>",
"    (10 to 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of body weight per hour) while the victim is still under the rubble. After 2 liters are given, the rate of administration should be decreased to 500",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    to avoid volume overload. However, this volume should be individualized. Factors to consider are age (fluid administration should be performed more carefully in the elderly); body mass index (more fluids are needed for the victims with larger body surface area); trauma pattern (more fluid is needed in patients with more serious trauma); and amount of presumed fluid losses (more fluids are needed in hot climates and in victims who produce urine or have ongoing blood losses).",
"   </p>",
"   <p>",
"    There is a role for isotonic bicarbonate therapy",
"    <strong>",
"     after",
"    </strong>",
"    extrication. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Use of bicarbonate'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Severe hyperkalemia is relatively frequent among patients with crush injuries. As a result, intravenous solutions containing potassium, such as Ringer's lactate, are contraindicated in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H428143791\">",
"    <span class=\"h2\">",
"     After extrication",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Use of bicarbonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the victim has been removed from the rubble, urine output has been documented, and overt alkalosis has been excluded, we agree with the RDRTF that an alkaline solution that is approximately isotonic may be used where feasible (such as in small-scale disasters) in an attempt to achieve a forced alkaline diuresis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/21\">",
"     21",
"    </a>",
"    ]. However the use of complex solutions such as bicarbonate-containing solutions may be limited by logistic circumstances in mass disasters. The preparation of such solutions is time-consuming and carries the risk of contamination and error in preparation.",
"   </p>",
"   <p>",
"    The rationale for this approach is that raising the urine pH above 6.5 may prevent heme-protein precipitation with Tamm-Horsfall protein, intratubular pigment cast formation, uric acid precipitation, correct metabolic acidosis and reduce hyperkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/1,3,22\">",
"     1,3,22",
"    </a>",
"    ]. Alkalinization may also decrease the release of free iron from myoglobin and the formation of F2-isoprostanes, which may enhance renal vasoconstriction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these potential benefits, there is no clear clinical evidence that an alkaline diuresis is more effective than a saline diuresis in preventing acute kidney injury, as no direct comparative trial has been performed. The best data in support of an alkaline diuresis are derived from uncontrolled case series. In a study cited above, for example, renal failure did not develop in seven patients with crush syndrome who were trapped under rubble and were treated with alkaline diuresis immediately after extrication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/17\">",
"     17",
"    </a>",
"    ]. By comparison, one patient who did not receive prophylactic volume developed acute kidney injury and required hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal regimen and rate of administration of bicarbonate are unknown. We generally administer one of the following two fluid regimens after extrication (",
"    <a class=\"graphic graphic_algorithm graphicRef83616 \" href=\"UTD.htm?27/33/28190\">",
"     algorithm 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One liter of isotonic saline alternating with 1 liter of half isotonic saline plus 50 meq of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Isotonic saline for the first 2 liters, followed by 1 liter of half isotonic saline plus 50 meq of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      . This sequence is then repeated, as indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice between these two regimens depends in part upon the general clinical and biochemical condition of the patient and the blood pH. As an example, if measured laboratory values reflect only a mild acidosis, more liters of isotonic saline and fewer liters of bicarbonate-containing solution are given.",
"   </p>",
"   <p>",
"    The rate of fluid administration with either regimen is based upon the ability to attain urinary output goals, and assessment of volume status. In general, we administer the intravenous solution at 500",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    for the first 24 hours as long as there is no evidence of fluid overload and the patient can be closely monitored. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Urine output goal'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The rate of fluid administration is decreased after the first 24 hours but is still maintained at a rate that is greater than the urine output, as long as there is no evidence of fluid overload. Generally, a total of 200 to 300 meq of bicarbonate is given on the first day as long as the patient is not alkalemic. The exact rate and regimen is altered based upon ongoing clinical assessment and laboratory values. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Urine output goal'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Potential risks associated with alkalinization of the plasma include promoting calcium phosphate deposition and inducing or worsening the manifestations of hypocalcemia by both a direct membrane effect and a reduction in ionized calcium levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/3\">",
"     3",
"    </a>",
"    ]. Manifestations of severe ionized hypocalcemia include tetany, seizures, and arrhythmias. To minimize the risk of these complications, the arterial pH should not exceed 7.5. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=see_link\">",
"     \"Clinical manifestations of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alkalinization can also reduce the plasma potassium concentration secondary to intracellular shift. This is often a beneficial effect, since the combination of tissue breakdown and renal failure often leads to hyperkalemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of hypokalemia\", section on 'Increased entry into cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the potential risks with bicarbonate therapy, we recommend close monitoring of serum bicarbonate, calcium, and potassium, and the urine pH. The urine pH can be measured by immersion of a simple urine dipstick, but this is only reliable on freshly voided urine, unless urine is collected under paraffin (which is difficult to obtain in chaotic disaster conditions). The goal urine pH is greater than 6.5. We recommend discontinuing the bicarbonate-containing solution (but continuing to replete volume with isotonic saline) if the arterial pH exceeds 7.5, the serum bicarbonate exceeds 31",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    or the patient develops symptomatic hypocalcemia. Calcium supplementation should be given only for symptomatic hypocalcemia or severe hyperkalemia, since early deposition of calcium in muscle is followed by hypercalcemia later in the injury process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link\">",
"     \"Treatment of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Use of mannitol",
"    </span>",
"    &nbsp;&mdash;&nbsp;If urinary flow is adequate (defined as &gt;20",
"    <span class=\"nowrap\">",
"     mL/hour),",
"    </span>",
"    50 mL of 20 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day [total, 120 g], given at a rate of 5 g per hour) may be added to each liter of fluid providing an increase in urine output is demonstrated following a test dose of mannitol. Among members of the RDRTF-ERBP crush recommendation work group, however, there was no consensus regarding mannitol administration, although most experts suggested assessing the response to a test dose first if mannitol were used [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/21\">",
"     21",
"    </a>",
"    ]. A reasonable test dose is 60 mL of a 20 percent solution of mannitol administered intravenously over three to five minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/21\">",
"     21",
"    </a>",
"    ]. If there is no significant increase in the urine output by at least 30 to 50",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    above baseline levels, mannitol should not be continued.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     Mannitol",
"    </a>",
"    should only be used if close monitoring is possible. Mannitol is contraindicated in patients with oligoanuria.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     Mannitol",
"    </a>",
"    should be discontinued if the desired diuresis of approximately 200 to 300",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    cannot be achieved, since there is a risk of hyperosmolality, volume overload, and hyperkalemia with continued mannitol administration under these conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32451?source=see_link\">",
"     \"Complications of mannitol therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism by which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    protects against heme pigment-induced ATN is not completely clear. Experimental studies have suggested that mannitol may be protective by causing a diuresis, which minimizes intratubular heme pigment deposition and cast formation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/23\">",
"     23",
"    </a>",
"    ]. It has also been proposed that mannitol may act as a free radical scavenger, thereby minimizing cell injury [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition to these beneficial effects on the kidney, mannitol may extract sequestered water from the injured muscles, thus preventing compartmental syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, at least some studies have shown no amelioration of proximal tubular necrosis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , and mannitol may cause hyperosmolality and other complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/23\">",
"     23",
"    </a>",
"    ]. The available retrospective series, most of which are uncontrolled, report conflicting results regarding the effectiveness of mannitol plus bicarbonate in preventing heme pigment-induced AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/16,17,25,26\">",
"     16,17,25,26",
"    </a>",
"    ]. As an example, 154 of 382 patients with serum CK concentration &gt;5000",
"    <span class=\"nowrap\">",
"     units/L",
"    </span>",
"    were treated with mannitol plus bicarbonate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/26\">",
"     26",
"    </a>",
"    ]. There was no statistically significant difference in the incidence of AKI (defined as creatinine &gt;2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [177",
"    <span class=\"nowrap\">",
"     micromol/L];",
"    </span>",
"    22 versus 18 percent), dialysis (7 versus 6 percent), or death (15 versus 18 percent) in patients who were or were not treated with mannitol plus bicarbonate. However, there was a trend toward improved outcomes in patients with extremely high CK levels (&gt;30,000",
"    <span class=\"nowrap\">",
"     units/L)",
"    </span>",
"    treated with mannitol and bicarbonate. This is relevant, given that such high levels are not unusual in victims of earthquakes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/17,20\">",
"     17,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interpretation of these findings is hampered by the lack of reporting of other elements of treatment, such as adequacy of volume resuscitation, presence of other factors contributing to AKI (eg, drugs, sepsis, hypotension), timing of interventions, and relatively low rate of severe AKI (eg, requiring dialysis).",
"   </p>",
"   <p>",
"    Unless the patient is carefully monitored and losses replaced when appropriate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    can lead to both volume depletion and, since free water is lost with mannitol, hypernatremia. Mannitol administered in very high doses, or to patients with reduced renal excretion due to renal insufficiency, can also raise plasma osmolality sufficiently to cause symptoms of hyperosmolality and volume expansion. The increase in plasma osmolality can also cause passive movement of potassium out of cells and raise the plasma potassium concentration. AKI may occur if patients are treated with more than 200 g of mannitol per day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32451?source=see_link\">",
"     \"Complications of mannitol therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Prevention of hyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although sporadic patients with rhabdomyolysis or the crush syndrome may develop hypokalemia, the large majority are hyperkalemic, which is life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/10,27-29\">",
"     10,27-29",
"    </a>",
"    ]. Hyperkalemia may occur even in the absence of AKI, since a large amount of potassium may be released from injured muscle. Since potassium measurements at first triage are seldom available in disaster conditions, transport of victims with a potential crush syndrome to safer areas for more intensive treatment should be started, if possible, after the administration of a preventive oral dose of the potassium binding resin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/16/43269?source=see_link\">",
"     sodium polystyrene sulfonate",
"    </a>",
"    , in combination with 33 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , at a 1:3 ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/16/43269?source=see_link\">",
"     sodium polystyrene sulfonate",
"    </a>",
"    has been questioned, and although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    has sporadically been associated with ulcers of the intestinal wall [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/30\">",
"     30",
"    </a>",
"    ], we suggest their use in disaster crush victims, since the risk of fatal hyperkalemia is extremely high. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment and prevention of hyperkalemia in adults\", section on 'Cation exchange resins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since a calcium load is to be avoided,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/16/43269?source=see_link\">",
"     sodium polystyrene sulfonate",
"    </a>",
"    should be preferred to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/8/24708?source=see_link\">",
"     calcium polystyrene sulfonate",
"    </a>",
"    . (Calcium polystyrene sulfonate is not available in the United States, although it is available elsewhere.)",
"   </p>",
"   <p>",
"    Many of the isotonic solutions for fluid repletion contain potassium (eg, Ringer's lactate). Because of the risk for life-threatening hyperkalemia, empiric administration of such preparations is absolutely contraindicated in patients at risk for the crush syndrome.",
"   </p>",
"   <p>",
"    We recommend monitoring plasma potassium several times daily until stabilized. In many victims fluid administration is initiated in the field or during transportation; but contrary to all recommendations, these solutions may contain potassium [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/31\">",
"     31",
"    </a>",
"    ]. Therefore, on admission to hospitals all fluid infusions should be checked, and potassium containing solutions should be stopped.",
"   </p>",
"   <p>",
"    Hyperkalemia should be appropriately treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If serum potassium concentration cannot be measured due to field conditions, electrocardiography (ECG) can offer useful information, although a normal ECG may be present in spite of overt hyperkalemia. In the 2010 Haiti earthquake, point-of-care devices (eg, iSTAT, Abbott, USA) were invaluable in disaster field conditions providing direct electrolyte and creatinine measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/32\">",
"     32",
"    </a>",
"    ]. These devices or ECG should be used for the early detection of hyperkalemia, which helps deciding whether dialysis treatment is needed or first volume resuscitation can be attempted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Urine output goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the patient can be closely monitored (such as hospital or triage setting), the administration of intravenous fluid should be adjusted to maintain the urinary output at approximately 200 to 300",
"    <span class=\"nowrap\">",
"     mL/hour.",
"    </span>",
"    This is done to help ensure adequate renal perfusion and to wash out any obstructing casts. Patients must be followed closely to ensure that fluid overload, as defined by signs of pulmonary congestion, does not occur. As previously mentioned, limb swelling alone may not represent volume overload.",
"   </p>",
"   <p>",
"    If a bladder catheter has not been placed before hospitalization, after excluding urethral bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laceration, it should be inserted to all crush victims to follow urine flow [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/21\">",
"     21",
"    </a>",
"    ]. Catheters carry a risk of infection, especially in the chaos accompanying most disasters. Therefore, unless there is an obligatory indication such as unconsciousness, pelvic trauma, possible urethral obstruction, immobilization or surgery, the catheter should be removed once the patient has established oligoanuric AKI or achieves normal kidney function and monitoring urine production provides no further useful information.",
"   </p>",
"   <p>",
"    If the urine output goal is achieved, intravenous fluids should be administered until the disappearance of myoglobinuria (either clinically or biochemically). This usually requires several days.",
"   </p>",
"   <p>",
"    However, if the desired diuresis is not established, we recommend placement of a central venous pressure (CVP) catheter when feasible, in addition to close monitoring of input and all losses (urinary volume plus other losses together) of the previous day. Forced diuresis should be abandoned if CVP measurements exceed acceptable thresholds (15 cm H2O).",
"   </p>",
"   <p>",
"    Therapy should be based on physical examination and, in circumstances where it is available, CVP measurements, biochemical analysis, close monitoring of fluid intake and output, and body weight. A stable weight may suggest that the appropriate amount of fluid is being administered to the patient. However, if the patient is anuric and catabolic, a stable body weight may be deceptive. In those cases, we administer 500 to 1000 mL of fluid in excess of all losses of the previous day.",
"   </p>",
"   <p>",
"    After serum CK levels begin to return to normal, the volume of administered fluids should be gradually tapered under close clinical and laboratory monitoring. A parallel decrease in urinary output together with normal clinical and biochemical findings indicates that tubular function has been restored.",
"   </p>",
"   <p>",
"    Dialysis should be initiated in the setting of persistent oligoanuria or other indications. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Treatment of established AKI'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Total volume administered",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total amount of volume administered depends upon the clinical scenario. A positive fluid balance is always necessary in crush syndrome casualties, since extreme amounts of fluids can diffuse into the damaged muscles.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     Mannitol",
"    </a>",
"    -alkaline solution can be administered at quantities of up to 12",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    to an adult weighing 75 kg and with appropriate urine response. Eight liters of urinary output can be expected following an infusion of 12 L of this solution. Therefore, it is reasonable to administer 4 to 4.5 L more fluid than all of the total losses of the previous 24-hour period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/2\">",
"     2",
"    </a>",
"    ]. Analysis of the Bingol earthquake demonstrated that dialysis was avoided in many patients with crush syndrome by administering more than 20 L of fluid per day to each patient [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/16\">",
"     16",
"    </a>",
"    ]. The relatively low number of victims injured in this particular disaster allowed for more careful monitoring of each victim, which allowed the vigorous volume repletion.",
"   </p>",
"   <p>",
"    Fluid administration should be individualized and may need to be less energetic in chaotic disaster circumstances when it is impossible to monitor patients appropriately to avoid volume overload. Under these circumstances, more modest volume repletion is recommended. Although the exact optimal limit is unknown, we suggest administering up to a maximum of 6 L of fluid per day under prolonged conditions in which close monitoring may not be possible. More cautious volume repletion is also warranted in victims who are prone to cardiac failure, such as the elderly, and in those who are anuric [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Calcium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium supplementation should be given only for symptomatic hypocalcemia or severe hyperkalemia, because early deposition of calcium in muscle is followed by hypercalcemia later in the injury process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link\">",
"     \"Treatment of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Loop diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loop diuretics have no impact on outcome in AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=see_link\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    .) In the context of rhabdomyolysis, loop diuretics may worsen the already existing trend for hypocalcemia, since they induce calciuria and may increase the risk of cast formation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/15,20\">",
"     15,20",
"    </a>",
"    ]. Despite these concerns, however, judicious use of loop diuretics may be justified in elderly patients, especially if volume overloaded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT OF ESTABLISHED AKI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other than maintenance of fluid and electrolyte balance and tissue perfusion, there is no specific therapy once the patient has developed AKI. Dialysis is initiated for the usual indications, including volume overload, hyperkalemia, severe acidemia, and uremia. Frequent (twice or even three times daily) hemodialysis may be indicated in patients with crush syndrome, given the high risk of fatal hyperkalemia. A detailed discussion of the indications for dialysis is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intermittent hemodialysis is suggested over other renal replacement modalities in the setting of crush syndrome. Compared with other modalities, intermittent hemodialysis is most efficient at removing potassium, which is one of the major causes of death [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15369/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9642?source=see_link\">",
"     \"Acute hemodialysis prescription\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other renal replacement modalities have the following additional limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peritoneal dialysis (PD) might be difficult to perform in case of abdominal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thoracic trauma, or in patients who cannot lie down due to hypervolemia-related heart failure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      respiratory failure. PD may also not adequately treat the metabolic and electrolyte derangements caused by rhabdomyolysis (eg, hyperkalemia and other abnormalities), especially in the heavily traumatized patients. Furthermore, PD may create logistic problems in mass disasters, due to the necessity to deliver large loads of bags containing sterile dialysis fluid to the disaster area. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12169?source=see_link\">",
"       \"Use of peritoneal dialysis for the treatment of acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Continuous dialysis strategies are limited by the need for large amounts of sterile replacement fluid that may be difficult to obtain in disaster conditions. In addition, only one patient can be treated per machine when continuous modalities are used. Finally, continuous anticoagulation by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      may enhance a bleeding tendency in heavily traumatized patients. Regional citrate anticoagulation avoids the problems associated with anticoagulation but is difficult to monitor in chaotic disaster circumstances. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38516?source=see_link\">",
"       \"Continuous renal replacement therapies: Overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=see_link\">",
"       \"Patient information: Acute kidney failure (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/59/22450?source=see_link\">",
"       \"Patient information: Rhabdomyolysis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypovolemia due to various reasons and high circulating levels in the plasma of myoglobin secondary to rhabdomyolysis can directly cause acute tubular necrosis (ATN), resulting in acute kidney injury (AKI). Rhabdomyolysis-associated AKI due to crush injury is a major source of morbidity and mortality in natural or man-made disasters. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among entrapped subjects prone to develop the crush syndrome, we suggest the following approach:",
"     </li>",
"     <li>",
"      We recommend the intravenous administration of an isotonic solution at a high fluid rate (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest starting intravenous fluid replacement prior to and during extrication of the victim whenever possible (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest giving isotonic saline rather than an isotonic alkaline solution (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Although the exact rate has not been defined by controlled studies, we suggest administering fluid at 1",
"      <span class=\"nowrap\">",
"       L/hour",
"      </span>",
"      initially. After 2 liters are given, the rate of administration should be decreased to 500",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      to avoid volume overload. The rate should be adjusted depending on age, body weight, trauma pattern, ambient temperature, urine production, and amount of overall estimated fluid losses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Since severe hyperkalemia is relatively common, intravenous solutions containing potassium, such as Ringer's lactate, are contraindicated. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Before and during extrication'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After the victim has been removed from the rubble and urine output has been documented, we suggest switching from isotonic saline to an isotonic bicarbonate solution (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The optimal regimen and rate of administration are unknown. Following extrication, we administer the intravenous solution at 500",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      for the first day, if there is no evidence of fluid overload and the patient can be closely monitored. We recommend close monitoring of serum bicarbonate, calcium, potassium, and serum and urine pH. We recommend discontinuing the alkaline solution if symptomatic hypocalcemia develops. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Use of bicarbonate'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If urinary flow is &gt;20",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      among victims removed from the rubble, we suggest adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      to the intravenous alkaline solution providing an increase in urine output is demonstrated following a test dose (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A suggested test dose is 60 mL of a 20 percent solution of mannitol administered intravenously over three to five minutes. If urine output increases by at least 30 to 50",
"      <span class=\"nowrap\">",
"       mL/h",
"      </span>",
"      above baseline levels in response to the test dose, 50 mL of 20 percent mannitol (1 to 2",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day [total, 120 g], may be given at a rate of 5",
"      <span class=\"nowrap\">",
"       g/hour).",
"      </span>",
"      Mannitol is contraindicated in patients with oligoanuria.",
"      <br/>",
"      <br/>",
"      We recommend discontinuing mannitol if the desired diuresis cannot be achieved (approximately 200 to 300",
"      <span class=\"nowrap\">",
"       mL/hour)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Use of mannitol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the patient can be closely monitored (such as hospital or triage setting), the administration of intravenous fluid should be adjusted to maintain the urinary output at approximately 200 to 300",
"      <span class=\"nowrap\">",
"       mL/hour.",
"      </span>",
"      If the urine output goal is achieved, we suggest continuing fluid therapy until the disappearance of myoglobinuria (either clinically or biochemically). This usually requires several days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest placement of a central venous pressure (CVP) catheter, when it is feasible, once the patient is in a hospital setting and closely monitoring input and all losses (urinary volume plus other losses together) of the previous day. In this setting, therapy should be based on physical examination, CVP measurements, biochemical analysis, close monitoring of fluid intake and output, and body weight. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Urine output goal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend monitoring plasma potassium and calcium several times daily until stabilized. We recommend treating hyperkalemia as discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"       \"Treatment and prevention of hyperkalemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with symptomatic hypocalcemia or severe hyperkalemia may require calcium supplementation. In patients with asymptomatic hypocalcemia, we suggest not providing calcium supplementation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of hypocalcemia\", section on 'Therapeutic approach'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"       \"Treatment and prevention of hyperkalemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dialysis is initiated for the usual indications, including volume overload, hyperkalemia, severe acidemia, and uremia. Among patients with heme pigment-induced AKI due to crush injury, we suggest intermittent hemodialysis rather than other renal replacement modalities (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9642?source=see_link\">",
"       \"Acute hemodialysis prescription\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/1\">",
"      Zager RA. Studies of mechanisms and protective maneuvers in myoglobinuric acute renal injury. Lab Invest 1989; 60:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/2\">",
"      Better OS, Stein JH. Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N Engl J Med 1990; 322:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/3\">",
"      Zager RA. Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int 1996; 49:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/4\">",
"      Odeh M. The role of reperfusion-induced injury in the pathogenesis of the crush syndrome. N Engl J Med 1991; 324:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/5\">",
"      Bartal C, Zeller L, Miskin I, et al. Crush syndrome: saving more lives in disasters: lessons learned from the early-response phase in Haiti. Arch Intern Med 2011; 171:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/6\">",
"      Sheng ZY. Medical support in the Tangshan earthquake: a review of the management of mass casualties and certain major injuries. J Trauma 1987; 27:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/7\">",
"      Sever MS, Erek E, Vanholder R, et al. The Marmara earthquake: epidemiological analysis of the victims with nephrological problems. Kidney Int 2001; 60:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/8\">",
"      Oda J, Tanaka H, Yoshioka T, et al. Analysis of 372 patients with Crush syndrome caused by the Hanshin-Awaji earthquake. J Trauma 1997; 42:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/9\">",
"      Hatamizadeh P, Najafi I, Vanholder R, et al. Epidemiologic aspects of the Bam earthquake in Iran: the nephrologic perspective. Am J Kidney Dis 2006; 47:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/10\">",
"      Sever MS, Erek E, Vanholder R, et al. Lessons learned from the Marmara disaster: Time period under the rubble. Crit Care Med 2002; 30:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/11\">",
"      Sever MS, Erek E, Vanholder R, et al. Treatment modalities and outcome of the renal victims of the Marmara earthquake. Nephron 2002; 92:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/12\">",
"      Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine (Baltimore) 1982; 61:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/13\">",
"      Ward MM. Factors predictive of acute renal failure in rhabdomyolysis. Arch Intern Med 1988; 148:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/14\">",
"      Vanholder R, Sever MS, Erek E, Lameire N. Rhabdomyolysis. J Am Soc Nephrol 2000; 11:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/15\">",
"      Sever MS, Vanholder R, Lameire N. Management of crush-related injuries after disasters. N Engl J Med 2006; 354:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/16\">",
"      Gunal AI, Celiker H, Dogukan A, et al. Early and vigorous fluid resuscitation prevents acute renal failure in the crush victims of catastrophic earthquakes. J Am Soc Nephrol 2004; 15:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/17\">",
"      Ron D, Taitelman U, Michaelson M, et al. Prevention of acute renal failure in traumatic rhabdomyolysis. Arch Intern Med 1984; 144:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/18\">",
"      Kazancio��lu R, Korular D, Sever MS, et al. The outcome of patients presenting with crush syndrome after the Marmara earthquake. Int J Artif Organs 2001; 24:17.",
"     </a>",
"    </li>",
"    <li>",
"     Reis, ND, Michaelson, M. Crush injury to the lower limbs. Treatment of the local injury. J Bone Joint Surg Am 1986; 68.414.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/20\">",
"      Slater MS, Mullins RJ. Rhabdomyolysis and myoglobinuric renal failure in trauma and surgical patients: a review. J Am Coll Surg 1998; 186:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/21\">",
"      Sever MS, Vanholder R, RDRTF of ISN Work Group on Recommendations for the Management of Crush Victims in Mass Disasters. Recommendation for the management of crush victims in mass disasters. Nephrol Dial Transplant 2012; 27 Suppl 1:i1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/22\">",
"      Moore KP, Holt SG, Patel RP, et al. A causative role for redox cycling of myoglobin and its inhibition by alkalinization in the pathogenesis and treatment of rhabdomyolysis-induced renal failure. J Biol Chem 1998; 273:31731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/23\">",
"      Zager RA. Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications. J Clin Invest 1992; 90:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/24\">",
"      Better OS, Rubinstein I, Winaver JM, Knochel JP. Mannitol therapy revisited (1940-1997). Kidney Int 1997; 52:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/25\">",
"      Homsi E, Barreiro MF, Orlando JM, Higa EM. Prophylaxis of acute renal failure in patients with rhabdomyolysis. Ren Fail 1997; 19:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/26\">",
"      Brown CV, Rhee P, Chan L, et al. Preventing renal failure in patients with rhabdomyolysis: do bicarbonate and mannitol make a difference? J Trauma 2004; 56:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/27\">",
"      Sever MS, Erek E, Vanholder R, et al. Serum potassium in the crush syndrome victims of the Marmara disaster. Clin Nephrol 2003; 59:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/28\">",
"      Collins AJ, Burzstein S. Renal failure in disasters. Crit Care Clin 1991; 7:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/29\">",
"      Noji EK. Acute renal failure in natural disasters. Ren Fail 1992; 14:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/30\">",
"      Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 2010; 21:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/31\">",
"      Sever MS, Erek E, Vanholder R, et al. The Marmara earthquake: admission laboratory features of patients with nephrological problems. Nephrol Dial Transplant 2002; 17:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/32\">",
"      Vanholder R, Borniche D, Claus S, et al. When the earth trembles in the Americas: the experience of Haiti and Chile 2010. Nephron Clin Pract 2011; 117:c184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/33\">",
"      Vanholder R, Sever MS, De Smet M, et al. Intervention of the Renal Disaster Relief Task Force in the 1999 Marmara, Turkey earthquake. Kidney Int 2001; 59:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/34\">",
"      Lameire N, Vanholder R, Van Biesen W. Loop diuretics for patients with acute renal failure: helpful or harmful? JAMA 2002; 288:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15369/abstract/35\">",
"      Mehta RL, Pascual MT, Soroko S, et al. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002; 288:2547.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7227 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-0ACB48A304-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_0_15369=[""].join("\n");
var outline_f15_0_15369=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dark urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      BIOCHEMICAL ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Before and during extrication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Evidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H428143791\">",
"      After extrication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Use of bicarbonate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Use of mannitol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Prevention of hyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Urine output goal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Total volume administered",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Calcium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Loop diuretics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT OF ESTABLISHED AKI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7227\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7227|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/44/1742\" title=\"algorithm 1\">",
"      Treatment algorithm for entrapped victims",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?27/33/28190\" title=\"algorithm 2\">",
"      Treatment algorithm for victims after extrication",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/26/9642?source=related_link\">",
"      Acute hemodialysis prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32451?source=related_link\">",
"      Complications of mannitol therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38516?source=related_link\">",
"      Continuous renal replacement therapies: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=related_link\">",
"      Definition of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/46/5859?source=related_link\">",
"      Patient information: Acute kidney failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/59/22450?source=related_link\">",
"      Patient information: Rhabdomyolysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=related_link\">",
"      Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12169?source=related_link\">",
"      Use of peritoneal dialysis for the treatment of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_0_15370="Chromoendoscopy";
var content_f15_0_15370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chromoendoscopy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/0/15370/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/0/15370/contributors\">",
"     Marcia Irene Canto, MD, MHS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/0/15370/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/0/15370/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/0/15370/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/0/15370/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/0/15370/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromoendoscopy involves the topical application of stains or pigments to improve tissue localization, characterization, or diagnosis during endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/1\">",
"     1",
"    </a>",
"    ]. Several agents have been described that can broadly be categorized as absorptive (vital) stains, contrast stains, and reactive stains (",
"    <a class=\"graphic graphic_table graphicRef68885 \" href=\"UTD.htm?16/5/16477\">",
"     table 1",
"    </a>",
"    ). Absorptive stains (eg, Lugol's solution and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    ) diffuse or are preferentially absorbed across specific epithelial cell membranes. Contrast stains (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    ) highlight surface topography and mucosal irregularities by permeating mucosal crevices. Reactive stains (eg, Congo red and phenol red) undergo chemical reactions with specific cellular constituents, resulting in a color change. The stains used for chromoendoscopy are transient, unlike the stains used to tattoo lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/51/30519?source=see_link&amp;anchor=H13#H13\">",
"     \"Tattooing and other methods for localizing colonic lesions\", section on 'Tattooing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chromoendoscopy has been applied in a variety of clinical settings and throughout the gastrointestinal tract. Interest in chromoendoscopy increased with the development of technologies such as endoscopic mucosal resection and photodynamic therapy that require precise visual tissue characterization. In addition, chromoendoscopy is being used in conjunction with other advances in endoscopic imaging, such as magnification endoscopy, confocal endomicroscopy, and confocal endocytoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=see_link\">",
"     \"Magnification endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3113?source=see_link\">",
"     \"Confocal laser endomicroscopy and endocytoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compared with other evolving diagnostic modalities, such as fluorescence spectroscopy, fluorescence endoscopy, and optical coherence tomography, the equipment needed for chromoendoscopy is widely available. Furthermore, the techniques are simple, quick, inexpensive, and safe. However, the interpretation of the findings is not always straightforward and, like many endoscopic techniques, the impact of chromoendoscopy on clinical outcomes relative to standard endoscopic and histologic methods has not been established in large controlled trials.",
"   </p>",
"   <p>",
"    This topic will review chromoendoscopy, which generally refers to the application of stains or pigments by spraying through a catheter. Endoscopic tattooing (the injection of dye through a needle to mark a site for future identification), optical coherence tomography, narrow band imaging, magnification endoscopy, and autofluorescence endoscopy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/51/30519?source=see_link&amp;anchor=H13#H13\">",
"     \"Tattooing and other methods for localizing colonic lesions\", section on 'Tattooing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/41/7831?source=see_link\">",
"     \"Optical coherence tomography in the gastrointestinal tract\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=see_link\">",
"     \"Narrow band imaging in Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=see_link\">",
"     \"Magnification endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13750?source=see_link\">",
"     \"Autofluorescence endoscopy for Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimal equipment is required for chromoendoscopy, and the reagents used are generally widely available. The procedure is carried out using standard endoscopic equipment. In addition, a special spray catheter (such as the Olympus PW-5L, Olympus America, Inc., Melville, New York) is essential, since it delivers a fine mist to the mucosa (",
"    <a class=\"graphic graphic_movie graphicRef76175 \" href=\"UTD.htm?13/40/13967\">",
"     movie 1",
"    </a>",
"    ). The catheters are reusable and last several years, even when used frequently. A new biopsy channel cap is preferable to minimize the amount of stain that leaks out.",
"   </p>",
"   <p>",
"    Stains that are used for chromoendoscopy include Lugol's solution,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    , toluidine blue, Congo red, phenol red, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    . In order to choose the appropriate stain, the endoscopist needs to be familiar with the characteristics of the individual stains and the staining features of specific tissues (",
"    <a class=\"graphic graphic_table graphicRef68885 \" href=\"UTD.htm?16/5/16477\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technique for staining is simple and easy to learn. Certain staining techniques require specific tissue preparations, which are described below. Once that has been accomplished, application of the stain is generally straightforward. The endoscope and catheter tip should be directed toward the mucosa using a combination of rotational clockwise-counterclockwise movements, while simultaneously withdrawing the endoscope tip.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    or glucagon can be administered immediately prior to staining to minimize contractility and thereby facilitate staining.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8675659\">",
"    <span class=\"h1\">",
"     SPECIFIC DYES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lugol's solution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lugol's solution contains potassium iodine and iodine, which have an affinity for glycogen in nonkeratinized squamous epithelium. The stock solution needs to be diluted to 1 to 4 percent (usually 2 to 3 percent strength works best) followed by spraying of 20 to 50 mL through a spray catheter. Normal squamous epithelium stains black, dark brown, or green-brown after a few minutes (",
"    <a class=\"graphic graphic_picture graphicRef71269 \" href=\"UTD.htm?3/11/3248\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An abnormal staining pattern (absence of dye uptake) is associated with conditions that result in depletion of glycogen in squamous cells, such as inflammatory change (eg, reflux esophagitis), dysplasia, or early malignancy. Staining with Lugol's solution is particularly helpful in patients at increased risk for squamous cell carcinoma (such as those who abuse alcohol) and in those with head and neck cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. As a result, it is most commonly used in the esophagus for detection of squamous dysplasia and early squamous cell carcinoma (",
"    <a class=\"graphic graphic_picture graphicRef71269 \" href=\"UTD.htm?3/11/3248\">",
"     picture 1",
"    </a>",
"    ). Because it can help in revealing the extent and delineation of a lesion, it can be used to guide endoscopic mucosal resection of early squamous cell carcinomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=see_link\">",
"     \"Overview of endoscopic resection of gastrointestinal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lugol's is also used to differentiate regenerating squamous epithelium from small areas of residual Barrett's mucosa in patients who have undergone mucosal ablation (eg, after photodynamic therapy or multipolar electrocoagulation). The residual areas of Barrett's esophagus will not stain, but the regenerating squamous islands and normal squamous epithelium will appear dark brown or black (",
"    <a class=\"graphic graphic_picture graphicRef75257 \" href=\"UTD.htm?28/3/28720\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7593976\">",
"    <span class=\"h3\">",
"     Efficacy of Lugol's staining",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the detection of squamous lesions, staining with Lugol's solution has a sensitivity of 91 to 100 percent and a specificity of 40 to 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of Lugol's staining has been demonstrated in studies looking at the detection and evaluation of esophageal squamous neoplasia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study that included 158 patients at high-risk for squamous cell cancer (because of a history of smoking and alcoholism) demonstrated that Lugol's staining improved the evaluation of the extent of lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/10\">",
"       10",
"      </a>",
"      ]. Twelve of the patients had cancerous lesions detected by endoscopy before Lugol's staining, with one additional patient with cancer being identified after staining. There was a significant difference in the size of the lesions detected before and after staining. The dye-free surfaces (suggestive of malignancy) after staining averaged 11.6 cm",
"      <sup>",
"       2",
"      </sup>",
"      compared with the endoscopically measured mucosal involvement before staining of 1.4 cm",
"      <sup>",
"       2",
"      </sup>",
"      .",
"     </li>",
"     <li>",
"      In a series of 225 patients, Lugol's staining increased the identification of both moderate and severe dysplasia, but not of cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/9\">",
"       9",
"      </a>",
"      ]. Of 31 patients with moderate dysplasia, 17 (55 percent) were identified only after staining with Lugol's solution. Of the 35 patients with severe dysplasia, eight (23 percent) were identified only after staining. In addition, 88 percent of the high-grade dysplasia and cancerous lesions were larger or more clearly defined after staining.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Safety of Lugol's staining",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lugol's staining may lead to a transient retrosternal discomfort. A controlled trial suggested that the application of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/18/17700?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    solution (20 mL of a 5 percent solution) following staining was associated with a significant reduction in discomfort 30 minutes after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients with a history of iodine allergy should not undergo Lugol's staining. Severe allergic reactions have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/12\">",
"     12",
"    </a>",
"    ], as have cases of chemical esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/13\">",
"     13",
"    </a>",
"    ] and gastritis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Methylene blue",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     Methylene blue",
"    </a>",
"    is a vital stain taken up by actively absorbing tissues such as small intestinal and colonic epithelium. It does not stain nonabsorptive epithelia such as squamous or gastric mucosa.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     Methylene blue",
"    </a>",
"    staining has been studied in the esophagus, stomach, and small and large intestines. In the small intestine and colon, a lack of staining suggests metaplastic, neoplastic, or inflammatory change, whereas in other areas of the gastrointestinal tract it is used to identify metaplastic absorptive mucosa (eg, Barrett's mucosa).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     Methylene blue",
"    </a>",
"    staining is used to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aid in the detection of Barrett's esophagus and associated dysplasia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      early cancer.",
"     </li>",
"     <li>",
"      Improve the diagnosis of early gastric cancer, either alone [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/15\">",
"       15",
"      </a>",
"      ] or in combination with Congo red dye [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Identify metaplastic absorptive epithelium, such as intestinal-type metaplasia in the stomach [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/17\">",
"       17",
"      </a>",
"      ]. In addition, because it only stains absorptive epithelium, it can identify metaplastic nonabsorptive epithelium (such as ectopic gastric metaplasia) in areas that have background staining, such as the small bowel.",
"     </li>",
"     <li>",
"      Highlight subtle mucosal changes in the small intestine (eg, celiac disease [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/18\">",
"       18",
"      </a>",
"      ]).",
"     </li>",
"     <li>",
"      Detect colonic neoplasia (flat adenomas and carcinomas) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Detect the extent of inflammatory changes and aid in the detection of intraepithelial neoplasia in patients with chronic ulcerative colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Methylene blue application",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     Methylene blue",
"    </a>",
"    staining involves the application of a mucolytic, followed by dye, followed by washing off excess dye. Surface mucus must be removed by applying a mucolytic agent to increase the uptake of the dye into epithelial cells. The original technique for staining reported by Japanese endoscopists involved ingestion of a proteolytic enzyme solution (proteinase or Pronase) followed by methylene blue in a capsule [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/15,21\">",
"     15,21",
"    </a>",
"    ]. The Japanese technique was adapted for use in the United States by substituting a 10 percent solution of N-acetylcysteine for Pronase and a 0.5 percent solution of methylene blue for the capsule [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reagents are sequentially sprayed onto the mucosa using a washing catheter (",
"    <a class=\"graphic graphic_picture graphicRef66043 \" href=\"UTD.htm?34/38/35438\">",
"     picture 3",
"    </a>",
"    ). Excess dye is then vigorously washed off with syringes. The endpoint of staining is subjective and is the most difficult part to learn. As a general rule, washing should continue until the staining pattern is stable. The most common mistake is failure to adequately rinse the mucosa following dye application. Positive staining is defined as the presence of blue-stained mucosa that persists despite vigorous water irrigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1997858\">",
"    <span class=\"h3\">",
"     Staining patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    is taken up by actively absorbing cells, such as small intestine or colonic epithelium, or ectopic intestinal mucosa. It does not stain nonabsorptive epithelia. Thus, staining in the small intestine or colon will normally lead to diffuse background absorption of the dye. Abnormal areas, such as inflamed or neoplastic tissue, will not stain. On the other hand, in the case of metaplastic intestinal mucosa, as is seen in Barrett's esophagus, the abnormal absorptive mucosa will appear blue, while the normal background mucosa will not take up the stain.",
"   </p>",
"   <p>",
"    In patients with Barrett's esophagus, staining may be focal (",
"    <a class=\"graphic graphic_picture graphicRef60183 \" href=\"UTD.htm?28/17/28944\">",
"     picture 4",
"    </a>",
"    ) or diffuse (&gt;75 percent of Barrett's mucosa stains blue) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/22\">",
"     22",
"    </a>",
"    ]. Most patients with long-segment Barrett's esophagus have diffuse staining because specialized intestinal metaplasia comprises the majority of the columnar mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/22\">",
"     22",
"    </a>",
"    ]. The pattern of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    staining is important because dysplastic and malignant Barrett's esophagus behave differently from nondysplastic epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/23\">",
"     23",
"    </a>",
"    ]. Increasing grades of dysplasia are associated with focal areas of decreased stain intensity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased stain heterogeneity (ie, increasing proportion of light blue or pink unstained mucosa compared to dark blue mucosa). This results from the differential absorption of methylene blue dye into dysplastic cells that have varying degrees of goblet cell loss and decreased cytoplasm (the sites where the dye is absorbed). High-grade dysplasia and endoscopically-inapparent adenocarcinomas in Barrett's esophagus can be diagnosed by sampling the heterogeneously stained or light",
"    <span class=\"nowrap\">",
"     blue/unstained",
"    </span>",
"    epithelium (",
"    <a class=\"graphic graphic_picture graphicRef73339 \" href=\"UTD.htm?29/60/30656\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Abnormal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    staining can be helpful in delineating dysplastic or malignant areas for endoscopic therapy, such as endoscopic mucosal resection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/24\">",
"     24",
"    </a>",
"    ] or photodynamic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/25\">",
"     25",
"    </a>",
"    ]. The addition of magnification endoscopy to methylene blue staining may aid in the detection of Barrett's esophagus by classifying its histologic features (",
"    <a class=\"graphic graphic_picture graphicRef71929 \" href=\"UTD.htm?16/30/16866\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=see_link\">",
"     \"Magnification endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     Methylene blue",
"    </a>",
"    staining has also been used to detect colonic dysplasia. Pit patterns, which are highlighted by the methylene blue, have been described that correlate with neoplastic lesions. (See",
"    <a class=\"local\" href=\"#H1997758\">",
"     'Colonic dysplasia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Efficacy of methylene blue staining",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Barrett's esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most extensive experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    staining in the United States, Europe, Asia, and Latin America has been in the evaluation of patients with Barrett's esophagus (",
"    <a class=\"graphic graphic_picture graphicRef75257 \" href=\"UTD.htm?28/3/28720\">",
"     picture 2",
"    </a>",
"    ). Multiple reports have been published in final form or as abstracts that have shown discrepant results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/22,23,25,28-41\">",
"     22,23,25,28-41",
"    </a>",
"    ]. The discrepancies appear to be related to the learning curve for this staining technique; investigators with experience and studies with large sample sizes have reported the best results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/22-26,28-31,42\">",
"     22-26,28-31,42",
"    </a>",
"    ]. Perhaps because of these issues, a meta-analysis of nine studies with heterogeneous study designs, methods, and study populations concluded that methylene blue chromoendoscopy did not significantly increase the yield of detection of specialized intestinal metaplasia and dysplasia compared with random biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential to improve the detection of intestinal metaplasia was illustrated in a study of 975 patients with areas in the distal esophagus that were macroscopically conspicuous for Barrett's esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/42\">",
"     42",
"    </a>",
"    ]. All patients underwent conventional biopsies, after which the distal esophagus was sprayed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    ; additional targeted biopsies were obtained based upon the staining pattern. All patients with documented intestinal metaplasia underwent a repeat endoscopy within one year to assess the reproducibility of the method.",
"   </p>",
"   <p>",
"    A total of 3900 conventional biopsies without staining and 130 biopsies with staining were obtained. Conventional biopsies were significantly less likely to show intestinal metaplasia compared with dye-directed biopsies (1.4 versus 88 percent). The conventional biopsies diagnosed Barrett's esophagus in 16 patients (1.6 percent), whereas the dye-directed biopsies diagnosed it in 35 patients (3.5 percent), including all of the patients diagnosed with conventional biopsies. Intestinal metaplasia was confirmed on the follow-up endoscopy in all dye-positive patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1997758\">",
"    <span class=\"h4\">",
"     Colonic dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromoendoscopy has been used in patients undergoing colonoscopy, including those undergoing surveillance for chronic ulcerative colitis. Using pit pattern classifications, chromoendoscopy has a sensitivity of 92 to 98 percent and a specificity of 91 to 95 percent for differentiating neoplastic from non-neoplastic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/44\">",
"     44",
"    </a>",
"    ]. The Kudo pit pattern classification is most commonly used (",
"    <a class=\"graphic graphic_figure graphicRef69425 \" href=\"UTD.htm?5/39/5750\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Lesions with gyrus-like pits or non-structural pits are more likely to be neoplastic than lesions with round pits or stellar pits.",
"   </p>",
"   <p>",
"    One study found that when combined with high-magnification endoscopy, 0.25 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    can aid in the visualization of aberrant crypt foci, the earliest neoplastic lesions of the colon that are precursors to adenomas and carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/47\">",
"     47",
"    </a>",
"    ]. In an examination of 97 biopsy samples, the combination of chromoendoscopy and magnification endoscopy had a sensitivity of 100 percent and a specificity of 97 percent for detecting dysplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=see_link\">",
"     \"Magnification endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a randomized trial, 174 patients with chronic ulcerative colitis were assigned to either undergo colonoscopy with chromoendoscopy using 0.1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    or conventional colonoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/44\">",
"     44",
"    </a>",
"    ]. Magnification endoscopy was used in the chromoendoscopy arm to classify the lesions detected by chromoendoscopy based upon the pit pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/45\">",
"     45",
"    </a>",
"    ]. The yield of chromoendoscopy for the detection of intraepithelial neoplasia was significantly higher than that for conventional colonoscopy (32 versus 10 lesions). In addition, chromoendoscopy had a 93 percent sensitivity and specificity for differentiating neoplastic from nonneoplastic lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13990791\">",
"    <span class=\"h4\">",
"     Gastric neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     Methylene blue",
"    </a>",
"    staining has been combined with magnification endoscopy in the evaluation of gastric neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In a study of 136 patients, the sensitivity and specificity of magnification chromoendoscopy for intestinal metaplasia were 76 and 87 percent, and for dysplasia were 97 and 81 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1999489\">",
"    <span class=\"h3\">",
"     Safety of methylene blue",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     Methylene blue",
"    </a>",
"    staining is generally considered to be safe. However, a concern has been raised regarding the potential to induce oxidative damage to DNA in tissues exposed to methylene plus white light (which is used during endoscopy) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/50\">",
"     50",
"    </a>",
"    ]. Such oxidative damage has the potential to accelerate carcinogenesis. However, this theoretical risk for increasing neoplastic transformation has not been proven by clinical studies showing increased cancers in patients who have undergone staining.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7595399\">",
"    <span class=\"h2\">",
"     Indigo carmine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     Indigo carmine",
"    </a>",
"    is derived from a blue plant dye (indigo) and a red coloring agent (carmine) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/1\">",
"     1",
"    </a>",
"    ]. Unlike the vital stains (which are taken up by tissues), indigo carmine is not absorbed by gastrointestinal epithelium. It pools in crevices between epithelial cells, highlighting small or flat lesions and defining irregularities in mucosal architecture, particularly when used with high-magnification or high-resolution endoscopy.",
"   </p>",
"   <p>",
"    It is used primarily in the colon for the detection and evaluation of colorectal neoplasia and is the most common form of chromoendoscopy applied in the colon. As with many other stains,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    is used to evaluate pit patterns (",
"    <a class=\"graphic graphic_figure graphicRef69425 \" href=\"UTD.htm?5/39/5750\">",
"     figure 1",
"    </a>",
"    ). These patterns can help discriminate between hyperplastic polyps (which have a typical \"pit\" pattern) and adenomatous polyps (which have a \"groove\" or \"sulci\" pattern) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/51\">",
"     51",
"    </a>",
"    ]. Pit patterns can also aid in the diagnosis of minute, flat, or depressed colorectal tumors and increase the detection of flat adenomas (",
"    <a class=\"graphic graphic_picture graphicRef54584 \" href=\"UTD.htm?43/5/44113\">",
"     picture 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/52-56\">",
"     52-56",
"    </a>",
"    ]. Indigo carmine can assist in the detection of dysplastic changes in patients with ulcerative colitis undergoing surveillance colonoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/57,58\">",
"     57,58",
"    </a>",
"    ], as well as aid in the detection of adenomas in patients with hereditary nonpolyposis colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     Indigo carmine",
"    </a>",
"    has also been used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In combination with high-magnification endoscopy and Lugol's staining to diagnose the villiform appearance of Barrett's esophagus [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/12,60\">",
"       12,60",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=see_link\">",
"       \"Magnification endoscopy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      To diagnose small gastric cancers used alone [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/15\">",
"       15",
"      </a>",
"      ] or in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      staining [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/61\">",
"       61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      To evaluate villous atrophy in patients suspected of having malabsorption from celiac disease or tropical sprue [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/62\">",
"       62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      To detect duodenal adenomas in patients with familial adenomatous polyposis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/63\">",
"       63",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several techniques described for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    staining. The oral route involves ingestion of a capsule or a dye-containing colonic electrolyte lavage solution. The dye (0.1 to 0.8 percent) can also be sprayed directly onto the mucosa. Indigo carmine has also been injected into the celiac artery (intra-arterial dye method) to facilitate endoscopic delineation of the size and extent of gastric cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7595490\">",
"    <span class=\"h3\">",
"     Efficacy for finding colorectal neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    in the colon has been examined in randomized controlled trials with variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/55,56,65-67\">",
"     55,56,65-67",
"    </a>",
"    ]. A meta-analysis from 2007 found a benefit from chromoendoscopy for the detection of polyps, both neoplastic and non-neoplastic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/68\">",
"     68",
"    </a>",
"    ]. The analysis found that patients who underwent chromoendoscopy were more likely to have a polyp detected (odds ratio 2.1), a benefit that persisted when only neoplastic lesions (odds ratio 1.6) or diminutive neoplastic lesions (odds ratio 1.7) were considered. Finally, chromoendoscopy also detected significantly more patients with three or more neoplastic lesions (odds ratio 2.6).",
"   </p>",
"   <p>",
"    Representative trials (including trials done subsequent to the meta-analysis) have demonstrated the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 660 patients were assigned to undergo either high-definition chromoendoscopy with spraying of the entire colon or high-definition white light colonoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/66\">",
"       66",
"      </a>",
"      ]. Chromoendoscopy showed a trend toward higher mean rates of detection of patients with at least one adenoma (56 versus 48 percent for white light colonoscopy, p = 0.07) and number of adenomas per patient (1.3 versus 1.1, p = 0.07). While the absolute differences were small, chromoendoscopy detected significantly more flat adenomas per patient (0.6 versus 0.4), more adenomas less than 5 mm in diameter per patient (0.8 versus 0.7), and more non-neoplastic lesions per patient (1.8 versus 1.0). The mean procedure time was longer for chromoendoscopy (30 versus 22 minutes).",
"     </li>",
"     <li>",
"      In a second large trial, 400 patients were assigned to undergo colonoscopy with chromoendoscopy performed by an endoscopist experienced in the technique (group A, n = 200), chromoendoscopy performed by an endoscopist who was not experienced in the technique (group B2, n = 100), or colonoscopy without chromoendoscopy, but with a minimum withdrawal time of 10 minutes (group B1, n = 100) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/69\">",
"       69",
"      </a>",
"      ]. After adjusting for confounders, the odds of finding a polyp were significantly lower in group B1 compared with group A (odds ratio 0.44). There was no significant difference in polyp detection between group A and group B2. While there was not a statistically significant difference in the rate of adenoma or cancer detection between group A and group B1, flat adenomas were detected less often in patients in group B1 compared with group A (odds ratio 0.24).",
"     </li>",
"     <li>",
"      In another trial, 259 patients were assigned to undergo either colonoscopy with spraying of the entire colon or routine colonoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/55\">",
"       55",
"      </a>",
"      ]. The study found no difference in the proportion of patients with at least one adenoma or the total number of adenomas detected between the two groups, though there were more adenomas less than 5 mm detected proximal to the sigmoid colon and more patients with three or more identified adenomas in the chromoendoscopy arm. The withdrawal time was significantly longer in the chromoendoscopy arm compared with the control arm (median 9 versus 5 minutes).",
"     </li>",
"     <li>",
"      A fourth trial compared the use of pancolonic chromoendoscopy and targeted chromoendoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/65\">",
"       65",
"      </a>",
"      ]. A total of 260 patients were assigned to one of the two arms. In an attempt to control for withdrawal time, a minimum withdrawal time of 8 minutes was established, and there was no difference in median withdrawal times (17 minutes in the chromoendoscopy group and 15 minutes in the control group). Significantly more adenomas were detected in the pan-chromoendoscopy group compared with the control group (57 versus 34), including more diminutive adenomas (&lt;4 mm) and more patients with greater than three adenomas detected.",
"     </li>",
"     <li>",
"      A fifth trial included 1008 patients who were assigned to either pancolonic chromoendoscopy or standard colonoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/67\">",
"       67",
"      </a>",
"      ]. The proportion of patients with at least one adenoma was higher in the chromoendoscopy group compared with the control group (46 versus 36 percent). In addition, chromoendoscopy increased the per patient detection rate for adenomas overall (09.5 verus 0.66), flat adenomas (0.56 versus 0.28), and serrated lesions (1.19 versus 0.49). Mean extubation times were longer in the chromoendoscopy group (11.6 verus 10.1 minutes).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Randomized trials using tandem colonoscopy studies have also been performed to evaluate adenoma detection rates for chromoendoscopy. In a tandem colonoscopy study, a standard colonoscopy is performed, and any polyps detected are removed. A second colonoscopy is then immediately carried out with patients assigned to have the exam either with chromoendoscopy or without (in an attempt to control for the fact that some lesions that were missed on the first examination might be detected on a second examination, even without dye spraying).",
"   </p>",
"   <p>",
"    Tandem colonoscopy trials have also had variable results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of 50 patients with a history of either colon cancer or colon adenomas, chromoendoscopy found additional adenomas in 44 percent of patients, compared with 17 percent for those who underwent a second colonoscopy with intensive inspection (inspection time of more than 20 minutes) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/70\">",
"       70",
"      </a>",
"      ]. The adenomas detected by chromoendoscopy were smaller than those detected with intensive inspection (mean 2.7 versus 3.2 mm). Chromoendoscopy took longer than intensive inspection (mean procedure time 37 versus 27 minutes). After controlling for inspection time, chromoendoscopy still detected more adenomas than intensive inspection.",
"     </li>",
"     <li>",
"      A second trial from the same group examined 54 patients with Lynch syndrome using the same protocol described above [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/71\">",
"       71",
"      </a>",
"      ]. After controlling for age, number of prior colonoscopies, procedure time, and history of prior colonic resection, chromoendoscopy detected more polyps overall, but there was no difference in the adenoma detection rate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"       \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There was no difference in polyp detection rate in a tandem colonoscopy trial that included 292 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/72\">",
"       72",
"      </a>",
"      ]. The patients in the chromoendoscopy group were also examined with structure enhancement (an electronic function that is supposed to enhance medically relevant structures). While more hyperplastic polyps were detected in the chromoendoscopy group, there was no difference between the groups with regard to the number of patients found to have adenomas or the total number of adenomas detected. The median procedure times were significantly longer in the chromoendoscopy group compared with the control group (27 versus 19 minutes).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given mixed results with regard to the effectiveness of chromoendoscopy for adenoma detection and the increased time required to perform the procedure, the use of chromoendoscopy for the routine detection of colorectal neoplasia needs to be individualized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7595497\">",
"    <span class=\"h3\">",
"     Efficacy in chronic ulcerative colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of 100 patients undergoing surveillance colonoscopy for longstanding, extensive ulcerative colitis used tandem colonoscopies to examine whether chromoendoscopy would increase the detection of dysplasia. After undergoing a routine colonoscopy that included non-targeted four quadrant biopsies obtained every 10 cm, patients underwent a colonoscopy with pancolonic staining with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/58\">",
"     58",
"    </a>",
"    ]. Biopsies were obtained from any additional visible abnormalities. The 2904 non-targeted biopsies did not detect dysplasia in any patient. Biopsies obtained of visible lesions detected during routine colonoscopy identified two patients with dysplasia associated",
"    <span class=\"nowrap\">",
"     lesions/masses.",
"    </span>",
"    Biopsies obtained using chromoendoscopy detected a total of seven dysplastic lesions in five patients. All seven lesions were considered to be adenomas. Chromoendoscopy targeted biopsies detected dysplasia in significantly more patients than non-targeted biopsies, and there was a trend toward an increased dysplasia detection rate compared with targeted biopsies obtained during standard colonoscopy (p = 0.06).",
"   </p>",
"   <p>",
"    While these data suggest that there may be a role for chromoendoscopy in patients with chronic ulcerative colitis, there is not yet enough evidence to recommend its routine use during surveillance colonoscopy. The American Gastroenterologic Association has taken the following position [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/73\">",
"     73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"[A]t this time, normal white light colonoscopy, using standard or high-definition colonoscopes along with multiple colon biopsies, remains a reasonable method of surveillance for patients with IBD. However, chromoendoscopy with targeted biopsies is considered an acceptable alternative to white light endoscopy for endoscopists who have experience with this technique.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1996899\">",
"    <span class=\"h2\">",
"     Toluidine blue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toluidine blue (also called tolonium chloride) is a basic dye that stains cellular nuclei. These properties make it useful for identifying malignant tissues, which have increased DNA synthesis and a high nuclear to cytoplasmic ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Staining is accomplished by spraying 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    (which acts as a mucolytic) before and after spraying a 1 percent aqueous solution of toluidine blue. The second application of acetic acid washes off excess dye. After staining, abnormal tissue appears blue, but false-positive results may occur if inflammatory or fibrotic lesions are present.",
"   </p>",
"   <p>",
"    Toluidine blue staining has been applied in several clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening for early squamous esophageal cancers in alcohol and tobacco abusers [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/75\">",
"       75",
"      </a>",
"      ] and patients with head and neck cancers [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/76,77\">",
"       76,77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Helping to distinguish benign from malignant ulcers in the stomach [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Detecting Barrett's esophagus. In one report, the sensitivity and specificity were 98 and 80 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/79\">",
"       79",
"      </a>",
"      ]. A limitation is that it cannot discriminate between gastric and intestinal metaplasia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No adverse effects from toluidine blue staining have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cresyl violet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cresyl violet has been used for staining uterine cervical lesions and enhancing the endoscopic diagnosis of early malignancies. It acts by staining cell nuclei and is applied as a 0.05 to 0.2 percent solution. It has been used in the colon to highlight pit patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/80\">",
"     80",
"    </a>",
"    ] and has been combined with magnification endoscopy to diagnose a characteristic staining pattern of early gastric carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17173386\">",
"    <span class=\"h2\">",
"     Crystal violet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crystal violet stains cell nuclei and can be used in the esophagus for the detection of Barrett's esophagus and Barrett's associated dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/82\">",
"     82",
"    </a>",
"    ]. It has also been used to highlight pit patterns in the colon [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/83\">",
"     83",
"    </a>",
"    ]. It is applied as a 0.05 to 0.1 percent solution.",
"   </p>",
"   <p>",
"    A double-staining technique has been used in the esophagus and colon to aid with lesion delineation. In the esophagus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    staining is performed to delineate the lesion, followed by crystal violet staining to enhance mucosal patterns. A similar technique has been used in the colon, substituting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    for methylene blue. In one study of 1250 patients, high-magnification chromoendoscopy, using a combination of indigo carmine and crystal violet staining in the colon, predicted incomplete endoscopic mucosal resection of flat, sessile colonic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Methylene blue'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7595399\">",
"     'Indigo carmine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Congo red",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congo red is a rarely-used pH-sensitive indicator that changes from red to dark blue or black in acidic conditions. The staining technique involves the stimulation of acid production with 250 &micro;g of pentagastrin given orally. During endoscopy, a 0.5 to 5 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    solution is sprayed prior to a 0.3 to 0.5 percent Congo red solution. A positive reaction (black color change) results within minutes, allowing acid-secreting areas (blue-black) to be distinguished from non-acid secreting areas (red).",
"   </p>",
"   <p>",
"    Congo red staining has been used to map acid-producing epithelium in the stomach or in ectopic sites:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It has primarily been used for screening for early gastric cancers and for detecting synchronous lesions when used in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"       methylene blue",
"      </a>",
"      (which stains gastric intestinal metaplasia) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/16\">",
"       16",
"      </a>",
"      ]. Early gastric cancer will usually be identified as a \"bleached\" area of mucosa that did not stain with either Congo red or methylene blue [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/1\">",
"       1",
"      </a>",
"      ]. In one study looking at patients with multiple gastric cancers, only 28 percent were detected by routine endoscopy, compared with 89 percent of patients who underwent staining with Congo red and methylene blue [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It can also aid in the detection of intestinal metaplasia of the stomach that is accompanied by gastric atrophy and decreased or absent acid production. A study of 124 patients, for example, suggested that its sensitivity was 100 percent and its positive predictive value was 90 percent compared with gastric biopsies as the gold standard [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/86\">",
"       86",
"      </a>",
"      ]. These values were significantly better than those of visual inspection alone (sensitivity and positive predictive values of 25 and 50 percent, respectively).",
"     </li>",
"     <li>",
"      It can help assess the completeness of vagotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Phenol red",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like Congo red, phenol red is a pH indicator. It detects alkaline pH by a color change from yellow to red.",
"    <strong>",
"    </strong>",
"    The technique involves the administration of a proton pump inhibitor the day prior to the examination or an H2 receptor antagonist given intravenously 30 minutes prior. The patient also ingests a mucolytic agent (dimethylpolysiloxane) before the endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/88\">",
"     88",
"    </a>",
"    ]. During endoscopy, a solution of 0.1 percent phenol red and 5 percent urea is sprayed evenly over the gastric mucosal surface. A positive test consists of a color change from yellow to red [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/88\">",
"     88",
"    </a>",
"    ]. Areas of gastric intestinal metaplasia will not change color [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A promising clinical application of phenol red is the detection of Helicobacter pylori infection. The urease produced by the bacterium catalyzes hydrolysis of urea to NH3 and CO2, resulting in an increase in pH. As a result, H. pylori can be observed in red stained mucosa. Its potential value was illustrated in a study of 108 patients undergoing endoscopy who had no obvious endoscopic findings. The sensitivity and specificity of phenol red dye spraying for H. pylori were 100 and 85 percent, respectively, compared to biopsy as the gold standard [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/89\">",
"     89",
"    </a>",
"    ]. This technique has also been used as a research tool to clarify the role of H. pylori in gastric carcinogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/88,90\">",
"     88,90",
"    </a>",
"    ]. Bile reflux may lead a false positive result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Acetic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     Acetic acid",
"    </a>",
"    has been used to stain abnormal tissues during examination of the cervix, where it whitens immature and dysplastic cervical squamous epithelium. More recently, it has also been applied in the gastrointestinal tract. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25156?source=see_link\">",
"     \"Cervical cancer screening tests: Visual inspection methods\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pilot studies have suggested that the application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    may help identify areas of intestinal metaplasia in the esophagus (Barrett's esophagus) and gastric cardia (",
"    <a class=\"graphic graphic_picture graphicRef62055 \" href=\"UTD.htm?1/40/1665\">",
"     picture 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef73908 \" href=\"UTD.htm?0/27/433\">",
"     picture 9",
"    </a>",
"    ) and to visualize areas of mucosal atrophy in patients suspected of having celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/91\">",
"     91",
"    </a>",
"    ]. Acetic acid has also been mixed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    to improve the visualization of early gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/61\">",
"     61",
"    </a>",
"    ] and as a mucolytic agent to enhance the visualization of the mucosal pattern with high-resolution (high-definition) endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=see_link\">",
"     \"Magnification endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     Acetic acid",
"    </a>",
"    provides contrast enhancement of the surface epithelium. It is typically used in combination with magnification endoscopy, in which case it is referred to as enhanced magnification endoscopy (EME). Approximately 10 mL of 1.5 to 3 percent acetic acid is sprayed onto the esophageal wall. Initially, both the esophageal mucosa and the gastric mucosa turn white, but after 2 to 3 minutes, the normal esophagus remains white, whereas Barrett's mucosa and gastric columnar mucosa will turn red. The effect is transient, lasting only 2 to 3 minutes, so repeated applications of acetic acid may be required.",
"   </p>",
"   <p>",
"    The diagnostic accuracy of EME for Barrett's esophagus ranges from 52 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/93-98\">",
"     93-98",
"    </a>",
"    ], but interobserver agreement for the findings is poor (kappa &lt;0.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/93,99\">",
"     93,99",
"    </a>",
"    ]. It has also been used to detect residual islands of Barrett's esophagus following mucosal ablative therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29121466\">",
"    <span class=\"h1\">",
"     LIMITATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While easy to perform and readily available, there are multiple limitations to chromoendoscopy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chromoendoscopy, especially in the colon, can be time-consuming.",
"     </li>",
"     <li>",
"      Many endoscopists lack training in chromoendoscopy, which can result in poor staining techniques and misinterpretation of findings (eg, failure to adequately wash following staining with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"       methylene blue",
"      </a>",
"      , resulting in false-positive results). Interpretation of the staining patterns requires familiarity and is not always straightforward. It is also prone to interobserver variability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a study of 51 patients undergoing magnificent chromoendoscopy for detecting Barrett's esophagus, there was a high level of interobserver variability (kappa &lt;0.4) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 163 small colon polyps from 104 patients, interobserver variability for interpreting pit patterns (",
"      <a class=\"graphic graphic_figure graphicRef69425 \" href=\"UTD.htm?5/39/5750\">",
"       figure 1",
"      </a>",
"      ) was low for experienced endoscopists (kappa 0.85), but high for trainees (kappa 0.40).",
"     </li>",
"     <li>",
"      In a study of various techniques for detecting Barrett's esophagus, the interobserver variability for chromoendoscopy using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"       indigo carmine",
"      </a>",
"      for various findings was low, with kappa values ranging from 0.32 to 0.46 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/101\">",
"       101",
"      </a>",
"      ]. Chromoendoscopy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      was not significantly better (kappa values ranging from 0.42 to 0.48). In addition, the values did not change significantly when only experts were evaluated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While some classification systems for chromoendoscopic findings exist (eg, the Kudo pit classification system), overall there is a lack of standardization.",
"     </li>",
"     <li>",
"      Studies have shown poor reproducibility with regard to the efficacy of chromoendoscopy (eg, as noted above, some studies have found that chromoendoscopy increases adenoma detection rates in the colon, while others have not).",
"     </li>",
"     <li>",
"      Studies looking at the impact of chromoendoscopy on patient outcomes are lacking.",
"     </li>",
"     <li>",
"      Studies comparing chromoendoscopy with other enhanced imaging technologies (such as narrow band imaging) are limited, and primarily focus on chromoendoscopy in the colon [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/102-105\">",
"       102-105",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One study randomized 114 patients to undergo magnifying colonoscopy with either computed virtual chromoendoscopy using Fujinon Intelligent Color Enhancement (FICE), which is similar to narrow band imaging (NBI), or targeted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"       indigo carmine",
"      </a>",
"      dye spraying for colonic lesions of 1 cm or less [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/102\">",
"       102",
"      </a>",
"      ]. There was no difference in sensitivity or specificity for the FICE group compared with the chromoendoscopy group (93 versus 97 percent and 82 versus 89 percent, respectively). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=see_link&amp;anchor=H2#H2\">",
"       \"Narrow band imaging in Barrett's esophagus\", section on 'Principles'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A study of 142 patients being screened for esophageal malignancy found that NBI performed well when compared with chromoendoscopy as the gold standard [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/103\">",
"       103",
"      </a>",
"      ]. NBI had a sensitivity of 91 percent for detecting squamous cell carcinoma or high-grade intraepithelial neoplasia, with a specificity of 95 percent.",
"     </li>",
"     <li>",
"      A study of 13 patients with familial adenomatous polyposis compared chromoendoscopy with NBI, autofluorescence endoscopy, and white light (standard) colonoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/0/15370/abstract/104\">",
"       104",
"      </a>",
"      ]. Chromoendoscopy detected a higher mean number of lesions per patient compared with NBI, autofluorescence, or white light colonoscopy (43 versus 20, 21, and 12 lesions, respectively). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13750?source=see_link&amp;anchor=H5#H5\">",
"       \"Autofluorescence endoscopy for Barrett's esophagus\", section on 'Autofluorescence for distinguishing tissue types'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13990831\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chromoendoscopy involves the topical application of stains or pigments to improve tissue localization, characterization, or diagnosis during endoscopy. Several agents have been described that can broadly be categorized as absorptive (vital) stains, contrast stains, and reactive stains (",
"      <a class=\"graphic graphic_table graphicRef68885 \" href=\"UTD.htm?16/5/16477\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lugol's solution is most commonly used in the esophagus for the detection of squamous dysplasia and early squamous cell carcinoma. It is also used to differentiate regenerating squamous epithelium from small areas of residual Barrett's mucosa in patients who have undergone mucosal ablation (eg, after photodynamic therapy or multipolar electrocoagulation). It is our preferred staining method for these indications because it is readily available, easily applied, and clinically useful. It can also be combined with other mucosal enhancement techniques, such as narrow band imaging. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Lugol's solution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"       Methylene blue",
"      </a>",
"      's main use is in the evaluation of Barrett's mucosa. In the stomach, it may be used with Congo red for the identification of early gastric cancer. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Methylene blue'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Congo red'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"       Indigo carmine",
"      </a>",
"      is used primarily in the colon for the detection and evaluation of colorectal neoplasia. It is the most common form of chromoendoscopy applied in the colon. Indigo carmine may be used alone or with crystal violet for the detection of early colorectal cancers. (See",
"      <a class=\"local\" href=\"#H7595399\">",
"       'Indigo carmine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17173386\">",
"       'Crystal violet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other stains that are used less frequently include toluidine blue, cresyl violet, phenol red, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H1996899\">",
"       'Toluidine blue'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Cresyl violet'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Phenol red'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Acetic acid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with endoscopic findings concerning for dysplastic Barrett's esophagus based upon findings from a standard endoscopy undergo chromoendoscopy using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"       methylene blue",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Barrett's esophagus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients who have undergone ablative therapy for Barrett's esophagus have a follow-up examination using chromoendoscopy with Lugol's solution to look for residual Barrett's mucosa. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Lugol's solution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that chromoendoscopy with Lugol's solution be performed prior to endoscopic mucosal resection of dysplasia or early cancer of the esophagus, using Lugol's solution for squamous lesions and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"       methylene blue",
"      </a>",
"      for lesions arising from Barrett's esophagus. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Lugol's solution'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Methylene blue'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest against the routine use of chromoendoscopy for the detection of colorectal neoplasia in patients undergoing colonoscopy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, in patients at high risk for dysplasia or malignancy, such as those with long-standing ulcerative colitis, there may be a role for chromoendoscopy using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"       indigo carmine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H7595399\">",
"       'Indigo carmine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/1\">",
"      Fennerty MB. Tissue staining. Gastrointest Endosc Clin N Am 1994; 4:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/2\">",
"      Chisholm EM, Williams SR, Leung JW, et al. Lugol's iodine dye-enhanced endoscopy in patients with cancer of the oesophagus and head and neck. Eur J Surg Oncol 1992; 18:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/3\">",
"      Okumura T, Aruga H, Inohara H, et al. Endoscopic examination of the upper gastrointestinal tract for the presence of second primary cancers in head and neck cancer patients. Acta Otolaryngol Suppl 1993; 501:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/4\">",
"      Yokoyama A, Ohmori T, Makuuchi H, et al. Successful screening for early esophageal cancer in alcoholics using endoscopy and mucosa iodine staining. Cancer 1995; 76:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/5\">",
"      Fagundes RB, de Barros SG, P&uuml;tten AC, et al. Occult dysplasia is disclosed by Lugol chromoendoscopy in alcoholics at high risk for squamous cell carcinoma of the esophagus. Endoscopy 1999; 31:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/6\">",
"      Hashimoto CL, Iriya K, Baba ER, et al. Lugol's dye spray chromoendoscopy establishes early diagnosis of esophageal cancer in patients with primary head and neck cancer. Am J Gastroenterol 2005; 100:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/7\">",
"      Fukuhara T, Hiyama T, Tanaka S, et al. Characteristics of esophageal squamous cell carcinomas and lugol-voiding lesions in patients with head and neck squamous cell carcinoma. J Clin Gastroenterol 2010; 44:e27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/8\">",
"      Woolf GM, Riddell RH, Irvine EJ, Hunt RH. A study to examine agreement between endoscopy and histology for the diagnosis of columnar lined (Barrett's) esophagus. Gastrointest Endosc 1989; 35:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/9\">",
"      Dawsey SM, Fleischer DE, Wang GQ, et al. Mucosal iodine staining improves endoscopic visualization of squamous dysplasia and squamous cell carcinoma of the esophagus in Linxian, China. Cancer 1998; 83:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/10\">",
"      Meyer V, Burtin P, Bour B, et al. Endoscopic detection of early esophageal cancer in a high-risk population: does Lugol staining improve videoendoscopy? Gastrointest Endosc 1997; 45:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/11\">",
"      Kondo H, Fukuda H, Ono H, et al. Sodium thiosulfate solution spray for relief of irritation caused by Lugol's stain in chromoendoscopy. Gastrointest Endosc 2001; 53:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/12\">",
"      Stevens PD, Lightdale CJ, Green PH, et al. Combined magnification endoscopy with chromoendoscopy for the evaluation of Barrett's esophagus. Gastrointest Endosc 1994; 40:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/13\">",
"      Thuler FP, de Paulo GA, Ferrari AP. Chemical esophagitis after chromoendoscopy with Lugol's solution for esophageal cancer: case report. Gastrointest Endosc 2004; 59:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/14\">",
"      Sreedharan A, Rembacken BJ, Rotimi O. Acute toxic gastric mucosal damage induced by Lugol's iodine spray during chromoendoscopy. Gut 2005; 54:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/15\">",
"      Ida K, Hashimoto Y, Takeda S, et al. Endoscopic diagnosis of gastric cancer with dye scattering. Am J Gastroenterol 1975; 63:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/16\">",
"      Tatsuta M, Iishi H, Okuda S, Taniguchi H. Diagnosis of early gastric cancers in the upper part of the stomach by the endoscopic Congo red-methylene blue test. Endoscopy 1984; 16:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/17\">",
"      Fennerty MB, Sampliner RE, McGee DL, et al. Intestinal metaplasia of the stomach: identification by a selective mucosal staining technique. Gastrointest Endosc 1992; 38:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/18\">",
"      Niveloni S, Fiorini A, Dezi R, et al. Usefulness of videoduodenoscopy and vital dye staining as indicators of mucosal atrophy of celiac disease: assessment of interobserver agreement. Gastrointest Endosc 1998; 47:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/19\">",
"      Masaki T, Sheffield JP, Talbot IC, Williams CB. Non-polypoid adenoma of the large intestine. Int J Colorectal Dis 1994; 9:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/20\">",
"      Kiesslich R, Burg J, Vieth M, et al. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology 2004; 127:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/21\">",
"      Suzuki S, Murakami H, Suzuki H, et al. An endoscopic staining method for detection and operation of early gastric cancer. Int Adv Surg Oncol 1979; 2:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/22\">",
"      Canto MI, Setrakian S, Petras RE, et al. Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 1996; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/23\">",
"      Canto MI, Setrakian S, Willis JE, et al. Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study. Endoscopy 2001; 33:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/24\">",
"      Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000; 118:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/25\">",
"      Canto MI, Wu TT, Kalloo AN. High magnification endoscopy with methylene blue chromoendoscopy for improved diagnosis of Barrett's esophagus and dysplasia (abstract). Gastrointest Endosc 2001; 53:(AB140).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/26\">",
"      Endo T, Awakawa T, Takahashi H, et al. Classification of Barrett's epithelium by magnifying endoscopy. Gastrointest Endosc 2002; 55:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/27\">",
"      Yagi K, Nakamura A, Sekine A. Accuracy of magnifying endoscopy with methylene blue in the diagnosis of specialized intestinal metaplasia and short-segment Barrett's esophagus in Japanese patients without Helicobacter pylori infection. Gastrointest Endosc 2003; 58:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/28\">",
"      Sharma P, Topalovski M, Mayo MS, Weston AP. Methylene blue chromoendoscopy for detection of short-segment Barrett's esophagus. Gastrointest Endosc 2001; 54:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/29\">",
"      Sueoka N, Tabuchi M, Nishigaki H, et al. Magnification endoscopy with vital dye staining for detection of a minute focus of early adenocarcinoma in Barrett's esophagus (abstract). Gastrointest Endosc 2001; 53:AB150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/30\">",
"      Kiesslich R, Hahn M, Herrmann G, Jung M. Screening for specialized columnar epithelium with methylene blue: chromoendoscopy in patients with Barrett's esophagus and a normal control group. Gastrointest Endosc 2001; 53:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/31\">",
"      Tabuchi M, Sueoka N, Fujimori T. Videoendoscopy with vital double dye staining (crystal violet and methylene blue) for detection of a minute focus of early stage adenocarcinoma in Barrett's esophagus: a case report. Gastrointest Endosc 2001; 54:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/32\">",
"      Dave U, Shousha S, Westaby D. Methylene blue staining: is it really useful in Barrett's esophagus? Gastrointest Endosc 2001; 53:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/33\">",
"      Wo JM, Ray MB, Mayfield-Stokes S, et al. Comparison of methylene blue-directed biopsies and conventional biopsies in the detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a preliminary study. Gastrointest Endosc 2001; 54:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/34\">",
"      Jobson B, Goenka P, Manalo G, Thomas E. Methylene blue staining for intestinal metaplasia in Barrett's esophagus - is it as good as we think? (abstract). Gastrointest Endosc 1999; 49(4 Part 2):(AB 52).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/35\">",
"      Gangarosa LM, Halter S, Mertz H. Methylene blue staining and endoscopic ultrasound evaluation of Barrett's esophagus with low-grade dysplasia. Dig Dis Sci 2000; 45:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/36\">",
"      Breyer HP, Silva De Barros SG, Maguilnik I, Edelweiss MI. Does methylene blue detect intestinal metaplasia in Barrett's esophagus? Gastrointest Endosc 2003; 57:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/37\">",
"      Horwhat J, Famos F, Celna R, et al. A prospective controlled study to compare the diagnostic yield of methylene-blue directed biopsies versus 4-quadrant random biopsies to identify the presence and grade of dysplasia in Barrett's esophagus (abstract). Gastroenterology 1999; 116:A189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/38\">",
"      Egger K, Roesch T, Allescher H, et al. Videoendoscopy and stepwise biopsy of Barrett's esophagus are still necessary despite sophisticated diagnostic methods (abstract). Gastrointest Endosc 2000; 41(4 Part 2):AB115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/39\">",
"      Ragunath K, Krasner N, Raman VS, et al. A randomized, prospective cross-over trial comparing methylene blue-directed biopsy and conventional random biopsy for detecting intestinal metaplasia and dysplasia in Barrett's esophagus. Endoscopy 2003; 35:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/40\">",
"      Lim CH, Rotimi O, Dexter SP, Axon AT. Randomized crossover study that used methylene blue or random 4-quadrant biopsy for the diagnosis of dysplasia in Barrett's esophagus. Gastrointest Endosc 2006; 64:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/41\">",
"      Horwhat JD, Maydonovitch CL, Ramos F, et al. A randomized comparison of methylene blue-directed biopsy versus conventional four-quadrant biopsy for the detection of intestinal metaplasia and dysplasia in patients with long-segment Barrett's esophagus. Am J Gastroenterol 2008; 103:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/42\">",
"      Kouklakis GS, Kountouras J, Dokas SM, et al. Methylene blue chromoendoscopy for the detection of Barrett's esophagus in a Greek cohort. Endoscopy 2003; 35:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/43\">",
"      Ngamruengphong S, Sharma VK, Das A. Diagnostic yield of methylene blue chromoendoscopy for detecting specialized intestinal metaplasia and dysplasia in Barrett's esophagus: a meta-analysis. Gastrointest Endosc 2009; 69:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/44\">",
"      Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/45\">",
"      Kudo S, Hirota S, Nakajima T, et al. Colorectal tumours and pit pattern. J Clin Pathol 1994; 47:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/46\">",
"      Kudo S, Tamura S, Nakajima T, et al. Diagnosis of colorectal tumorous lesions by magnifying endoscopy. Gastrointest Endosc 1996; 44:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/47\">",
"      Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998; 339:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/48\">",
"      Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, et al. Magnification chromoendoscopy for the diagnosis of gastric intestinal metaplasia and dysplasia. Gastrointest Endosc 2003; 57:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/49\">",
"      Taghavi SA, Membari ME, Eshraghian A, et al. Comparison of chromoendoscopy and conventional endoscopy in the detection of premalignant gastric lesions. Can J Gastroenterol 2009; 23:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/50\">",
"      Olliver JR, Wild CP, Sahay P, et al. Chromoendoscopy with methylene blue and associated DNA damage in Barrett's oesophagus. Lancet 2003; 362:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/51\">",
"      Axelrad AM, Fleischer DE, Geller AJ, et al. High-resolution chromoendoscopy for the diagnosis of diminutive colon polyps: implications for colon cancer screening. Gastroenterology 1996; 110:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/52\">",
"      Kudo S, Kashida H, Nakajima T, et al. Endoscopic diagnosis and treatment of early colorectal cancer. World J Surg 1997; 21:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/53\">",
"      Jaramillo E, Watanabe M, Slezak P, Rubio C. Flat neoplastic lesions of the colon and rectum detected by high-resolution video endoscopy and chromoscopy. Gastrointest Endosc 1995; 42:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/54\">",
"      Kiesslich R, von Bergh M, Hahn M, et al. Chromoendoscopy with indigocarmine improves the detection of adenomatous and nonadenomatous lesions in the colon. Endoscopy 2001; 33:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/55\">",
"      Brooker JC, Saunders BP, Shah SG, et al. Total colonic dye-spray increases the detection of diminutive adenomas during routine colonoscopy: a randomized controlled trial. Gastrointest Endosc 2002; 56:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/56\">",
"      Le Rhun M, Coron E, Parlier D, et al. High resolution colonoscopy with chromoscopy versus standard colonoscopy for the detection of colonic neoplasia: a randomized study. Clin Gastroenterol Hepatol 2006; 4:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/57\">",
"      Matsumoto T, Nakamura S, Jo Y, et al. Chromoscopy might improve diagnostic accuracy in cancer surveillance for ulcerative colitis. Am J Gastroenterol 2003; 98:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/58\">",
"      Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 2004; 53:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/59\">",
"      Lecomte T, Cellier C, Meatchi T, et al. Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome. Clin Gastroenterol Hepatol 2005; 3:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/60\">",
"      Sharma P, Weston AP, Topalovski M, et al. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus. Gut 2003; 52:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/61\">",
"      Sakai Y, Eto R, Kasanuki J, et al. Chromoendoscopy with indigo carmine dye added to acetic acid in the diagnosis of gastric neoplasia: a prospective comparative study. Gastrointest Endosc 2008; 68:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/62\">",
"      Siegel LM, Stevens PD, Lightdale CJ, et al. Combined magnification endoscopy with chromoendoscopy in the evaluation of patients with suspected malabsorption. Gastrointest Endosc 1997; 46:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/63\">",
"      Dekker E, Boparai KS, Poley JW, et al. High resolution endoscopy and the additional value of chromoendoscopy in the evaluation of duodenal adenomatosis in patients with familial adenomatous polyposis. Endoscopy 2009; 41:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/64\">",
"      Ikeda K, Sannohe Y, Araki S, Inutsuka S. Intra-arterial dye method with vasomotors (PIAD method) applied for the endoscopic diagnosis of gastric cancer and the side effects of indigo carmine. Endoscopy 1982; 14:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/65\">",
"      Hurlstone DP, Cross SS, Slater R, et al. Detecting diminutive colorectal lesions at colonoscopy: a randomised controlled trial of pan-colonic versus targeted chromoscopy. Gut 2004; 53:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/66\">",
"      Kahi CJ, Anderson JC, Waxman I, et al. High-definition chromocolonoscopy vs. high-definition white light colonoscopy for average-risk colorectal cancer screening. Am J Gastroenterol 2010; 105:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/67\">",
"      Pohl J, Schneider A, Vogell H, et al. Pancolonic chromoendoscopy with indigo carmine versus standard colonoscopy for detection of neoplastic lesions: a randomised two-centre trial. Gut 2011; 60:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/68\">",
"      Brown SR, Baraza W, Hurlstone P. Chromoscopy versus conventional endoscopy for the detection of polyps in the colon and rectum. Cochrane Database Syst Rev 2007; :CD006439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/69\">",
"      Togashi K, Hewett DG, Radford-Smith GL, et al. The use of indigocarmine spray increases the colonoscopic detection rate of adenomas. J Gastroenterol 2009; 44:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/70\">",
"      Stoffel EM, Turgeon DK, Stockwell DH, et al. Chromoendoscopy detects more adenomas than colonoscopy using intensive inspection without dye spraying. Cancer Prev Res (Phila) 2008; 1:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/71\">",
"      Stoffel EM, Turgeon DK, Stockwell DH, et al. Missed adenomas during colonoscopic surveillance in individuals with Lynch Syndrome (hereditary nonpolyposis colorectal cancer). Cancer Prev Res (Phila) 2008; 1:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/72\">",
"      Lapalus MG, Helbert T, Napoleon B, et al. Does chromoendoscopy with structure enhancement improve the colonoscopic adenoma detection rate? Endoscopy 2006; 38:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/73\">",
"      Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/74\">",
"      Herlin P, Marnay J, Jacob JH, et al. A study of the mechanism of the toluidine blue dye test. Endoscopy 1983; 15:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/75\">",
"      Seitz JF, Monges G, Navarro P, et al. [Endoscopic detection of dysplasia and subclinical cancer of the esophagus. Results of a prospective study using toluidine blue vital staining in 100 patients with alcoholism and smoking]. Gastroenterol Clin Biol 1990; 14:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/76\">",
"      Hix WR, Wilson WR. Toluidine blue staining of the esophagus. A useful adjunct in the panendoscopic evaluation of patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1987; 113:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/77\">",
"      Contini S, Consigli GF, Di Lecce F, et al. Vital staining of oesophagus in patients with head and neck cancer: still a worthwhile procedure. Ital J Gastroenterol 1991; 23:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/78\">",
"      Giler S, Kadish U, Urca I. Use of tolonium chloride in the diagnosis of malignant gastric ulcers. Arch Surg 1978; 113:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/79\">",
"      Chobanian SJ, Cattau EL Jr, Winters C Jr, et al. In vivo staining with toluidine blue as an adjunct to the endoscopic detection of Barrett's esophagus. Gastrointest Endosc 1987; 33:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/80\">",
"      Thorlacius H, Toth E. Role of chromoendoscopy in colon cancer surveillance in inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/81\">",
"      Furuta Y, Kobori O, Shimazu H, et al. A new in vivo staining method, cresyl violet staining, for fiberoptic magnified observation of carcinoma of the gastric mucosa. Gastroenterol Jpn 1985; 20:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/82\">",
"      Amano Y, Kushiyama Y, Ishihara S, et al. Crystal violet chromoendoscopy with mucosal pit pattern diagnosis is useful for surveillance of short-segment Barrett's esophagus. Am J Gastroenterol 2005; 100:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/83\">",
"      Hurlstone DP, Cross SS, Adam I, et al. Endoscopic morphological anticipation of submucosal invasion in flat and depressed colorectal lesions: clinical implications and subtype analysis of the kudo type V pit pattern using high-magnification-chromoscopic colonoscopy. Colorectal Dis 2004; 6:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/84\">",
"      Hurlstone DP, Cross SS, Brown S, et al. A prospective evaluation of high-magnification chromoscopic colonoscopy in predicting completeness of EMR. Gastrointest Endosc 2004; 59:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/85\">",
"      Iishi H, Tatsuta M, Okuda S. Diagnosis of simultaneous multiple gastric cancers by the endoscopic Congo red--methylene blue test. Endoscopy 1988; 20:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/86\">",
"      Toth E, Sjolund K, Fork FT, Lindstrom C. Chronic atrophic fundic gastritis diagnosed by a modified Congo red test. Endoscopy 1995; 27:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/87\">",
"      Donahue PE, Bombeck CT, Yoshida J, Nyhus LM. The simplified endoscopic Congo Red test for completeness of vagotomy. Surg Gynecol Obstet 1986; 163:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/88\">",
"      Iseki K, Tatsuta M, Iishi H, et al. Helicobacter pylori infection in patients with early gastric cancer by the endoscopic phenol red test. Gut 1998; 42:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/89\">",
"      Kohli Y, Kato T, Ito S. Helicobacter pylori an chronic atrophic gastritis. J Gastroenterol 1994; 29 Suppl 7:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/90\">",
"      Coyle WJ, Lawson JM. Helicobacter pylori infection in patients with early gastric cancer by the endoscopic phenol red test. Gastrointest Endosc 1998; 48:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/91\">",
"      Lo A, Guelrud M, Essenfeld H, Bonis P. Classification of villous atrophy with enhanced magnification endoscopy in patients with celiac disease and tropical sprue. Gastrointest Endosc 2007; 66:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/92\">",
"      Pohl J, May A, Rabenstein T, et al. Comparison of computed virtual chromoendoscopy and conventional chromoendoscopy with acetic acid for detection of neoplasia in Barrett's esophagus. Endoscopy 2007; 39:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/93\">",
"      Meining A, R&ouml;sch T, Kiesslich R, et al. Inter- and intra-observer variability of magnification chromoendoscopy for detecting specialized intestinal metaplasia at the gastroesophageal junction. Endoscopy 2004; 36:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/94\">",
"      Toyoda H, Rubio C, Befrits R, et al. Detection of intestinal metaplasia in distal esophagus and esophagogastric junction by enhanced-magnification endoscopy. Gastrointest Endosc 2004; 59:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/95\">",
"      Fortun PJ, Anagnostopoulos GK, Kaye P, et al. Acetic acid-enhanced magnification endoscopy in the diagnosis of specialized intestinal metaplasia, dysplasia and early cancer in Barrett's oesophagus. Aliment Pharmacol Ther 2006; 23:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/96\">",
"      R&eacute;aud S, Croue A, Boyer J. Diagnostic accuracy of magnifying chromoendoscopy with detection of intestinal metaplasia and dysplasia using acetic acid in Barrett's esophagus. Gastroenterol Clin Biol 2006; 30:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/97\">",
"      Hoffman A, Kiesslich R, Bender A, et al. Acetic acid-guided biopsies after magnifying endoscopy compared with random biopsies in the detection of Barrett's esophagus: a prospective randomized trial with crossover design. Gastrointest Endosc 2006; 64:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/98\">",
"      Ferguson DD, DeVault KR, Krishna M, et al. Enhanced magnification-directed biopsies do not increase the detection of intestinal metaplasia in patients with GERD. Am J Gastroenterol 2006; 101:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/99\">",
"      Mayinger B, Oezturk Y, Stolte M, et al. Evaluation of sensitivity and inter- and intra-observer variability in the detection of intestinal metaplasia and dysplasia in Barrett's esophagus with enhanced magnification endoscopy. Scand J Gastroenterol 2006; 41:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/100\">",
"      Guelrud M, Herrera I. Acetic acid improves identification of remnant islands of Barrett's epithelium after endoscopic therapy. Gastrointest Endosc 1998; 47:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/101\">",
"      Curvers W, Baak L, Kiesslich R, et al. Chromoendoscopy and narrow-band imaging compared with high-resolution magnification endoscopy in Barrett's esophagus. Gastroenterology 2008; 134:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/102\">",
"      dos Santos CE, Lima JC, Lopes CV, et al. Computerized virtual chromoendoscopy versus indigo carmine chromoendoscopy combined with magnification for diagnosis of small colorectal lesions: a randomized and prospective study. Eur J Gastroenterol Hepatol 2010; 22:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/103\">",
"      Takenaka R, Kawahara Y, Okada H, et al. Narrow-band imaging provides reliable screening for esophageal malignancy in patients with head and neck cancers. Am J Gastroenterol 2009; 104:2942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/104\">",
"      Matsumoto T, Esaki M, Fujisawa R, et al. Chromoendoscopy, narrow-band imaging colonoscopy, and autofluorescence colonoscopy for detection of diminutive colorectal neoplasia in familial adenomatous polyposis. Dis Colon Rectum 2009; 52:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/0/15370/abstract/105\">",
"      Togashi K, Osawa H, Koinuma K, et al. A comparison of conventional endoscopy, chromoendoscopy, and the optimal-band imaging system for the differentiation of neoplastic and non-neoplastic colonic polyps. Gastrointest Endosc 2009; 69:734.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2670 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_0_15370=[""].join("\n");
var outline_f15_0_15370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13990831\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8675659\">",
"      SPECIFIC DYES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lugol's solution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7593976\">",
"      - Efficacy of Lugol's staining",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Safety of Lugol's staining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Methylene blue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Methylene blue application",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1997858\">",
"      - Staining patterns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Efficacy of methylene blue staining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1997758\">",
"      Colonic dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13990791\">",
"      Gastric neoplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1999489\">",
"      - Safety of methylene blue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7595399\">",
"      Indigo carmine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7595490\">",
"      - Efficacy for finding colorectal neoplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7595497\">",
"      - Efficacy in chronic ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1996899\">",
"      Toluidine blue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cresyl violet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17173386\">",
"      Crystal violet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Congo red",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Phenol red",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Acetic acid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29121466\">",
"      LIMITATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13990831\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2670\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2670|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/39/5750\" title=\"figure 1\">",
"      Kudo Pit Pattern Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2670|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/11/3248\" title=\"picture 1\">",
"      Esophageal squamous ca Lugols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/3/28720\" title=\"picture 2\">",
"      Residual Barretts Lugol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/38/35438\" title=\"picture 3\">",
"      Washing catheter chromoendosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/17/28944\" title=\"picture 4\">",
"      Barretts methylene blue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/60/30656\" title=\"picture 5\">",
"      Barretts high grade methyl blue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/30/16866\" title=\"picture 6\">",
"      Barretts methylene magnify",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/5/44113\" title=\"picture 7\">",
"      Flat adenoma indigo carmine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/40/1665\" title=\"picture 8\">",
"      Acetic acid mag Endosc1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/27/433\" title=\"picture 9\">",
"      Acetic acid mag Endosc2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2670|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?13/40/13967\" title=\"movie 1\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2670|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/5/16477\" title=\"table 1\">",
"      Tissue stains for endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13750?source=related_link\">",
"      Autofluorescence endoscopy for Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25156?source=related_link\">",
"      Cervical cancer screening tests: Visual inspection methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3113?source=related_link\">",
"      Confocal laser endomicroscopy and endocytoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4248?source=related_link\">",
"      Magnification endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/40/29316?source=related_link\">",
"      Narrow band imaging in Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/41/7831?source=related_link\">",
"      Optical coherence tomography in the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4970?source=related_link\">",
"      Overview of endoscopic resection of gastrointestinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/51/30519?source=related_link\">",
"      Tattooing and other methods for localizing colonic lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_0_15371="Symptoms pineal tumors";
var content_f15_0_15371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Signs and symptoms of pineal tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headaches (73 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vision abnormalities (47 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea and vomiting (40 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired ambulation (37 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papilledema (60 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ataxia (50 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of upward gaze (30 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tremor (20 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Altered pupillary reflexes (17 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperactive deep tendon reflexes (13 percent)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Chang, CG, Kegeyama, N, Kobayashi T, et al. Pineal tumors: Clinical diagnosis, with special emphasis on the significance of pineal calcification. Neurosurgery 1981; 8:656.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_0_15371=[""].join("\n");
var outline_f15_0_15371=null;
var title_f15_0_15372="Costs iron chelation";
var content_f15_0_15372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimated annual costs for iron chelation medications*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Deferoxamine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Deferiprone",
"       </td>",
"       <td class=\"subtitle1\">",
"        Deferasirox",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Moderate dose regimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        (mg/kg/day)",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        United States",
"       </td>",
"       <td>",
"        16,200",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        39,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Italy",
"       </td>",
"       <td>",
"        4000",
"       </td>",
"       <td>",
"        6700",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        India",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        800",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Higher dose regimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        (mg/kg/day)",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        99-100",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        United States",
"       </td>",
"       <td>",
"        26,000",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        58,500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Italy",
"       </td>",
"       <td>",
"        6400",
"       </td>",
"       <td>",
"        8900",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        India",
"       </td>",
"       <td>",
"        ND",
"       </td>",
"       <td>",
"        1100",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: drug not available in this country; ND: cost estimate not available.",
"     <br/>",
"     * Estimated annual costs are those for a 60 kg adult at two different dose intensities. Costs are approximate and do not include drug monitoring or infusion costs (eg, infusion pump, needles, tubing, diluent). At Stanford University, costs for infusing deferoxamine are approximately $20,000/year.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Neufeld EJ. Blood 2006; 107:3436.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_0_15372=[""].join("\n");
var outline_f15_0_15372=null;
var title_f15_0_15373="Nematode characteristics";
var content_f15_0_15373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nematode characteristics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Angiostrongylus costaricensis",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Anisakiasis",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Capillariasis",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Dirofilariasis",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Dracunculiasis",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Trichostrongyliasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        C. philippinensis",
"       </td>",
"       <td class=\"subtitle2\">",
"        C. hepatica",
"       </td>",
"       <td class=\"subtitle2\">",
"        D. immitis",
"       </td>",
"       <td class=\"subtitle2\">",
"        D. repens",
"       </td>",
"       <td class=\"subtitle2\">",
"        D. tenuis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Mode of acquisition",
"        </strong>",
"       </td>",
"       <td>",
"        Usually via ingestion of raw snails/slugs or raw produce contaminated with larva-containing slug secretions",
"       </td>",
"       <td>",
"        Ingestion of undercooked or raw fish",
"       </td>",
"       <td>",
"        Ingestion of raw or undercooked fish",
"       </td>",
"       <td>",
"        Ingestion of eggs in contaminated food, water, or soil",
"       </td>",
"       <td class=\"centered\" colspan=\"3\">",
"        Mosquito bite",
"       </td>",
"       <td>",
"        Ingestion of water containing copepods infected with larvae",
"       </td>",
"       <td>",
"        Ingestion of unwashed vegetables fertilized with contaminated manure",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Main organ system affected",
"        </strong>",
"       </td>",
"       <td>",
"        Intestine",
"       </td>",
"       <td>",
"        Stomach or intestine",
"       </td>",
"       <td>",
"        Intestine",
"       </td>",
"       <td>",
"        Liver",
"       </td>",
"       <td>",
"        Lung",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        Subcutaneous nodules",
"       </td>",
"       <td>",
"        Skin",
"       </td>",
"       <td>",
"        Intestine",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Diagnosis",
"        </strong>",
"       </td>",
"       <td>",
"        Intestinal biopsy",
"       </td>",
"       <td>",
"        Visualization of worm (in vomitus or at endoscopy)",
"       </td>",
"       <td>",
"        Stool specimen",
"       </td>",
"       <td>",
"        Liver biopsy",
"       </td>",
"       <td class=\"centered\" colspan=\"3\">",
"        Biopsy of involved tissue",
"       </td>",
"       <td>",
"        Clinical",
"       </td>",
"       <td>",
"        Stool",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Treatment",
"        </strong>",
"       </td>",
"       <td>",
"        Not required",
"       </td>",
"       <td>",
"        Physical removal of the parasite; possibly albendazole",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        Albendazole or mebendazole",
"       </td>",
"       <td class=\"centered\" colspan=\"3\">",
"        Extraction/excision",
"       </td>",
"       <td>",
"        Symptomatic only",
"       </td>",
"       <td>",
"        Albendazole or mebendazole",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Hosts",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Definitive host: Rats",
"        </p>",
"        <p>",
"         Intermediate host: Snails/slugs",
"        </p>",
"       </td>",
"       <td>",
"        Marine mammals, crustaceans, fish/squid",
"       </td>",
"       <td>",
"        Fish-eating birds, fish",
"       </td>",
"       <td>",
"        Rats, mammals",
"       </td>",
"       <td>",
"        Dog",
"       </td>",
"       <td>",
"        Cats",
"       </td>",
"       <td>",
"        Racoons",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        Herbivorous mammals, including sheep and cattle",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Humans",
"        </strong>",
"       </td>",
"       <td>",
"        Dead-end host",
"       </td>",
"       <td>",
"        Incidental hosts",
"       </td>",
"       <td class=\"centered\" colspan=\"2\">",
"        Incidental hosts",
"       </td>",
"       <td class=\"centered\" colspan=\"3\">",
"        Accidental, dead-end hosts",
"       </td>",
"       <td>",
"        Only known host",
"       </td>",
"       <td>",
"        Incidental hosts",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Main geographical area",
"        </strong>",
"       </td>",
"       <td>",
"        Central and South America",
"       </td>",
"       <td>",
"        Japan",
"       </td>",
"       <td>",
"        Thailand, Philippines",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"       <td class=\"centered\" colspan=\"3\">",
"        Mediterranean region",
"       </td>",
"       <td>",
"        Mainly Sudan, also Chad, Ethiopia, Ghana, and Mali",
"       </td>",
"       <td>",
"        Worldwide, especially Middle East and Asia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter Weller, MD and Karin Leder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_0_15373=[""].join("\n");
var outline_f15_0_15373=null;
var title_f15_0_15374="Rx infertility endometrios";
var content_f15_0_15374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62685&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flow for management of infertility in women with endometriosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 389px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    IVF = in vitro fertilization",
"    <br>",
"     IUI = intrauterine insemination",
"     <br>",
"      x6 months = for six months",
"      <br>",
"       stages refer to stages of endometriosis",
"       <div class=\"footnotes\">",
"        * Laparoscopy may be remote from time of attempting pregnancy.",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_0_15374=[""].join("\n");
var outline_f15_0_15374=null;
var title_f15_0_15375="Alendronate versus ERT";
var content_f15_0_15375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Effects of different therapies on bone mineral density in postmenopausal osteoporosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 395px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean percentage change (&plusmn;SE) from baseline in bone mineral density at the lumbar spine, total hip, total body, and one-third distal forearm during four years of therapy in healthy postmenopausal women. Red lines represent treatment with estradiol-norethisterone acetate (E-N); blue lines represent estrogen-medroxyprogesterone acetate (E-MPA); green lines represent alendronate, 5 mg/day (Al-5); orange lines represent alendronate, 2.5 mg/day (Al-2.5); and black dashed lines represent placebo. For graphical presentation, results from groups that received the same dose of alendronate during the first two years of the study were pooled. All of the therapies prevented bone loss, with E-N having the greatest effect at the spine and total body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999; 131:935.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_0_15375=[""].join("\n");
var outline_f15_0_15375=null;
    